Using O
the O
Quality O
Adjusted O
Life O
Year O
outcome, O
the O
intervention O
was O
not O
cost O
effective O
from O
an O
NHS/PSS O
perspective. O

RESULTS: O
No O
statistical O
differences O
in O
the O
implantation B-outcome
rate O
(42.6% O
vs O
39.1%, O
P O
= O
.737, O
rate O
ratio O
0.868, O
95% O
confidence O
interval O
[CI]: O
0.379-1.986) O
and O
the O
clinical B-outcome
pregnancy I-outcome
rate O
(23.4% O
vs O
26.1%, O
P O
= O
.764, O
rate O
ratio O
1.155, O
95% O
CI: O
0.450-2.966) O
were O
detected O
between O
the O
placebo O
and O
the O
treatment O
groups. O

The O
last O
date O
of O
follow-up O
was O
June O
12, O
2018. O

The O
return O
of O
symmetrical B-outcome
pelvic I-outcome
floor I-outcome
muscles I-outcome
(PFM) I-outcome
work O
after O
pelvis O
reposition O
exercise O
was O
observed O
in O
the O
experimental O
group. O

MATERIALS O
AND O
METHODS: O
This O
study O
was O
a O
clinical O
trial O
in O
which O
80 O
patients O
suffering O
from O
cancer O
were O
randomly O
assigned O
to O
two O
groups O
of O
experimental O
and O
control. O

CONCLUSIONS: O
Similar O
skeletal B-outcome
, O
dental B-outcome
, O
and O
soft B-outcome
tissue I-outcome
changes O
were O
obtained O
in O
both O
groups O
after O
Herbst O
therapy. O

PMID: O
31596411 O

The O
PaCO(2) B-outcome
in O
group O
A O
was O
(62.0+/-4.7) O
mmHg O
, O
which O
was O
significantly O
higher O
than O
group O
B O
at O
the O
end O
of O
operation[(51.9+/-4.2) O
mmHg, O
t=2.432, O
P<0.05]. O
The O
time B-outcome
spent I-outcome
successfully I-outcome
positioning I-outcome
the Seperator
insertion I-outcome
in O
group O
A O
and O
group O
B O
were O
(17.6+/-7.5), O
(29.8+/-13.6)s, O
the O
endoscope B-outcome
indwelling I-outcome
duration I-outcome
were(0.8+/-0.1), O
(1.4+/-0.3)min, O
and O
the O
operation B-outcome
time I-outcome
were(32.3+/-4.3), O
(46.8+/-4.8)min, O
there O
were O
significantly O
difference O
between O
group O
A O
and O
group O
B(t=2.670, O
2.214, O
2.166, O
all O
P<0.05). O

Title: O
Controlled O
Trial O
of O
Two O
Incremental O
Milk-Feeding O
Rates O
in O
Preterm O
Infants. O

CONCLUSIONS: O
Contrast B-outcome
enhancement I-outcome
was O
equivalent O
under O
both O
protocols. O

Conical O
implant O
interfaces, O
but O
not O
flat-to-flat O
or O
platform-switched O
implant O
interfaces, O
were O
associated O
with O
no O
marginal B-outcome
bone I-outcome
level O
(MBL) O
changes O
over O
3 O
years. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Therefore, O
our O
results O
do O
not O
support O
the O
use O
of O
antibiotic O
treatment O
for O
chronic O
low O
back O
pain O
and O
Modic O
changes. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Journal-Name:Indian O
heart O
journal O

This O
paper O
presents O
the O
MIM's O
intervention O
effect O
on O
self-efficacy B-outcome
to O
cope O
with O
stress, O
emotional O
coping B-outcome
response, O
social B-outcome
support I-outcome
for O
stress O
management, O
stress B-outcome
, O
depressive B-outcome
symptoms I-outcome
, O
and O
positive B-outcome
and Seperator
negative B-outcome
affect E1-outcome
. O
METHODS: O
Participants O
(N O
= O
612) O
were O
recruited O
from O
the O
Special O
Supplemental O
Nutrition O
Program O
for O
Women, O
Infants, O
and O
Children O
in O
Michigan. O

Title: O
Comparison O
of O
oncological O
benefits O
of O
deep O
neuromuscular O
block O
in O
obese O
patients O
with O
gastric O
cancer O
(DEBLOQS_GC O
study): O
A O
study O
protocol O
for O
a O
double-blind, O
randomized O
controlled O
trial. O

Publication O
date: O
2019/01/08 O
06:00 O
[medline] O

This O
study O
evaluated O
clinical O
and O
radiographic O
twelve-month O
outcomes O
of O
root O
canal O
treatments O
(CT) O
with O
smear O
layer O
removal, O
performed O
in O
primary O
teeth, O
using O
two O
different O
root O
canal O
filling O
materials. O

PC O
may O
help O
prevent O
dangerous O
hyperthermia O
in O
athletes. O

OBJECTIVE: O
One O
of O
the O
important O
aspects O
involved O
in O
achieving O
optimal O
outcomes O
after O
assisted O
reproductive O
treatment O
(ART) O
is O
the O
endometrium. O

Publication O
date: O
2019/01/15 O
06:00 O
[medline] O

OBJECTIVE: O
to O
measure O
the O
effect O
of O
an O
infant O
stimulation O
therapy O
(auditory, O
tactile, O
visual O
and O
vestibular) O
on O
the O
adaptation B-outcome
to I-outcome
postnatal I-outcome
life I-outcome
of O
the O
mother-child O
dyad. O

A O
fragility B-outcome
fracture I-outcome
occurred O
in O
190 O
women O
in O
the O
placebo O
group O
and O
in O
122 O
women O
in O
the O
zoledronate O
group O
(hazard O
ratio O
with O
zoledronate, O
0.63; O
95% O
confidence O
interval, O
0.50 O
to O
0.79; O
P<0.001). O

OBJECTIVE: O
The O
aim O
of O
the O
study O
was O
to O
test O
the O
applicability B-outcome
of O
low-dose O
MDCT O
protocols O
for O
decision-making O
of O
sinus O
surgeries O
of O
patients O
with O
uncontrolled O
chronic O
rhinosinusitis. O

The O
study O
compares O
the O
efficacy O
of O
MCP O
using O
the O
AIMhi O
Stay O
Strong O
App O
with O
two O
control O
groups O
(control O
app O
intervention O
and O
treatment O
as O
usual) O
on O
participant-reported O
psychological B-outcome
distress I-outcome
(the O
primary O
outcome) O
using O
the O
Kessler O
Distress O
Scale O
(K10)]; O
depressive B-outcome
symptoms I-outcome
using O
the O
adapted O
Patient O
Health B-outcome
Questionnaire O
(PHQ-9)]; O
quality B-outcome
of I-outcome
life I-outcome
using O
the O
EuroQoL O
instrument O
( O
EQ5D]) O
and O
adherence B-outcome
to O
dialysis O
treatment O
planning O
through O
file O
audit. O

Contrary O
to O
the O
progress O
in O
the O
management O
of O
severe O
AP, O
the O
MAP O
has O
not O
presented O
significant O
changes O
in O
recent O
years. O

Title: O
ED50 O
and O
ED95 O
of O
intrathecal O
hyperbaric O
ropivacaine O
for O
parturients O
undergoing O
cesarean O
section O
with O
prophylactic O
infusion O
of O
phenylephrine: O
A O
Prospective O
dose-finding O
Study. O

RESULTS: O
The O
ED95 O
and O
95% O
confidence O
intervals O
(95% O
CI) O
of O
spinal O
hyperbaric O
bupivacaine O
in O
group O
D O
and O
group O
C O
were O
7.4 O
mg O
(95% O
CI, O
5.6-12.4 O
mg) O
and O
11.0 O
mg O
(95% O
CI, O
4.4-56.8 O
mg), O
respectively. O

Here, O
we O
present O
the O
impact O
of O
the O
diet O
intervention O
on O
cost-effectiveness O
and O
explore O
changes O
in O
quality B-outcome
of I-outcome
life I-outcome
(QOL) I-outcome
. O
METHODS: O
A O
total O
of O
110 O
postpartum O
women O
with O
overweight/obesity O
were O
randomly O
assigned O
to O
diet O
(D-group) O
or O
control O
(C-group). O

Medical O
sciences O

A O
partial O
support O
of O
the O
MAT O
and O
of O
ruminations O
reduction O
to O
the O
MBI's O
efficacy O
was O
found. O

Title: O
Randomized O
controlled O
trial O
comparing O
the O
efficacy O
of O
daily O
and O
every O
other O
day O
atorvastatin O
therapy O
and O
its O
correlation O
with O
serum O
hydroxymethylglutaryl-CoA B-outcome
reductase I-outcome
enzyme I-outcome
levels O
in O
naive O
dyslipidemic O
patients. O

There O
were O
no O
Significant O
differences O
in O
operation B-outcome
time I-outcome
, O
liquid B-outcome
input I-outcome
and O
blood B-outcome
output I-outcome
between O
group O
C O
and O
group O
D(all O
P>0.05). O

The O
intake O
of O
CSO O
in O
the O
CSO O
group, O
but O
not O
the O
increase O
in O
plasma O
ALA O
proportions, O
correlated O
inversely O
with O
the O
IFNG O
mRNA B-outcome
expression I-outcome
in O
PBMCs O
(P O
= O
0.08). O

The O
incidence O
of O
severe B-outcome
disability I-outcome
in O
the O
SBH O
treatment O
group O
was O
significantly O
lower O
than O
that O
in O
the O
routine O
treatment O
group O
[5.6% O
(1/18) O
vs. O
44.4% O
(8/18), O
P O
< O
0.05]. O
There O
was O
1 O
child O
death B-outcome
in O
the O
routine O
treatment O
group O
and O
no O
death O
in O
the O
SBH O
treatment O
group. O

There O
is O
currently O
no O
standard O
therapeutic O
regimen O
available O
for O
patients O
with O
advanced O
colorectal O
cancer O
in O
whom O
the O
disease O
continues O
to O
progress O
after O
2 O
or O
more O
lines O
of O
chemotherapy. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

The O
patients O
in O
the O
experimental O
group O
and O
control O
group O
will O
take O
2.5 O
g O
of O
Bosinji O
granule O
(1.523 O
g O
of O
Bosinji O
extract) O
or O
Loxonin O
tablet O
(60 O
mg O
of O
loxoprofen) O
3 O
times O
a O
day O
for O
6 O
weeks. O

At O
the O
end O
of O
an O
8-week O
consumption O
period, O
all O
subjects O
were O
determined O
serum O
bone B-outcome
markers O
including O
calcium B-outcome
, O
alkaline B-outcome
phosphatase I-outcome
, O
osteocalcin B-outcome
, O
and O
beta B-outcome
CTX I-outcome
. O
In O
addition, O
the O
hematological B-outcome
and O
blood O
clinical B-outcome
chemistry I-outcome
changes, O
and O
total O
phenolic B-outcome
content O
in O
the O
serum O
were O
also O
determined. O

Trial O
Registration: O
ClinicalTrials.gov O
Identifier: O
NCT02241655. O

Teachers O
assigned O
to O
the O
waitlist O
control O
condition O
will O
receive O
an O
alternative O
training O
on O
how O
to O
monitor O
physical O
functional O
capacity O
in O
children O
with O
special O
needs. O

Publication O
date: O
2019/01/10 O
06:00 O
[entrez] O

Publication O
date: O
2019/01/17 O
06:00 O
[medline] O

Journal O
ID: O
8908809 O

A O
heat B-outcome
stress I-outcome
test O
(120min, O
45% O
V O
O2peak) O
before O
(Pre O
HA) O
and O
after O
HA O
(Post O
HA) O
in O
similar O
hot O
conditions O
assessed O
heat B-outcome
acclimation I-outcome
status. O

Both O
groups O
showed O
significant O
gains O
at O
the O
Fugl-Meyer O
motor B-outcome
assessment I-outcome
(FMA) O
(ST: O
5+/-4 O
points/FT: O
6+/-4 O
points; O
P=0.04) O
and O
Wolf O
motor B-outcome
function I-outcome
test O
(ST: O
0.4+/-0.3 O
points/FT: O
0.6+/-0.4 O
points; O
P=0.05), O
which O
were O
comparable O
between O
groups O
(P>/=0.47). O

METHODS: O
One O
hundred O
and O
three O
high O
school O
athletes O
completed O
the O
study O
(M O
age O
= O
15.3, O
SD O
= O
1.2; O
70.9% O
male; O
37.9% O
Afr. O

Publication O
date: O
2019/03/09 O
06:00 O
[medline] O

Journal-Name:Indian O
heart O
journal O

Recovery B-outcome
conditions I-outcome
, O
postoperative O
agitation B-outcome
were O
also O
recorded. O

Depression B-outcome
and O
heart B-outcome
rate I-outcome
variability I-outcome
were O
measured O
using O
the O
GDS O
and O
digital O
electrocardiogram O
at O
baseline O
and O
after O
the O
24-week O
intervention. O

On O
each O
visit O
the O
participants O
consumed O
either O
a O
CA O
+ O
C O
(100 O
mg O
of O
CA O
and O
100 O
mg O
of O
C) O
or O
placebo O
(dextrose) O
capsule. O

BACKGROUND: O
Alveolar O
osteitis O
is O
a O
frequent O
postoperative O
complication O
of O
third O
molar O
surgery. O

INTERPRETATION: O
Compared O
with O
ICSI, O
PICSI O
does O
not O
significantly O
improve O
term O
livebirth B-outcome
rates. O

DISCUSSION: O
This O
trial O
will O
assess O
the O
effect O
of O
selenium O
supplementation O
on O
pregnancy B-outcome
outcome I-outcome
and O
HIV B-outcome
disease I-outcome
progression I-outcome
among O
HIV-infected O
pregnant O
women O
in O
Lagos. O

The O
success O
rates O
of O
hemostasis B-outcome
for O
3 O
minutes O
and O
5 O
minutes, O
the O
time B-outcome
of I-outcome
operation I-outcome
, O
the O
amount O
of O
intraoperative O
bleeding B-outcome
, O
the O
volume O
of O
autogenously O
blood B-outcome
transfusion I-outcome
, O
the O
amount O
of O
blood B-outcome
during O
hemostasis, O
the O
amount O
of O
blood B-outcome
transfusion I-outcome
, O
and O
BP B-outcome
, O
red B-outcome
blood I-outcome
cell I-outcome
count I-outcome
(RBC) I-outcome
, O
haematocrit B-outcome
(HCT) I-outcome
, O
haemoglobin B-outcome
(HB) I-outcome
of O
preoperative, O
2 O
to O
3 O
days, O
and O
5 O
to O
7 O
days O
following O
operation O
were O
recorded O
to O
compare. O

Publication O
date: O
2019/02/16 O
06:00 O
[medline] O

CONCLUSION: O
The O
results O
of O
this O
study O
demonstrated O
that O
NES O
may O
help O
to O
relieve O
CINV O
in O
patients O
with O
AGC. O

OBJECTIVE: O
The O
aim O
of O
the O
present O
study O
was O
to O
observe O
the O
feasibility B-outcome
and O
effect O
of O
cornea O
slice O
acquired O
from O
femtosecond O
laser O
surgery, O
small O
incision O
lenticule O
extraction O
(SMILE) O
as O
patch O
graft O
for O
the O
prevention O
of O
drainage B-outcome
tube I-outcome
exposure I-outcome
and O
to O
compare O
with O
the O
sclera. O

Journal O
ID: O
9435674 O

Metabolomics O
was O
employed O
to O
investigate O
cellular B-outcome
metabolism I-outcome
. O
RESULTS: O
DKD O
patients O
had O
decreased O
mtDNA B-outcome
copy I-outcome
numbers O
and O
increased O
mtDNA B-outcome
damage I-outcome
compared O
to O
DCs. O

Patient O
satisfaction B-outcome
at O
24 O
h O
postoperatively O
was O
filed O
on O
a O
11-point O
numeric O
rating O
scale O
(SFS24; O
0=fully O
unsatisfied; O
10=fully O
satisfied). O

Lastly, O
EMLA O
lowered O
overall B-outcome
pain I-outcome
score O
at O
the O
time O
of O
first O
analgesic O
request O
in O
ward O
compared O
to O
control O
group O
(P O
= O
.02). O

The O
menstrual O
disturbances O
as O
a O
health O
problem O
among O
young O
girls O
affect O
not O
only O
reproductive, O
but O
also O
psychical O
health O
and O
quality O
of O
life. O

METHODS: O
We O
evaluated O
40 O
patients O
aged O
>/=18 O
years O
who O
underwent O
elective O
muscle O
sparing O
thoracotomies. O

CONCLUSIONS: O
This O
study's O
findings O
showed O
that O
an O
educational O
video O
can O
be O
as O
beneficial O
as O
expert O
proctoring, O
which O
implies O
that O
the O
development O
of O
a O
standardized O
educational O
video O
would O
be O
worthwhile. O

Journal-Name:Hematology O
(Amsterdam, O
Netherlands) O

Title: O
Taping O
to O
Improve O
Scapular B-outcome
Dyskinesis I-outcome
, O
Scapular B-outcome
Upward I-outcome
Rotation I-outcome
, O
and O
Pectoralis B-outcome
Minor I-outcome
Length I-outcome
in O
Overhead O
Athletes. O

Before O
and O
after O
the O
intervention O
anthropometric B-outcome
parameters, O
serum O
lipid B-outcome
profile, O
serum O
concentrations O
of O
alanine B-outcome
aminotransferase I-outcome
, O
aspartate B-outcome
aminotransferase I-outcome
, O
insulin B-outcome
, O
glucose B-outcome
, O
insulin-like B-outcome
growth I-outcome
factor-1 I-outcome
, O
HOMA-IR B-outcome
(homeostatic O
model O
assessment), O
and O
visceral B-outcome
adiposity I-outcome
index O
(VAI), O
and O
their O
changes O
were O
registered. O

Comparison O
of O
the O
mean O
differences O
at O
the O
beginning O
and O
two O
months O
after O
the O
study O
in O
the O
two O
groups O
showed O
that O
the O
scores O
related O
to O
quality B-outcome
of I-outcome
life I-outcome
(QOL) I-outcome
dimensions O
in O
the O
experimental O
group O
were O
significantly O
greater O
than O
the O
control O
group O
(p</=0.05). O

TRIAL O
REGISTRATION: O
The O
study O
is O
registered O
at O
EudraCT O
(2016-003017-10, O
date O
of O
registration: O
22 O
July O
2016) O
and O
( O
NCT02868385 O
, O
date O
of O
registration: O
16 O
August O
2016). O

Journal-Name:Journal O
of O
shoulder O
and O
elbow O
surgery O

OBJECTIVE: O
This O
study O
means O
to O
determine O
whether O
Mg O
supplementation O
improves O
glycemic B-outcome
control I-outcome
indicators O
in O
patients O
with O
T2D. O
METHODS: O
After O
one O
week O
of O
the O
dietary O
stabilization O
phase, O
42 O
T2D O
patients O
were O
stratified O
according O
to O
sex, O
age, O
fasting O
blood O
sugar O
(FBS) O
and O
Mg O
levels O
and O
then O
randomly O
allocated O
into O
two O
groups. O

Participants O
were O
critically O
ill O
patients O
who O
regained O
mental O
capacity O
following O
receipt O
of O
level O
3 O
(intensive) O
care. O

The O
primary O
and O
secondary O
endpoints, O
excluding O
quality B-outcome
of I-outcome
life I-outcome
(QoL) I-outcome
, O
have O
been O
published. O

The O
patients O
were O
randomly O
assigned, O
in O
a O
2:1 O
ratio, O
to O
receive O
a O
single O
300-mg O
dose O
of O
tafenoquine O
or O
15 O
mg O
of O
primaquine O
once O
daily O
for O
14 O
days O
(administered O
under O
supervision); O
all O
patients O
received O
a O
3-day O
course O
of O
chloroquine O
and O
were O
followed O
for O
180 O
days. O

In O
the O
current O
exploratory O
analysis, O
these O
ardms O
were O
categorized O
into O
the O
moderate O
hypofractionated O
(MHF) O
group O
(52 O
patients O
in O
Arms O
1-3) O
and O
the O
extreme O
hypofractionated O
(EHF) O
group O
(30 O
patients O
in O
Arms O
4-5). O

Journal O
ID: O
2985248R O

Intravenous O
boluses O
of O
50 O
mug O
were O
administered O
for O
breakthrough O
pain. O

Hence, O
the O
primary O
objective O
was O
to O
study O
the O
hypothesis O
that O
methohexital O
confers O
a O
better O
hemodynamic B-outcome
profile O
than O
propofol O
for O
anesthetic O
induction, O
in O
patients O
receiving O
AAB. O

Publication O
Type: O
Journal O
Article O

Highly B-outcome
sensitive I-outcome
troponin I-outcome
(HS-Tp) I-outcome
as O
a O
biomarker O
of O
irreversible O
damage O
to O
the O
myocardium O
was O
evaluated O
before O
PCI O
and O
after O
PCI O
in O
24 O
hours. O

Incremental O
cost-effectiveness O
ratios O
were O
calculated, O
with O
uncertainty O
around O
the O
values O
estimated O
using O
bootstrapping. O

Clear O
recommendations O
regarding O
the O
dosage O
should O
be O
established. O

The O
objective O
of O
this O
study O
was O
to O
evaluate O
right B-outcome
heart I-outcome
size I-outcome
and Seperator
function S2-outcome
assessed O
by O
echocardiography O
during O
long O
term O
treatment O
with O
riociguat. O

Publication O
date: O
2019/02/08 O
06:00 O
[medline] O

Journal-Name:Einstein O
(Sao O
Paulo, O
Brazil) O

2) O
Simulated O
scuba O
results O
in O
vitro: O
under O
VCV O
mode, O
exhaled B-outcome
tidal I-outcome
volume I-outcome
monitored O
by O
respirator O
and O
tidal B-outcome
volume I-outcome
showed O
by O
simulated O
scuba O
in O
different O
preset O
VT O
groups O
were O
continuously O
increased O
with O
the O
increase O
in O
oxygen O
atomization O
flow, O
while O
inspiratory B-outcome
tidal I-outcome
volume I-outcome
monitored O
by O
ventilator O
was O
not O
significantly O
changed. O

METHODS: O
This O
pragmatic, O
randomized, O
controlled, O
parallel-group O
clinical O
trial O
will O
compare O
the O
effectiveness O
of O
the O
motivational O
interviewing O
to O
an O
educational O
intervention, O
including O
the O
distribution O
of O
an O
information O
flyer O
as O
standard O
of O
care O
on O
vaccination O
coverage O
in O
four O
maternity O
wards O
across O
the O
Province O
of O
Quebec O
(PromovaQ). O

Modified O
classical O
pilates O
exercises O
were O
performed O
by O
the O
experimental O
group O
three O
times O
a O
week O
over O
a O
12-week O
period. O

Publication O
date: O
2018/12/20 O
06:00 O
[entrez] O

CONCLUSION: O
RIPC O
does O
not O
result O
in O
significant O
reduction O
of O
contrast B-outcome
induced I-outcome
nephropathy I-outcome
. O
However O
RIPC O
helps O
in O
the O
prevention O
of O
post O
procedural O
worsening O
in O
eGFR B-outcome
and O
serum O
creatinine B-outcome
even O
up O
to O
6 O
weeks. O

Effectiveness O
of O
a O
national O
quality O
improvement O
programme O
to O
improve O
survival O
after O
emergency O
abdominal O
surgery O
(EPOCH): O
a O
stepped-wedge O
cluster-randomised O
trial. O

Title: O
Vitamin O
D O
and O
probiotic O
co-supplementation O
affects O
mental B-outcome
health I-outcome
, O
hormonal B-outcome
, O
inflammatory B-outcome
and O
oxidative B-outcome
stress I-outcome
parameters O
in O
women O
with O
polycystic O
ovary O
syndrome. O

Thus, O
reasons O
for O
engaging O
in O
weight O
loss O
interventions O
needs O
exploring, O
in O
order O
to O
engage O
more O
workplaces O
in O
weight O
loss O
interventions. O

Publication O
Type: O
Journal O
Article O

RESULTS: O
There O
were O
significant O
increases O
in O
the O
scores O
of O
quality B-outcome
of I-outcome
life I-outcome
(QOL) I-outcome
dimensions O
in O
the O
experimental O
group O
after O
the O
intervention O
(p</=0.05). O

Publication O
date: O
2019/01/17 O
06:00 O
[medline] O

Level O
of O
evidence O
II-2. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

OBJECTIVE: O
To O
compare O
the O
chest O
tube O
drainage O
by O
the O
same O
thoracotomy O
intercostal O
space O
with O
the O
traditional O
approach O
in O
patients O
undergoing O
muscle-sparing O
thoracotomy. O

BACKGROUND: O
A O
high-fidelity O
task O
simulator O
for O
cricothyroidotomy O
was O
created O
using O
data O
from O
a O
3-dimensional O
(3D) O
computed O
tomography O
scan O
using O
a O
3D O
printer. O

The O
visual O
analogue O
scale O
(VAS) O
of O
taste B-outcome
disturbance I-outcome
symptoms I-outcome
and O
the O
gustatory B-outcome
tests O
were O
assessed O
before O
and O
8 O
weeks O
after O
treatment O
with O
esomeprazole, O
a O
PPI O
(20 O
patients, O
aged O
50.0 O
+/- O
1.7 O
years) O
or O
famotidine, O
a O
H2 O
blocker O
(20 O
patients, O
aged O
47.1 O
+/- O
1.8 O
years). O

The O
final O
follow-up O
visit O
was O
April O
2017. O

The O
scores O
of O
unintentional O
injury O
risk B-outcome
behavior I-outcome
for O
children O
in O
the O
intervention O
group O
at O
3 O
and O
6 O
months O
after O
intervention O
were O
14.42+/-5.67 O
and O
14.14+/-8.95, O
respectively, O
lower O
than O
those O
before O
the O
intervention O
(16.85+/-8.48) O
and O
in O
the O
control O
group O
(P=0.001). O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Eradication B-outcome
failures O
were O
not O
associated O
with O
factors O
including O
gender, O
age, O
body O
mass O
index, O
smoking, O
alcohol O
consumption, O
educational O
level, O
and O
urban-rural O
distribution O
in O
this O
observation O
(P O
> O
.05).Despite O
increasing O
drug B-outcome
resistance I-outcome
to O
CLA, O
Hp B-outcome
eradication I-outcome
rates O
in O
FZD O
and O
CLA O
groups O
have O
no O
significant O
difference O
at O
present; O
as O
FZD-based O
quadruple O
therapy O
is O
more O
cost-effective, O
we O
recommend O
this O
regimen O
be O
a O
first-line O
choice O
for O
Hp O
eradication. O

No O
other O
complications B-outcome
, O
such O
as O
infection B-outcome
or O
deep B-outcome
vein I-outcome
thrombosis I-outcome
, O
occurred O
in O
both O
groups. O

Title: O
Hippotherapy O
in O
Rehabilitation O
Care O
for O
Children O
With O
Neurological O
Impairments O
and O
Developmental O
Delays: O
A O
Case O
Series. O

PMID: O
31613346 O

METHODS: O
Cross-sectional O
analyses O
of O
the O
PREDIMED-Plus O
trial. O

TRIAL O
REGISTRATION: O
Clinicaltrials.gov O
, O
NCT03236961, O
retrospectively O
registered O
on O
the O
2nd O
of O
August O
2017. O

Publication O
date: O
2018/12/29 O
00:00 O
[accepted] O

Methods O
Sixty O
older O
individuals O
with O
depression O
score O
of O
10 O
or O
above O
(the O
Geriatric O
Depression O
Scale, O
GDS]) O
were O
randomly O
assigned O
into O
two O
groups: O
TC O
(n O
= O
30) O
and O
control O
group O
(n O
= O
30). O

Publication O
date: O
2019/03/05 O
06:00 O
[medline] O

Conclusions O
and O
Relevance: O
Among O
patients O
with O
MI, O
provision O
of O
vouchers O
to O
offset O
medication O
co-payments O
for O
P2Y12 O
inhibitors, O
compared O
with O
no O
vouchers, O
resulted O
in O
a O
3.3% O
absolute O
increase O
in O
patient-reported O
persistence B-outcome
with O
P2Y12 O
inhibitors O
and O
no O
significant O
reduction O
in O
1-year O
major B-outcome
adverse I-outcome
cardiovascular I-outcome
events I-outcome
(MACE) I-outcome
outcomes. O

Palo O
Alto, O
CA, O
USA. O

Children O
were O
filmed O
playing O
pre-, O
mid-, O
and O
postintervention, O
using O
the O
Test O
of O
Playfulness B-outcome
(ToP) O
to O
assess O
playfulness B-outcome
. O
The O
PICIHBI O
comprised O
of O
10 O
monthly O
sessions O
facilitated O
by O
an O
occupational O
therapist, O
involving O
group O
discussions O
with O
caregivers O
and O
periods O
of O
experiential O
play. O

Journal O
ID: O
101225531 O

METHODS: O
Forty-four O
children O
(27 O
girls O
and O
17 O
boys) O
between O
13 O
and O
17 O
years O
of O
age O
with O
unilateral O
recurrent O
patellar O
dislocation O
underwent O
medial O
patellofemoral O
ligament O
(MPFL) O
reconstruction. O

The O
population O
studied O
had O
a O
mean O
age O
of O
60.6 O
years. O

There O
was O
no O
significant O
difference O
in O
the O
success B-outcome
rate O
or O
procedure B-outcome
time I-outcome
between O
the O
2 O
groups O
(success O
rate: O
P O
= O
.24, O
procedure O
time: O
P O
= O
.34). O

Further O
additional O
benefits O
are O
better O
quality B-outcome
of I-outcome
life I-outcome
(QoL) I-outcome
and O
shorter O
immunosuppressive B-outcome
treatment I-outcome
compared O
with O
standard O
GVHD O
prophylaxis O
without O
ATLG. O

PURPOSE: O
While O
some O
micro-organisms, O
such O
as O
Staphylococcus O
aureus, O
are O
clearly O
implicated O
in O
causing O
tissue O
damage O
in O
diabetic O
foot O
ulcers O
(DFUs), O
our O
knowledge O
of O
the O
contribution O
of O
the O
entire O
microbiome O
to O
clinical O
outcomes O
is O
limited. O

Journal-Name:JAMA O

Materials O
and O
Methods: O
A O
total O
of O
240 O
(129 O
females O
and O
111 O
male) O
aged O
18 O
- O
65 O
years O
were O
referred O
and O
integrated O
in O
this O
clinical O
trial, O
All O
patients O
presented O
with O
a O
vital O
maxillary O
or O
mandibular O
molar, O
premolar O
or O
front O
teeth O
designated O
for O
conventional O
root O
canal O
treatment O
for O
prosthetic O
reasons O
detected O
with O
only O
vital O
pulps. O

The O
purpose O
of O
this O
study O
was O
to O
compare O
the O
analgesic B-outcome
benefits O
and O
physiotherapy B-outcome
(PT) I-outcome
outcomes O
of O
single-shot O
ACB O
to O
two O
different O
regimens O
of O
infusion O
of O
the O
continuous O
ACB, O
24-hour O
and O
48-hour O
infusion. O

CONCLUSION: O
The O
strong O
efficacy O
and O
favorable O
benefit-risk O
profile O
of O
DMF O
extends O
to O
Japanese, O
and O
more O
broadly, O
East O
Asian O
patients O
with O
RRMS. O

Participants O
were O
divided O
into O
groups O
that O
received O
16 O
weeks O
of O
either O
usual O
care O
or O
exercise O
intervention. O

Publication O
date: O
2018/03/20 O
00:00 O
[accepted] O

At O
late O
follow-up O
(24 O
to O
32 O
days O
after O
initiation O
of O
therapy), O
fewer O
patients O
in O
the O
plazomicin O
group O
than O
in O
the O
meropenem O
group O
had O
microbiologic B-outcome
recurrence I-outcome
(3.7% O
vs. O
8.1%) O
or O
clinical B-outcome
relapse I-outcome
(1.6% O
vs. O
7.1%). O

Title: O
Gua O
Sha O
therapy O
for O
chronic O
low O
back O
pain: O
A O
randomized O
controlled O
trial. O

Title: O
Contrast O
Material O
Injection O
Protocol O
With O
the O
Dose O
Determined O
According O
to O
Lean O
Body O
Weight O
at O
Hepatic O
Dynamic O
Computed O
Tomography: O
Comparison O
Among O
Patients O
With O
Different O
Body O
Mass O
Indices. O

Visual O
impairment O
is O
common O
among O
rural O
Chinese O
children, O
but O
fewer O
than O
a O
quarter O
of O
children O
who O
need O
glasses O
actually O
own O
and O
use O
them. O

For O
the O
secondary O
endpoint, O
from O
baseline O
to O
week O
24, O
the O
total O
number O
of O
new O
gadolinium-enhancing B-outcome
(Gd(+)) I-outcome
lesions I-outcome
was O
reduced O
by O
75% O
and O
the O
mean O
number O
of O
new/newly O
enlarging O
T2 B-outcome
hyperintense I-outcome
lesions I-outcome
was O
reduced O
by O
63% O
(both O
p O
< O
0.0001). O

A O
mixed O
analysis O
of O
variance O
(ANOVA) O
with O
repeated O
measures O
showed O
no O
significant O
effects O
for O
self-reported O
pain B-outcome
perception. O

BACKGROUND: O
Persistent O
post-surgical O
pain O
and O
associated O
disability O
are O
common O
after O
a O
traumatic O
fracture O
repair. O

Journal O
ID: O
0255562 O

The O
surgical B-outcome
findings I-outcome
and O
success B-outcome
rate O
in O
two O
subgroups O
were O
compared. O

Results: O
Operative B-outcome
time I-outcome
of O
the O
TAP O
group O
and O
parecoxib O
+ O
TAP O
group O
was O
significantly O
longer O
than O
that O
of O
the O
parecoxib O
group O
and O
control O
group. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

The O
trial O
was O
conducted O
at O
seven O
hospitals O
or O
clinics O
in O
Peru, O
Brazil, O
Colombia, O
Vietnam, O
and O
Thailand O
and O
involved O
patients O
with O
normal O
glucose-6-phosphate O
dehydrogenase O
(G6PD) O
enzyme O
activity O
and O
female O
patients O
with O
moderate O
G6PD O
enzyme O
deficiency; O
all O
patients O
had O
confirmed O
P. O
vivax O
parasitemia. O

CONCLUSION: O
Findings O
suggest O
that O
restricting O
elite O
sport O
sponsorship O
to O
healthier O
food O
brands O
that O
meet O
set O
nutritional O
criteria O
could O
help O
promote O
healthier O
eating O
among O
young O
adults. O

BACKGROUND: O
The O
aim O
of O
this O
analysis O
was O
to O
ascertain O
the O
type O
of O
relationship O
between O
fish O
and O
seafood O
consumption, O
omega-3 O
polyunsaturated O
fatty O
acids O
(omega-3 O
PUFA) O
intake, O
and O
depression B-outcome
prevalence. O

Publication O
date: O
2019/02/23 O
06:00 O
[medline] O

Pain B-outcome
score O
in O
the O
paracetamol O
group O
was O
significantly O
lower O
than O
that O
in O
the O
dexmedetomidine O
group O
(P O
= O
.04); O
nevertheless, O
there O
were O
no O
group O
differences O
in O
the O
mean O
scores O
of O
pain B-outcome
during O
these O
hours O
(P O
> O
.05). O

Intranasal O
DEX O
2 O
mug/kg O
is O
an O
effective O
and O
safe O
alternative O
for O
premedication O
in O
children. O

Assuming O
null O
hypothesis, O
80% O
power O
and O
5% O
alpha O
error, O
to O
detect O
a O
10% O
difference, O
adjusting O
for O
10% O
loss O
of O
follow O
up, O
sample O
size O
was O
204. O

METHODS: O
The O
central B-outcome
corneal I-outcome
endothelium I-outcome
was O
evaluated O
by O
serial O
specular O
microscopy O
at O
0 O
to O
24 O
months. O

All O
included O
patients O
were O
randomly O
allocated O
to O
a O
treatment O
group O
(n O
= O
43) O
or O
a O
sham O
group O
(n O
= O
43). O

Journal-Name:Medicine O

Journal-Name:Nutrients O

The O
subjects, O
who O
had O
inclusion O
criteria, O
were O
selected O
through O
convenience O
sampling O
based O
on O
inclusion O
criteria O
and O
randomly O
allocated O
into O
three O
groups. O

In O
addition, O
no O
adverse B-outcome
events I-outcome
related O
to O
the O
treatment O
were O
recorded O
in O
either O
group. O

Approximately O
6% O
of O
galcanezumab-treated O
patients O
maintained O
>/=75% O
response B-outcome
all O
6 O
months O
versus O
2% O
of O
placebo-treated O
patients. O

During O
the O
study O
period O
(0-12 O
months) O
mean O
total O
costs B-outcome
were O
lowest O
in O
the O
Combined-arm O
(euro476 O
vs. O
euro1062-euro1992, O
p O
< O
0.001) O
as O
were O
the O
mean O
number O
of O
sickness B-outcome
absence I-outcome
days O
(0.15 O
vs. O
2.29-4.17, O
p O
= O
0.025). O

METHODS: O
We O
randomly O
assigned O
adults O
attending O
U.K. O
National O
Health O
Service O
stop-smoking O
services O
to O
either O
nicotine-replacement O
products O
of O
their O
choice, O
including O
product O
combinations, O
provided O
for O
up O
to O
3 O
months, O
or O
an O
e-cigarette O
starter O
pack O
(a O
second-generation O
refillable O
e-cigarette O
with O
one O
bottle O
of O
nicotine O
e-liquid O
[18 O
mg O
per O
milliliter]), O
with O
a O
recommendation O
to O
purchase O
further O
e-liquids O
of O
the O
flavor O
and O
strength O
of O
their O
choice. O

Participants O
who O
underwent O
SCTG+CAF+EMD O
application O
were O
identified O
as O
the O
test O
group O
(n O
= O
19) O
and O
those O
who O
underwent O
SCTG+CAF O
as O
control O
group O
(n O
= O
19). O

Publication O
Type: O
Randomized O
Controlled O
Trial O

However, O
its O
effectiveness O
is O
controversial. O

We O
found O
significant O
positive O
correlations O
of O
Delta O
insulin-like B-outcome
growth I-outcome
factor-1 I-outcome
with O
initial O
and O
Delta O
values O
of: O
HOMA-IR B-outcome
, O
triglyceride/high-density B-outcome
cholesterol I-outcome
ratio I-outcome
, O
visceral B-outcome
adiposity I-outcome
index O
(VAI). O

Achaogen, O
South O
San O
Francisco, O
CA. O

Results: O
The O
age, O
sex O
ratio, O
body O
mass O
index O
(BMI) O
and O
ASA O
grading O
ratio O
in O
two O
groups O
were O
not O
significantly O
different(all O
P>0.05). O

METHODS: O
This O
pilot O
randomized O
controlled O
trial O
compared O
BZSF O
as O
an O
adjunctive O
therapy O
to O
ceftriaxone O
with O
ceftriaxone O
alone O
for O
Chinese O
female O
patients O
with O
uncomplicated O
gonorrhea. O

All O
three O
indicators O
of O
CHW O
functioning O
(as O
measured O
by O
reports O
submitted O
from O
CHWs) O
improved O
more O
in O
the O
intervention O
area O
relative O
to O
the O
comparison O
area, O
with O
2 O
out O
of O
3 O
measures O
of O
improvement O
reaching O
statistical O
significance. O

Publication O
date: O
2019/03/07 O
06:00 O
[medline] O

Dietary O
carbohydrate O
reduction O
has O
been O
suggested O
as O
non-pharmacological O
therapy O
for O
T2DM, O
but O
the O
acute O
effects O
on O
non-esterified B-outcome
fatty I-outcome
acid I-outcome
(NEFA) I-outcome
and O
triglyceride B-outcome
(TG) I-outcome
during O
subsequent O
meals O
remain O
to O
be O
investigated. O

However, O
consistent O
with O
previous O
research, O
we O
present O
further O
evidence O
of O
a O
role O
for O
active B-outcome
B12 I-outcome
, O
HcY B-outcome
and O
folate B-outcome
in O
supporting O
cognitive B-outcome
improvement O
in O
adults O
with O
low O
B O
vitamin O
status. O

Title: O
Role O
of O
Lactobacillus O
rhamnosus O
(FloraActive) O
19070-2 O
and O
Lactobacillus O
reuteri O
(FloraActive) O
12246 O
in O
Infant O
Colic: O
A O
Randomized O
Dietary O
Study. O

This O
trial O
began O
in O
January O
2013 O
and O
was O
registered O
with O
the O
UMIN O
Clinical O
Trials O
Registry O
(UMIN000009634). O

Journal O
ID: O
101281800 O

316 O
(29%) O
of O
1093 O
infants O
in O
the O
intervention O
group O
acquired O
a O
late-onset O
infection B-outcome
versus O
334 O
(31%) O
of O
1089 O
in O
the O
control O
group. O

Baseline O
characteristics O
were O
comparable O
between O
both O
groups. O

CONCLUSIONS: O
This O
study O
concluded O
that O
if O
targeting O
the O
increasing O
worldwide O
obesity O
problem O
through O
workplace O
initiated O
weight O
loss O
programs, O
the O
sales O
pitch O
to O
managements O
and O
employers O
have O
to O
be O
tailored O
in O
order O
to O
increase O
the O
participation O
and O
the O
motivation O
for O
the O
initiative. O

In O
conclusion, O
intraduodenal O
infusion O
of O
L-valine, O
at O
loads O
that O
are O
moderately O
(3.3 O
g) O
or O
substantially O
(9.9 O
g) O
above O
World O
Health O
Organization O
valine O
requirement O
recommendations, O
does O
not O
appear O
to O
have O
energy B-outcome
intake I-outcome
- O
or O
blood B-outcome
glucose I-outcome
-lowering O
effects. O

OBJECTIVES: O
To O
study O
if O
four O
cycles O
of O
remote O
ischemic O
preconditioning O
(RIPC) O
could O
offer O
protection O
against O
contrast B-outcome
induced I-outcome
nephropathy I-outcome
(CIN) I-outcome
and O
post O
procedural O
renal B-outcome
dysfunction I-outcome
in O
high O
risk O
patients O
undergoing O
percutaneous O
coronary O
intervention O
(PCI). O

Journal O
ID: O
101521595 O

A O
prenatal O
diet O
affects O
materno-foetal O
outcomes. O

Publication O
date: O
2019/01/20 O
06:00 O
[entrez] O

Journal O
ID: O
101234168 O

DESIGN: O
A O
parallel-group O
randomized O
controlled O
trial. O

However, O
blood O
loss O
and O
fibrinolytic O
activity, O
accounting O
for O
a O
poor O
prognosis O
following O
TKA O
operation, O
were O
relieved O
by O
fibrinolytic O
inhibitor O
tranexamic O
acid O
(TXA). O

108 O
(27%) O
of O
394 O
patients O
in O
the O
ixazomib O
group O
and O
51 O
(20%) O
of O
259 O
patients O
in O
the O
placebo O
group O
experienced O
serious B-outcome
adverse I-outcome
events I-outcome
. O
During O
the O
treatment O
period, O
one O
patient O
died B-outcome
in O
the O
ixazomib O
group O
and O
none O
died B-outcome
in O
the O
placebo O
group. O

Participants O
were O
randomized O
in O
a O
1:1 O
ratio O
to O
receive O
either O
800 O
mug O
of O
misoprostol O
or O
placebo O
sublingually O
if O
PPH O
was O
diagnosed, O
having O
previously O
received O
a O
prophylactic O
oral O
dose O
of O
600 O
mug O
misoprostol. O

RESULTS: O
the O
adaptive B-outcome
capacity I-outcome
was O
measured O
in O
two O
modes. O

The O
control O
group O
(n O
= O
43) O
was O
only O
received O
HRT. O

Title: O
Performance O
of O
Litholyme O
compared O
with O
Sodasorb O
carbon O
dioxide O
absorbents O
in O
a O
standard O
clinical O
setting. O

Journal O
ID: O
101599229 O

Journal O
ID: O
101521595 O

Publication O
date: O
['2019/10/16 O
06:00' O

Publication O
Type: O
Randomized O
Controlled O
Trial O

CONCLUSION: O
Longitudinal O
profiling O
is O
an O
essential O
tool O
for O
improving O
our O
understanding O
of O
the O
microbiology O
of O
chronic O
wounds, O
as O
community O
dynamics O
associated O
with O
clinical O
events O
can O
only O
be O
identified O
by O
examining O
changes O
over O
multiple O
time O
points. O

The O
median O
opioid B-outcome
use I-outcome
in O
24 O
hours O
after O
operation O
in O
the O
paracetamol O
group O
was O
lower O
when O
compared O
with O
that O
in O
the O
dexmedetomidine O
group, O
and O
the O
mean O
duration B-outcome
of I-outcome
analgesia I-outcome
in O
the O
paracetamol O
group O
was O
higher O
when O
comparing O
with O
dexmedetomidine O
group. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

DISCUSSION: O
This O
trial O
is O
designed O
to O
confirm O
the O
effectiveness O
of O
Simvastatin O
to O
protect O
healthy O
and O
steatotic O
livers O
undergoing O
cold O
storage O
and O
warm O
reperfusion O
before O
transplantation O
and O
to O
evaluate O
if O
the O
addition O
of O
Simvastatin O
translates O
into O
improved O
graft B-outcome
outcomes. O

The O
future O
researches O
with O
longer O
pursuing O
period's O
efficacy O
continuation O
are O
suggested. O

Publication O
Type: O
Journal O
Article O

METHODS: O
In O
this O
experimental O
human O
laboratory O
study, O
participants O
(n O
= O
128) O
were O
randomised O
to O
a O
self-affirmation O
or O
control O
group. O

Crossover O
to O
the O
sorafenib O
group O
was O
permitted O
for O
patients O
in O
the O
placebo O
group O
who O
had O
disease O
progression. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

INTERPRETATION: O
Front-line O
treatment O
with O
A+CHP O
is O
superior O
to O
CHOP O
for O
patients O
with O
CD30-positive O
peripheral O
T-cell O
lymphomas O
as O
shown O
by O
a O
significant O
improvement O
in O
progression-free B-outcome
survival I-outcome
and O
overall B-outcome
survival I-outcome
with O
a O
manageable O
safety O
profile. O

Randomization O
began O
on O
November O
8, O
2010. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Journal O
ID: O
100968562 O

Journal-Name:BMC O
public O
health O

Publication O
Type: O
Journal O
Article O

Patients O
were O
tested O
4 O
weeks O
post-treatment O
to O
confirm O
eradication. O

Journal-Name:Medicine O

Little O
is O
known O
regarding O
the O
optimal O
method O
of O
instruction O
for O
this O
critical O
skill. O

Title: O
A O
Fully O
Automated O
Method O
for O
the O
Determination O
of O
Serum O
Belatacept O
and O
Its O
Application O
in O
a O
Pharmacokinetic O
Investigation O
in O
Renal O
Transplant O
Recipients. O

Journal-Name:Zhonghua O
liu O
xing O
bing O
xue O
za O
zhi O
= O
Zhonghua O
liuxingbingxue O
zazhi O

BACKGROUND: O
Observational O
data O
have O
shown O
that O
slow O
advancement O
of O
enteral O
feeding O
volumes O
in O
preterm O
infants O
is O
associated O
with O
a O
reduced O
risk O
of O
necrotizing O
enterocolitis O
but O
an O
increased O
risk O
of O
late-onset O
sepsis. O

The O
haemoglobin B-outcome
and O
hematocrit B-outcome
were O
recorded; O
the O
total O
blood B-outcome
loss I-outcome
and O
intraoperative O
blood B-outcome
loss I-outcome
were O
calculated. O

However, O
there O
was O
a O
statistically O
significant O
improvement O
in O
child O
and O
parent O
reported O
pain B-outcome
, O
coordination B-outcome
and O
grip B-outcome
strength I-outcome
in O
both O
groups. O

Systolic B-outcome
(SBP) I-outcome
and X
mean X
(MBP) X
blood I-outcome
pressure I-outcome
, O
and O
cardiac B-outcome
index O
(CI) O
were O
related O
to O
time O
after O
polynomial O
transformation, O
and O
showed O
an O
increase O
after O
intubation O
in O
Group O
SM O
but O
a O
decrease O
in O
Group O
S O
(Ptime2*group<0.0001). O

RESULTS: O
The O
number O
of O
task B-outcome
repetitions I-outcome
required O
to O
reach O
the O
learning O
curve O
plateau O
was O
45, O
42, O
and O
37 O
repetitions O
in O
groups O
I, O
II, O
and O
III, O
which O
means O
that O
there O
was O
continuous O
improvement O
in O
performing B-outcome
the Seperator
task I-outcome
after O
40 O
repetitions O
only O
in O
groups O
I O
and O
II. O

METHODS: O
In O
this O
prospective, O
controlled O
study, O
60 O
age-related O
cataract O
patients O
with O
mild O
Meibomian O
gland O
dysfunction O
(MGD) O
were O
randomized O
to O
treatment O
with O
an O
ocular O
bandage O
contact O
lens O
(BCL) O
(n O
= O
30) O
or O
to O
an O
untreated O
control O
group O
(n O
= O
30) O
after O
phacoemulsification O
and O
intraocular O
lens O
implantation. O

This O
study O
adds O
to O
a O
growing O
body O
of O
research O
showing O
that O
TC O
may O
be O
effective O
in O
treating O
depression O
of O
the O
elderly. O

At O
10 O
minutes O
after O
the O
beginning O
of O
atomization, O
the O
inspiratory B-outcome
tidal I-outcome
volume I-outcome
monitored O
by O
ventilator O
in O
different O
preset O
suction O
pressure O
groups O
was O
significantly O
lower O
than O
tidal B-outcome
volume I-outcome
showed O
by O
simulated O
water O
lung O
(mL: O
917.33+/-4.51 O
vs. O
1 O
103.33+/-5.77 O
at O
20 O
cmH2O O
of O
preset O
suction O
pressure O
and O
9 O
L/min O
of O
atomized O
oxygen O
flow, O
P O
< O
0.05), O
and O
exhaled B-outcome
tidal I-outcome
volume I-outcome
was O
significantly O
higher O
than O
tidal B-outcome
volume I-outcome
showed O
by O
simulated O
water O
lung O
(mL: O
1 O
433.33+/-4.73 O
vs. O
1 O
103.33+/-5.77 O
at O
20 O
cmH2O O
of O
preset O
suction O
pressure O
and O
9 O
L/min O
of O
atomized O
oxygen O
flow, O
P O
< O
0.05). O

Background: O
Foot O
and O
ankle O
characteristics O
and O
dynamic O
knee O
valgus O
differ O
in O
people O
with O
and O
without O
patellofemoral O
(PF) O
pain. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Title: O
Rectus O
Sheath O
Block O
(RSB) O
Analgesia O
Could O
Enhance O
Significantly O
the O
Patient O
Satisfaction B-outcome
Following O
Midline O
Laparotomy O
in O
Benign O
Disease O
and O
in O
Cancer: O
A O
Prospective O
Study O
With O
Special O
Reference O
to O
Nitrosative O
Stress O
Marker O
Nitrotyrosine B-outcome
(NT) I-outcome
Plasma O
Concentrations. O

Methods: O
Post O
hoc O
analysis O
of O
two O
multicenter, O
randomized, O
double-blind, O
vehicle-controlled O
Phase O
3 O
studies O
in O
moderate O
or O
severe O
acne. O

These O
findings O
may O
caution O
the O
use O
of O
erythromycin O
as O
empirical O
therapy O
in O
these O
patients. O

Asthma O
and O
body O
posture O
abnormalities O
in O
children O
and O
young O
people O
are O
major O
epidemiological O
problems O
worldwide. O

Journal-Name:Nutrients O

Other O
dentoalveolar B-outcome
changes O
in O
both O
groups O
were O
intrusion B-outcome
of I-outcome
the Seperator
maxillary I-outcome
first I-outcome
molars I-outcome
, O
and O
extrusion B-outcome
of I-outcome
the Seperator
mandibular I-outcome
first I-outcome
molars I-outcome
and Seperator
maxillary I-outcome
incisors S3-outcome
. O
The O
mentolabial B-outcome
sulcus I-outcome
was O
flattened, O
soft B-outcome
tissue I-outcome
convexity I-outcome
was O
reduced, O
and O
forward O
movement B-outcome
of I-outcome
mandibular I-outcome
soft I-outcome
tissues I-outcome
was O
seen O
after O
Herbst O
therapy. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Energy B-outcome
intake I-outcome
from O
a O
buffet-meal O
immediately O
after O
the O
infusions O
was O
quantified. O

Implants, O
titanium O
abutments, O
and O
provisional O
crowns O
were O
placed O
in O
healed O
ridges O
5 O
months O
following O
preservation O
after O
tooth O
extraction O
with O
recombinant O
human O
bone O
morphogenetic O
protein-2 O
(rhBMP-2). O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Antropyloroduodenal B-outcome
pressures I-outcome
, O
plasma O
cholecystokinin B-outcome
, O
blood B-outcome
glucose I-outcome
, O
appetite B-outcome
perceptions I-outcome
and O
gastrointestinal B-outcome
symptoms I-outcome
were O
measured O
during O
90-min O
intraduodenal O
infusions O
of O
L-valine O
at O
0.15 O
kcal/min O
(total: O
3.3 O
g) O
or O
0.45 O
kcal/min O
(total: O
9.9 O
g), O
or O
0.9% O
saline O
(control). O

CONCLUSIONS: O
Amongst O
patients O
undergoing O
surgical O
repair O
of O
open O
extremity O
fractures, O
high O
SPOC O
questionnaire O
scores O
at O
6 O
weeks O
post-surgery O
were O
predictive O
of O
persistent B-outcome
pain I-outcome
, O
reduced O
quality B-outcome
of I-outcome
life I-outcome
, O
and O
pain B-outcome
interference I-outcome
at O
1 O
yr. O

Journal O
ID: O
101225531 O

White O
sweet O
potato O
(WSP; O
Ipomoea O
batatas O
L.), O
used O
in O
traditional O
medicine O
in O
Brazil, O
Japan, O
and O
Taiwan, O
is O
a O
healthy O
carbohydrate O
source. O

Journal O
ID: O
101215359 O

Journal O
ID: O
16210490R O

Publication O
date: O
2018/12/29 O
06:00 O
[entrez] O

During O
induction O
chemotherapy, O
the O
incidence O
rates O
of O
leukocytopenia B-outcome
(43.3% O
vs. O
80%, O
P O
= O
0.003), O
thrombocytopenia B-outcome
(26.7% O
vs. O
56.7%, O
P O
= O
0.018), O
and O
nausea/vomiting B-outcome
(40% O
vs. O
66.7%, O
P O
= O
0.038) O
were O
significantly O
lower O
in O
the O
CC O
group O
than O
in O
the O
RC O
group. O

Plasma O
vitamins B-outcome
and O
phytonutrients B-outcome
were O
significantly O
correlated O
with O
ROS O
scavenging O
and O
DNA O
damage. O

Total O
180 O
patients O
were O
randomly O
divided O
into O
Group O
A O
in O
which O
patients O
received O
0.2% O
bio-adhesive O
chlorhexidine O
gel O
and O
Group O
B O
where O
patients O
received O
placebo O
gel O
in O
the O
extraction O
socket O
after O
removal O
of O
mandibular O
third O
molar. O

CONCLUSION: O
We O
propose O
that O
CSO O
intake O
may O
partly O
exert O
its O
benefits O
through O
immuno-inflammatory O
molecular O
regulation O
in O
PBMCs, O
while O
modulation O
of O
ICAM1 O
expression, O
an O
endothelial/vascular-related O
gene, O
may O
be O
more O
dependent O
on O
the O
type O
of O
fish O
consumed. O

RESULTS: O
After O
6-week O
treatment O
and O
2-week O
follow-up, O
although O
ET O
plus O
montelukast O
did O
not O
show O
better O
effectiveness O
in O
improving O
lung B-outcome
function I-outcome
, O
as O
evaluated O
by O
the O
forced B-outcome
expiratory I-outcome
volume I-outcome
in Seperator
1 I-outcome
second I-outcome
(FEV1) I-outcome
(P O
> O
.05) O
and O
FEV1/FVC B-outcome
(P O
> O
.05) O
than O
montelukast O
alone, O
significant O
relief O
in O
clinical B-outcome
symptoms I-outcome
(P O
< O
.01), O
and O
improvement O
in O
Quality B-outcome
of I-outcome
Life I-outcome
(P O
< O
.01) O
have O
achieved. O

The O
average O
available O
energy O
(calorie) O
content O
of O
a O
28 O
g O
serving O
of O
cashew O
nuts O
was O
137 O
kcal O
(+/-3.4 O
kcal O
SEM) O
and O
ranged O
from O
105 O
to O
151 O
kcal. O

The O
patients O
with O
exercise O
habit O
(n O
= O
31) O
showed O
lower O
incidence O
of O
pain B-outcome
than O
patients O
without O
exercise O
habit O
(n O
= O
26) O
(P O
= O
.002, O
P O
= O
.005, O
and O
P O
= O
.037 O
in O
overall, B-outcome
abdominal, B-outcome
and Seperator
shoulder B-outcome
pain E1-outcome
, O
respectively). O

This O
trial O
is O
registered O
with O
ClinicalTrials.gov, O
number O
NCT01777152. O

The O
secondary O
outcomes O
consisted O
of O
shoulder B-outcome
disorder I-outcome
, O
measured O
by O
the O
score O
of O
shoulder B-outcome
pain I-outcome
and O
disability B-outcome
index O
(SPADI)]; O
quality B-outcome
of I-outcome
life I-outcome
, O
assessed O
by O
the O
Short O
Form-36 O
questionnaire O
(SF-36)]; O
and O
any O
adverse B-outcome
events I-outcome
(AEs) I-outcome
during O
the O
treatment O
period. O

Trial O
Registration: O
ClinicalTrials.gov O
Identifier: O
NCT01656278. O

This O
trial O
was O
registered O
with O
ClinicalTrials.gov, O
number O
NCT02413372. O

Journal O
ID: O
8102988 O

Pain B-outcome
scores O
and O
the O
use B-outcome
of I-outcome
rescue I-outcome
analgesics I-outcome
were O
not O
significantly O
different O
between O
2 O
groups. O

Publication O
date: O
2019/02/12 O
06:00 O
[medline] O

Publication O
Type: O
Randomized O
Controlled O
Trial O

We O
enrolled O
522 O
patients O
with O
microscopically O
confirmed O
P. O
vivax O
infection O
(>100 O
to O
<100,000 O
parasites O
per O
microliter) O
and O
normal O
glucose-6-phosphate O
dehydrogenase O
(G6PD) O
activity O
(with O
normal O
activity O
defined O
as O
>/=70% O
of O
the O
median O
value O
determined O
at O
each O
trial O
site O
among O
36 O
healthy O
male O
volunteers O
who O
were O
otherwise O
not O
involved O
in O
the O
trial). O

Publication O
date: O
2018/12/17 O
00:00 O
[accepted] O

We O
studied O
whether O
a O
DHA O
supply O
modified O
plasma O
docosahexaenoic B-outcome
acid I-outcome
(DHA) I-outcome
and O
neurological B-outcome
and Seperator
intellectual B-outcome
functioning E1-outcome
in O
PKU. O

ETHNOPHARMACOLOGICAL O
RELEVANCE: O
Polygala O
tenuifolia O
Willdenow O
root O
extract O
(BT-11) O
has O
beneficial O
effects O
on O
central O
nervous O
system O
disorders O
in O
human. O

Journal O
ID: O
0374675 O

Maternal B-outcome
outcomes O
and O
other O
obstetric B-outcome
interventions I-outcome
did O
not O
differ O
between O
the O
strategies. O

Journal-Name:The O
New O
England O
journal O
of O
medicine O

The O
interventions O
were O
conducted O
by O
means O
of O
home O
visits O
over O
6 O
months. O

Publication O
date: O
2019/03/02 O
06:00 O
[medline] O

During O
the O
trial O
there O
were O
16 O
serious B-outcome
adverse I-outcome
events I-outcome
for O
infants O
in O
the O
lactoferrin O
group O
and O
10 O
for O
infants O
in O
the O
control O
group. O

At O
6 O
min, O
hemostasis B-outcome
was O
achieved O
in O
93.0% O
(238/256) O
of O
the O
HP O
group O
compared O
to O
77.3% O
(102/132) O
of O
the O
G O
+ O
T O
group O
(non-inferiority O
P O
< O
0.0001, O
superiority O
P O
< O
0.0001). O

The O
efficacy O
of O
PZQ O
will O
be O
evaluated O
in O
stool O
samples O
using O
the O
KK O
technique O
and O
real-time O
PCR O
as O
well O
as O
in O
urine O
using O
the O
point-of-care O
circulating O
cathodic O
antigen O
test O
and O
the O
up-converting O
phosphor, O
lateral O
flow, O
circulating O
anodic O
antigen O
assay. O

Journal-Name:Nutrients O

BACKGROUND: O
We O
examined O
whether O
enhancing O
self-affirmation O
among O
a O
population O
of O
drinkers, O
prior O
to O
viewing O
threatening O
alcohol O
pictorial O
health O
warning O
labels, O
would O
reduce O
defensive B-outcome
reactions I-outcome
and O
promote O
reactions B-outcome
related O
to O
behaviour O
change. O

For O
observed O
pain B-outcome
, O
ANOVA O
results O
did O
show O
a O
significant O
interaction O
(p O
< O
.05) O
between O
group O
and O
study O
interval. O

The O
sterol B-outcome
regulatory I-outcome
element-binding I-outcome
protein-1 I-outcome
(SREBP1) I-outcome
expression I-outcome
in O
endometrial O
tissues O
was O
detected O
by O
qRT-PCR. O

This O
study O
was O
performed O
in O
a O
double-blind, O
randomized O
crossover O
fashion O
consisting O
of O
two O
exhaustive O
exercise O
protocols. O

Electromyographic B-outcome
amplitude I-outcome
did O
not O
differ O
between O
limbs O
or O
groups O
at O
the O
end O
of O
the O
intervention. O

Compared O
to O
controls, O
subcutaneous B-outcome
and Seperator
intra-abdominal B-outcome
fat E1-outcome
reduced O
significantly O
with O
both O
diet O
(- O
12.5% O
and O
- O
12.0%) O
and O
exercise O
plus O
diet O
(- O
16.0% O
and O
- O
14.6%). O

FINDINGS: O
Between O
Feb O
1, O
2014, O
and O
Aug O
31, O
2016, O
2772 O
couples O
were O
randomly O
assigned O
to O
receive O
PICSI O
(n=1387) O
or O
ICSI O
(n=1385), O
of O
whom O
2752 O
(1381 O
in O
the O
PICSI O
group O
and O
1371 O
in O
the O
ICSI O
group) O
were O
included O
in O
the O
primary O
analysis. O

In O
patients O
with O
episodic O
migraine, O
>/=50% O
response O
was O
maintained O
in O
41.5 O
and O
41.1% O
of O
galcanezumab-treated O
patients O
(120 O
mg O
and O
240 O
mg, O
respectively) O
for O
>/=3 O
consecutive O
months O
(until O
patient's O
endpoint) O
and O
19.0 O
and O
20.5%, O
respectively, O
for O
6 O
consecutive O
months O
and O
was O
significantly O
greater O
than O
the O
21.4 O
and O
8.0% O
of O
placebo-treated O
patients O
at O
>/=3 O
and O
6 O
months O
consecutively O
(P O
< O
0.001). O

Journal O
ID: O
2985248R O

Main O
Outcomes O
and O
Measures: O
Independent O
coprimary O
outcomes O
were O
patient-reported O
persistence B-outcome
with O
P2Y12 O
inhibitor O
(defined O
as O
continued O
treatment O
without O
gap O
in O
use O
>/=30 O
days) O
and O
major B-outcome
adverse I-outcome
cardiovascular I-outcome
events I-outcome
(MACE) I-outcome
( O
death B-outcome
, O
recurrent B-outcome
MI I-outcome
, O
or O
stroke B-outcome
) O
at O
1 O
year O
among O
patients O
discharged O
with O
a O
prescription O
for O
clopidogrel O
or O
ticagrelor. O

Journal O
ID: O
101213819 O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Department O
of O
Pharmacy O
Practice, O
Sri O
Adichunchanagiri O
College O
of O
Pharmacy, O
B. O
G. O
Nagara, O
Karnataka, O
India. O

RESULTS: O
After O
treatment, O
patients O
in O
the O
Gua O
Sha O
group O
reported O
lower O
pain B-outcome
intensity I-outcome
(p<0.001) O
and O
better O
overall O
health B-outcome
status O
(p=0.002) O
compared O
to O
the O
waitlist O
group. O

In O
logistic O
regression O
models, O
treatment O
group O
membership O
was O
significantly O
associated O
with O
spectacle B-outcome
ownership I-outcome
(Odds O
Ratio O
[OR] O
= O
11.9, O
p O
< O
0.001) O
and O
wearing B-outcome
behavior I-outcome
(OR O
= O
7.2, O
p O
< O
0.001). O

Journal-Name:Lancet O
(London, O
England) O

Electromyographic B-outcome
amplitude I-outcome
and Seperator
median X
frequency S1-outcome
did O
not O
differ O
between O
limbs O
at O
the O
start O
of O
the O
intervention. O

The O
EMID O
study O
is O
a O
randomized O
and O
controlled O
clinical O
trial O
with O
two O
parallel O
groups O
and O
a O
12-month O
follow-up O
period. O

RESULTS: O
A O
2 O
(group) O
x O
2 O
(time) O
repeated O
measures O
ANOVA O
showed O
there O
was O
a O
significant O
main O
effect O
on O
time O
for O
increase O
in O
the O
composite O
strength B-outcome
score O
(p O
= O
.002, O
engp2 O
= O
.18). O

Hops, O
the O
immature O
inflorescences O
of O
the O
female O
hop O
plant O
(Humulus O
lupulus O
L.) O
are O
one O
of O
the O
main O
components O
of O
beer O
and O
provides O
flavor O
and O
bitterness. O

Journal-Name:Complementary O
therapies O
in O
clinical O
practice O

Publication O
Type: O
Clinical O
Trial, O
Phase O
III O

No O
serious B-outcome
adverse I-outcome
events I-outcome
occurred. O

Journal-Name:JAMA O

Journal-Name: O
Lin O
chuang O
er O
bi O
yan O
hou O
tou O
jing O
wai O
ke O
za O
zhi O
= O
Journal O
of O
clinical O
otorhinolaryngology, O
head, O
and O
neck O
surgery O

Journal-Name:Medicine O

The O
7-year O
biochemical B-outcome
failure-free I-outcome
survival I-outcome
(BCFFS) I-outcome
of O
the O
MHF O
and O
EHF O
groups O
were O
90.5 O
and O
57.1% O
in O
the O
low-risk O
group O
(p O
= O
0.154); O
83.5 O
and O
42.9% O
in O
the O
intermediate O
risk O
group O
(p O
= O
0.018); O
and O
41.7 O
and O
40.0% O
in O
the O
high O
risk O
group O
(p O
= O
0.786), O
respectively. O

At O
Month O
6, O
there O
was O
no O
significant O
difference O
between O
the O
groups O
(P O
= O
.85) O
with O
regard O
to O
analgesics B-outcome
and O
social B-outcome
impact. O

Meanwhile, O
active B-outcome
flexional I-outcome
angle I-outcome
and O
passive B-outcome
flexional I-outcome
angle I-outcome
in O
preoperative O
analgesia O
group O
were O
larger O
than O
that O
in O
postoperative O
analgesia O
group O
at O
72 O
hours O
post O
operation. O

Title: O
Baltimore O
CONNECT: O
A O
Randomized O
Trial O
to O
Build O
Partnership O
Between O
Community O
Organizations O
and O
a O
Local O
Health O
System. O

Both O
PPI O
and O
H2 O
blocker O
could O
inhibit O
acid B-outcome
reflux I-outcome
. O
LPR O
was O
diagnosed O
with O
reflux O
finding O
score O
and O
reflux O
symptom O
index. O

Journal O
ID: O
101249598 O

This O
was O
a O
post O
hoc O
investigation O
of O
serum O
noggin B-outcome
levels O
among O
TDT O
patients O
with O
osteoporosis O
who O
participated O
in O
a O
randomized, O
placebo-control, O
phase O
2b O
study. O

Journal-Name:The O
New O
England O
journal O
of O
medicine O

Journal O
ID: O
0374675 O

Journal-Name:Medicine O

OBJECTIVE: O
To O
evaluate O
the O
effect O
of O
lacrimal O
duct O
probing O
combined O
with O
tobramycin/dexamethasone O
eye O
drops O
or O
ointment O
on O
persistent O
CNLDO O
in O
children O
older O
than O
1-year-old. O

Yi O
xue O
ban O
= O
Journal O
of O
Peking O
University. O

Extracorporeal O
magnetic O
innervation O
(ExMI) O
is O
a O
relatively O
new O
conservative O
treatment O
method O
for O
UI. O

Journal O
ID: O
101126433 O

CONCLUSIONS: O
Omadacycline O
was O
noninferior O
to O
linezolid O
for O
the O
treatment O
of O
acute O
bacterial O
skin O
and O
skin-structure O
infections O
and O
had O
a O
similar O
safety O
profile. O
( O

The O
mean O
increase O
in O
peak B-outcome
oxygen I-outcome
uptake I-outcome
, O
relative O
to O
control, O
was O
greater O
following O
HIIT O
than O
MICT O
(2.4 O
vs. O
0.7 O
mL/kg/min). O

In O
terms O
of O
adverse B-outcome
reactions I-outcome
, O
the O
incidence O
of O
bone B-outcome
marrow I-outcome
suppression I-outcome
, O
gastrointestinal B-outcome
reaction I-outcome
and O
low-protein B-outcome
reaction I-outcome
was O
significantly O
lower O
in O
group O
A O
than O
that O
in O
group O
BP<0.05. O

There O
was O
no O
significant O
difference O
in O
intraoperative O
blood B-outcome
loss I-outcome
, O
total O
blood B-outcome
loss I-outcome
, O
hemoglobin B-outcome
and O
hematocrit B-outcome
before O
operation O
and O
at O
1 O
and O
3 O
days O
after O
operation, O
and O
C-reactive B-outcome
protein I-outcome
and O
erythrocyte B-outcome
sedimentation I-outcome
rate I-outcome
before O
operation O
and O
at O
1, O
3, O
and O
14 O
days O
between O
2 O
groups O
( O
P>0.05). O

Global B-outcome
health I-outcome
status O
showed O
a O
more O
favourable O
time O
course O
in O
the O
ATLG O
group O
compared O
with O
the O
non-ATLG O
group O
(p=0.02; O
treatment O
by O
visit O
interaction). O

Journal-Name:Medicine O

Mean O
steps/day B-outcome
were O
significantly O
lower O
in O
the O
intervention O
vs O
control O
group O
(adjusted O
mean O
difference O
= O
- O
336, O
95% O
CI: O
-612 O
to O
- O
60, O
p O
= O
0.02) O
at O
6 O
months. O

Methods: O
A O
total O
of O
52 O
women O
were O
included O
in O
the O
analysis: O
28 O
participants O
were O
allocated O
to O
the O
experimental O
group O
(EG) O
and O
24 O
to O
the O
control O
group O
(CG). O

RESULTS: O
Improved O
physical B-outcome
fitness I-outcome
was O
demonstrated O
in O
the O
exercise O
group O
by O
increases O
in O
median O
estimated O
VO2max O
(Baseline: O
43.41mls/kg/min; O
post-intervention: O
46.01mls/kg/min; O
p O
= O
0.03). O

SUBJECTS/METHODS: O
Samples O
from O
72 O
participants O
randomized O
to O
one O
of O
the O
following O
12-week O
intervention O
groups, O
FF O
(n O
= O
19), O
LF O
(n O
= O
19), O
CSO O
(n O
= O
17) O
or O
a O
control O
group O
(n O
= O
17), O
were O
available O
for O
the O
PBMC O
study. O

A O
sample O
of O
210 O
pregnant O
women O
within O
gestational O
ages O
of O
16-24 O
wk O
were O
recruited O
at O
antenatal O
clinics O
and O
equally O
randomized O
to O
either O
a O
two-dose O
SP O
or O
three-dose O
SP O
group. O

MATERIALS O
AND O
METHODS: O
Participants O
requiring O
replacement O
of O
single O
maxillary O
anterior O
and O
first O
premolar O
teeth O
were O
recruited O
and O
treated O
under O
an O
institutional O
review O
board O
(IRB)-approved O
protocol. O

However, O
Kruskal O
Wallis O
test O
did O
not O
show O
a O
significant O
relationship O
between O
the O
three O
positions O
under O
study O
and O
the O
mean O
gastric B-outcome
residual I-outcome
volume I-outcome
. O
CONCLUSION: O
Prone O
position O
was O
featured O
with O
the O
lowest O
gastric B-outcome
residual I-outcome
volume I-outcome
and O
highest O
possibility O
of O
absorbing B-outcome
nutrient I-outcome
. O
Still, O
given O
the O
fact O
that O
no O
significant O
difference O
was O
found O
in O
the O
three O
groups, O
further O
and O
deeper O
studies O
are O
needed. O

Rectal B-outcome
temperature I-outcome
, O
heart B-outcome
rate I-outcome
, O
thermal B-outcome
sensation I-outcome
, O
and O
ratings O
of O
perceived B-outcome
exertion I-outcome
were O
measured O
at O
various O
times O
before, O
during, O
and O
after O
exercise. O

CONCLUSIONS/SIGNIFICANCE: O
The O
extended O
treatment O
strategy O
with O
the O
combination O
regimen O
showed O
the O
highest O
documented O
efficacy O
in O
HIV-VL O
patients; O
these O
results O
support O
a O
recommendation O
of O
this O
regimen O
as O
first-line O
treatment O
strategy O
for O
HIV-VL O
patients O
in O
eastern O
Africa. O

Journal O
ID: O
2985248R O

Treatment B-outcome
failure I-outcome
occurred O
in O
74 O
of O
506 O
participants O
(14.6%) O
in O
the O
intravenous O
group O
and O
67 O
of O
509 O
participants O
(13.2%) O
in O
the O
oral O
group. O

Furthermore, O
trends O
for O
sex O
differences O
were O
discovered O
in O
urinary, O
but O
not O
salivary, O
hydration B-outcome
markers, O
with O
discrepancies O
in O
kinetics O
between O
fluid O
compartments O
both O
warranting O
further O
study. O

TRIAL O
REGISTRATION: O
This O
trial O
is O
registered O
on O
ClinicalTrials.gov O
(identifier: O
NCT01838668 O
), O
April O
20, O
2013 O
(retrospectively O
registered). O

4) O
Conclusion: O
The O
effects O
found O
in O
the O
present O
study O
agree O
with O
antihypertensive O
and O
antioxidant O
effects O
previously O
reported O
for O
Spirulina O
maxima. O

CONCLUSIONS:: O
We O
suggest O
that O
after O
reposition O
exercises, O
the O
pelvis O
was O
more O
symmetrically O
aligned O
in O
relation O
to O
body O
axis; O
therefore, O
the O
muscles O
of O
the O
pelvic O
floor O
have O
functional O
length O
and O
did O
not O
shorten O
or O
lengthen O
due O
to O
pelvis O
rotation. O

Title: O
Rehydrating B-outcome
efficacy O
of O
maple O
water O
after O
exercise-induced O
dehydration. O

Publication O
date: O
2018/10/29 O
00:00 O
[accepted] O

At O
D58, O
the O
adjusted O
efficacy O
was O
55% O
(95% O
CI O
32-78%) O
in O
the O
monotherapy O
arm, O
and O
88% O
(95% O
CI O
79-98%) O
in O
the O
combination O
arm. O

Title: O
The O
impact O
of O
unhealthy O
food O
sponsorship O
vs. O
pro-health O
sponsorship O
models O
on O
young O
adults' O
food B-outcome
preferences I-outcome
: O
a O
randomised O
controlled O
trial. O

Following O
a O
16-week O
washout O
phase, O
they O
consumed O
the O
alternative O
supplement. O

However, O
it O
was O
confirmed O
that O
they O
were O
not O
associated O
with O
the O
test O
product. O

Greater O
proclination B-outcome
and Seperator
more X
protrusion B-outcome
of I-outcome
mandibular I-outcome
incisors E3-outcome
were O
found O
in O
the O
IA O
group. O

Journal O
ID: O
101273480 O

Journal-Name:Nutrients O

We O
found O
no O
significant O
differences O
in O
the O
overall O
experience, O
helpfulness O
of O
the O
meeting, O
or O
stress O
levels O
of O
the O
meeting O
between O
those O
who O
met O
via O
videoconference O
vs. O
in-person O
(p=0.9909; O
p=0.8420; O
p=0.2352, O
respectively). O

2.1% O
reported O
thinking O
they O
would O
be O
better O
off O
dead O
or O
of O
hurting O
themselves O
in O
some O
way O
in O
the O
past O
2 O
weeks. O

Title: O
Corneal B-outcome
Endothelial I-outcome
Cell I-outcome
Density I-outcome
and Seperator
Morphology S3-outcome
After O
Phacoemulsification O
in O
Patients O
With O
Primary O
Open-Angle O
Glaucoma O
and O
Cataracts: O
2-Year O
Results O
of O
a O
Randomized O
Multicenter O
Trial. O

Significant O
differences O
were O
not O
observed O
in O
the O
remaining O
Makoto O
tests. O

Our O
results O
support O
the O
efficacy O
of O
vitamin O
D3 O
given O
monthly O
both O
for O
correcting O
hypovitaminosis B-outcome
and O
for O
maintaining O
vitamin O
D O
levels. O

BACKGROUND: O
This O
pilot O
study O
aimed O
to O
investigate O
the O
feasible O
effectiveness O
and O
safety O
of O
Bazhengsan O
formula O
(BZSF) O
as O
an O
adjunctive O
therapy O
to O
ceftriaxone O
for O
female O
patients O
with O
uncomplicated O
gonorrhea. O

Follow-up O
was O
completed O
December O
2017. O

Publication O
date: O
2019/02/14 O
06:00 O
[entrez] O

At O
T3, O
the O
intervention O
group O
still O
reported O
significantly O
higher O
self-efficacy B-outcome
to O
cope O
with O
stress O
(d O
= O
0.32) O
and O
better O
emotional O
coping B-outcome
response O
(d O
= O
0.34) O
than O
the O
comparison O
group O
but O
did O
not O
report O
significantly O
higher O
social B-outcome
support I-outcome
for O
stress O
management, O
stress B-outcome
, O
depressive B-outcome
symptoms I-outcome
, O
and O
positive B-outcome
and Seperator
negative B-outcome
affect E1-outcome
. O
CONCLUSIONS: O
To O
help O
young, O
low-income O
women O
with O
overweight O
or O
obesity O
manage O
stress, O
researchers O
and O
program O
planners O
may O
consider O
focusing O
on O
building O
self-efficacy B-outcome
to O
cope O
with O
stress. O

Objective: O
To O
determine O
whether O
a O
therapeutic O
strategy O
involving O
low-dose O
intracoronary O
fibrinolytic O
therapy O
with O
alteplase O
infused O
early O
after O
coronary O
reperfusion O
will O
reduce O
microvascular B-outcome
obstruction I-outcome
. O
Design, O
Setting, O
and O
Participants: O
Between O
March O
17, O
2016, O
and O
December O
21, O
2017, O
440 O
patients O
presenting O
at O
11 O
hospitals O
in O
the O
United O
Kingdom O
within O
6 O
hours O
of O
STEMI O
due O
to O
a O
proximal-mid-vessel O
occlusion O
of O
a O
major O
coronary O
artery O
were O
randomized O
in O
a O
1:1:1 O
dose-ranging O
trial O
design. O

Simulation O
has O
been O
shown O
in O
similar O
settings O
to O
enhance O
performance O
and O
knowledge. O

Journal O
ID: O
101476450 O

Journal O
ID: O
101479826 O

The O
differences O
of O
morbidity B-outcome
, O
pulmonary B-outcome
function I-outcome
, O
quality B-outcome
of I-outcome
life I-outcome
were O
compared O
between O
the O
two O
groups. O

Eighteen O
healthy O
adults O
were O
enrolled O
in O
a O
randomized, O
crossover O
study O
with O
two O
treatment O
periods. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Publication O
date: O
2019/02/28 O
06:00 O
[medline] O

Outcome O
measures O
used O
were O
Barthel O
index O
(BI)], O
modified O
Ashworth O
scale], O
manual O
muscle O
testing, O
and O
goniometry O
for O
range B-outcome
of I-outcome
motion I-outcome
(ROM) I-outcome
assessment. O

Journal O
ID: O
101479826 O

All O
analyses O
were O
performed O
with O
the O
use O
of O
proportional-hazards O
models O
in O
the O
per-protocol O
population O
(all O
participants O
who O
underwent O
randomization, O
met O
the O
inclusion O
criteria, O
and O
survived O
beyond O
the O
recruitment O
hospitalization) O
and O
as-treated O
population O
(participants O
stratified O
according O
to O
adherence). O

There O
was O
no O
difference O
in O
FPPA O
(knee O
valgus O
angle) O
between O
groups O
(15, O
0.63-377.99). O

Likely O
due O
to O
greater O
beverage O
osmolality O
(81 O
+/- O
1.4 O
vs. O
11 O
+/- O
0.7 O
mOsmol/kg), O
thirst B-outcome
sensation I-outcome
remained O
12% O
higher O
with O
MW O
(p O
< O
0.05). O

There O
were O
no O
statistical O
differences O
in O
the O
incidence O
of O
adverse B-outcome
reactions I-outcome
between O
the O
two O
groups. O

The O
patient O
satisfaction B-outcome
scores O
were O
significantly O
higher O
in O
the O
sedation O
group O
(Z=2.07, O
P O
&lt; O
0.05). O

In O
acute, O
the O
maximum O
levels O
of O
resveratrol B-outcome
(RSV) I-outcome
were O
detected O
both O
in O
serum O
and O
whole O
blood O
60 O
min O
after O
the O
administration O
of O
Taurisolo((R)); O
in O
chronic, O
a O
significant O
increase O
of O
resveratrol B-outcome
(RSV) I-outcome
was O
detected O
in O
serum O
after O
the O
4-week O
treatment. O

Methods: O
Participants O
(n O
= O
30) O
came O
to O
the O
lab O
on O
three O
consecutive O
days O
after O
being O
overnight O
smoking O
abstinent. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Title: O
Menthol O
chewing O
gum O
on O
preoperative O
thirst B-outcome
management: O
randomized O
clinical O
trial. O

Publication O
date: O
2019/02/26 O
06:00 O
[medline] O

Patients O
with O
clinically O
diagnosed O
osteoarthritis O
of O
knee O
were O
injected O
either O
Triamcinolone O
or O
Placebo O
after O
recording O
the O
baseline O
scores O
of O
the O
knee O
by O
Knee O
injury O
and O
Osteoarthritis O
Outcome O
Score O
(KOOS) O
- O
Physical O
Function O
Short O
form O
(KOOS-PS), O
the O
Western O
Ontario O
and O
McMaster O
Universities O
Osteoarthritis O
Index O
(WOMAC) O
and O
Visual O
Analogue O
Scale O
(VAS). O

Vaping O
did O
not O
affect O
exhaled B-outcome
CO I-outcome
. O
Cigarette B-outcome
craving I-outcome
reduced O
significantly O
after O
product O
use, O
with O
the O
decline O
being O
stronger O
for O
smoking O
than O
for O
e-cigarettes O
or O
IQOS(TM). O

CONCLUSION: O
This O
study O
demonstrated O
the O
potential O
benefits O
and O
high O
clinical O
relevance O
of O
exercise O
programs O
to O
improve O
quality B-outcome
of I-outcome
life I-outcome
in O
older O
breast O
cancer O
survivors O
undergoing O
aromatase O
inhibitor O
therapy. O

Department O
of O
Pharmacy O
Practice, O
Sri O
Adichunchanagiri O
College O
of O
Pharmacy, O
B. O
G. O
Nagara, O
Karnataka, O
India O
- O
rajesh.venkyresearch01@gmail.com. O

Objective: O
To O
evaluate O
the O
effect O
of O
postoperative O
intravenous O
(IV) O
acetaminophen O
(paracetamol) O
vs O
placebo O
combined O
with O
IV O
propofol O
vs O
dexmedetomidine O
on O
postoperative O
delirium B-outcome
among O
older O
patients O
undergoing O
cardiac O
surgery. O

Journal-Name:Medicine O

Osteoporosis O
is O
a O
common O
complication O
of O
transfusion O
dependent O
beta-thalassemia O
(TDT) O
and O
denosumab O
has O
been O
recently O
emerged O
as O
a O
promising O
therapeutic O
option. O

Journal O
ID: O
101215702 O

Title: O
"We O
find O
what O
we O
look O
for, O
and O
we O
look O
for O
what O
we O
know": O
factors O
interacting O
with O
a O
mental O
health O
training O
program O
to O
influence O
its O
expected O
outcomes O
in O
Tunisia. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

All O
biomarkers O
of O
metabolic B-outcome
recovery I-outcome
were O
equivalent O
when O
evaluating O
R1 O
v O
R2. O

Stratified O
by O
country, O
patients O
were O
randomized O
1:1 O
to O
receive O
DMF O
240 O
mg O
twice O
daily O
or O
placebo. O

Qualitative O
data O
was O
analyzed O
using O
thematic O
analysis. O

CLINICAL O
SIGNIFICANCE: O
Curcumin O
gel O
as O
an O
adjunct O
to O
SRP O
showed O
a O
marked O
improvement O
in O
restoring O
gingival B-outcome
health I-outcome
by O
an O
improvement O
in O
clinical O
parameters. O

Title: O
Effect O
of O
a O
short-term O
low O
fermentable O
oligiosaccharide, O
disaccharide, O
monosaccharide O
and O
polyol O
(FODMAP) O
diet O
on O
exercise-related O
gastrointestinal B-outcome
symptoms I-outcome
. O

Journal O
ID: O
0255562 O

BACKGROUND: O
Although O
conventional O
60 O
mg O
of O
prasugrel O
allows O
for O
rapid O
and O
potent O
platelet O
inhibition O
within O
30 O
min O
after O
loading O
dose, O
the O
efficacy O
and O
safety O
of O
lower O
doses O
of O
prasugrel O
in O
Indian O
patients O
has O
not O
yet O
been O
investigated. O

Journal-Name:Zhong O
nan O
da O
xue O
xue O
bao. O

Whether O
positive-pressure O
ventilation O
with O
a O
bag-mask O
device O
(bag-mask O
ventilation) O
during O
tracheal O
intubation O
of O
critically O
ill O
adults O
prevents O
hypoxemia O
without O
increasing O
the O
risk O
of O
aspiration O
remains O
controversial. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Objective: O
To O
assess O
whether O
EEG-guided O
anesthetic O
administration O
decreases O
the O
incidence O
of O
postoperative O
delirium B-outcome
. O
Design, O
Setting, O
and O
Participants: O
Randomized O
clinical O
trial O
of O
1232 O
adults O
aged O
60 O
years O
and O
older O
undergoing O
major O
surgery O
and O
receiving O
general O
anesthesia O
at O
Barnes-Jewish O
Hospital O
in O
St O
Louis. O

Journal O
ID: O
7501160 O

RESULTS: O
All O
mandibular B-outcome
skeletal I-outcome
dimensions O
increased, O
and O
improvements O
of O
the O
sagittal B-outcome
maxillomandibular I-outcome
parameters O
were O
found O
in O
both O
groups. O

Journal-Name:Medicine O

Most O
subjects O
were O
vitD(3) O
deficient O
at O
enrolment, O
but O
a O
gradual O
and O
significant O
improvement O
of O
vitD(3) B-outcome
status O
was O
demonstrated O
in O
the O
vitD(3) O
+ O
PBA O
group O
compared O
with O
placebo O
(p O
< O
0.0001) O
from O
week O
0 O
to O
16 O
(median O
37.5 O
versus O
115.5 O
nmol/L). O

In O
the O
current O
clinical O
trial, O
we O
examined O
the O
antioxidant B-outcome
and O
DNA B-outcome
protection I-outcome
capacity O
of O
a O
plant-based, O
multi-vitamin/mineral, O
and O
phytonutrient O
(PMP) O
supplementation O
in O
healthy O
adults O
who O
were O
habitually O
low O
in O
the O
consumption O
of O
fruits O
and O
vegetables. O

BACKGROUND: O
Registered O
healthcare O
workers O
worldwide O
have O
a O
high O
prevalence O
of O
work-related O
musculoskeletal O
disorders, O
particularly O
of O
the O
back. O

Conclusion: O
Supraglottic O
tracheal O
tube O
ventilation O
for O
painless O
fiberbronchoscopy O
is O
a O
safe O
and O
effective O
procedure. O

Journal O
ID: O
2985248R O

At O
baseline, O
mean O
(SD) O
duration O
of O
cry B-outcome
and Seperator
fuss B-outcome
time E1-outcome
was O
comparable O
in O
the O
probiotic O
and O
control O
groups: O
305 O
(81) O
vs. O
315 O
(90) O
min., O

Journal-Name:Oncology O
reports O

Title: O
The O
use O
of O
ETView O
endotracheal O
tube O
for O
surveillance O
after O
tube O
positioning O
in O
patients O
undergoing O
lobectomy, O
randomized O
trial. O

To O
this O
end, O
we O
tested O
the O
effects O
of O
two O
commercially-available O
drinks O
on O
strength O
in O
a O
field-based O
setting O
with O
both O
male O
and O
female O
high O
school O
athletes O
completing O
a O
summer O
training O
program. O

METHODS: O
We O
randomly O
assigned O
609 O
patients O
with O
complicated O
urinary O
tract O
infections O
(UTIs), O
including O
acute O
pyelonephritis, O
in O
a O
1:1 O
ratio O
to O
receive O
intravenous O
plazomicin O
(15 O
mg O
per O
kilogram O
of O
body O
weight O
once O
daily) O
or O
meropenem O
(1 O
g O
every O
8 O
hours), O
with O
optional O
oral O
step-down O
therapy O
after O
at O
least O
4 O
days O
of O
intravenous O
therapy, O
for O
a O
total O
of O
7 O
to O
10 O
days O
of O
therapy. O

Journal O
ID: O
7501160 O

The O
ETView O
single O
lumen O
endotracheal O
tube O
had O
fewer O
associated O
complications B-outcome
and O
is O
superior O
to O
the O
2 O
double-lumen O
tubes. O

DISCUSSION: O
Halitosis O
treatment O
is O
a O
topic O
that O
still O
needs O
attention. O

Journal O
ID: O
0374675 O

This O
tendency O
of O
the O
improvement O
was O
maintained, O
in O
favour O
of O
the O
IG, O
at O
the O
12-month O
follow-up O
visit. O

There O
was O
a O
significant O
interaction O
of O
composite O
strength B-outcome
score O
between O
groups, O
(p O
= O
.04, O
engp2 O
= O
.08). O

Journal O
ID: O
2985213R O

They O
were O
randomly O
assigned O
to O
either O
neoadjuvant O
chemotherapy O
or O
upfront O
surgery. O

REGISTRATION: O
This O
trial O
was O
registered O
at O
ClinicalTrials.govNCT01925924. O

Secondary O
endpoints O
include O
symptomatic B-outcome
malaria I-outcome
, O
Polymerase O
Chain O
Reaction O
(PCR)-detectable O
Plasmodium B-outcome
spp I-outcome
Infections I-outcome
, O
molecular O
markers O
of O
drug B-outcome
resistance I-outcome
and O
antibodies B-outcome
specific I-outcome
for Seperator
Plasmodium I-outcome
spp I-outcome
Parasites I-outcome
. O
DISCUSSION: O
This O
study O
has O
been O
approved O
by O
relevant O
institutional O
ethics O
committees O
in O
Myanmar O
and O
Australia. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

BACKGROUND: O
Mothers O
of O
preterm O
infants O
often O
have O
symptoms O
of O
anxiety O
and O
depression, O
recognized O
as O
risk O
factors O
for O
the O
development O
of O
cardiovascular O
diseases O
and O
associated O
with O
low O
rates O
of O
heart O
rate O
variability O
(HRV). O

Participants O
recovered O
in O
a O
similar O
time-dependent O
manner O
in O
all O
markers O
of O
metabolism B-outcome
following O
the O
PLA O
and O
CA O
+ O
C O
trials. O

Results: O
A O
total O
of O
240 O
of O
279 O
patients O
(129 O
females O
and O
111 O
male) O
aged O
18 O
- O
65 O
years O
were O
referred O
and O
integrated O
in O
this O
clinical O
trial, O
whereas O
29 O
were O
rejected O
as O
not O
completing O
the O
requirements O
needed. O

PATIENT O
AND O
METHODS: O
We O
propose O
a O
prospective, O
double-blinded, O
randomized O
phase O
2 O
study O
of O
2 O
parallel O
groups O
of O
eligible O
adult O
patients. O

Methods: O
A O
feasibility O
randomized O
control O
trial O
allowed O
for O
comparison O
of O
PICIHBI O
and O
conventional O
one-on-one O
occupational O
therapy O
interventions. O

Study O
1 O
tested O
8-week O
group-based O
Monitor O
+ O
Accept O
and O
Monitor O
Only O
interventions O
compared O
with O
a O
no O
treatment O
control O
group. O

Title: O
Effect O
of O
the O
soft-tissue O
techniques O
in O
the O
quality B-outcome
of I-outcome
life I-outcome
in O
patients O
with O
Crohn's O
disease: O
A O
randomized O
controlled O
trial. O

Tai O
Chi O
as O
a O
mild O
to O
moderate O
mind-body O
exercise O
is O
suitable O
for O
older O
individuals O
who O
suffer O
from O
depression. O

CONCLUSION: O
While O
methohexital O
was O
shown O
to O
confer O
greater O
hemodynamic B-outcome
stability O
in O
patients O
taking O
ACEi/ARB, O
the O
measured O
hormone B-outcome
levels O
could O
not O
explain O
the O
mechanism O
for O
this O
effect. O

RESULTS: O
In O
the O
modified O
intention-to-treat O
population, O
omadacycline O
(316 O
patients) O
was O
noninferior O
to O
linezolid O
(311 O
patients) O
with O
respect O
to O
early O
clinical O
response O
(rate O
of O
response, O
84.8% O
and O
85.5%, O
respectively; O
difference, O
-0.7 O
percentage O
points; O
95% O
confidence O
interval O
[CI], O
-6.3 O
to O
4.9). O

Therefore, O
we O
conducted O
this O
study O
to O
determine O
the O
95% O
effective O
dose B-outcome
(ED95) O
of O
intrathecal O
hyperbaric O
ropivacaine O
for O
cesarean O
section O
in O
parturients O
receiving O
prophylactic O
infusion O
of O
phenylephrine O
to O
prevent O
spinal-induced O
hypotension. O

The O
view O
from O
the O
tip O
appears O
continuously O
on O
a O
portable O
monitor O
in O
the O
anesthesia O
area. O

Journal-Name:Therapeutic O
drug O
monitoring O

BACKGROUND O
AND O
PURPOSE: O
There O
is O
a O
need O
to O
investigate O
the O
effects O
of O
pilates O
exercises O
on O
the O
quality B-outcome
of I-outcome
life I-outcome
(QOL) I-outcome
of O
patients O
with O
chronic O
kidney O
diseases O
(CKD). O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Publication O
date: O
2018/12/14 O
06:00 O
[entrez] O

Publication O
date: O
2019/01/05 O
06:00 O
[medline] O

Bilateral O
strength O
training O
did O
not O
correct O
the O
unilateral O
strength B-outcome
deficit I-outcome
observed O
in O
this O
group O
of O
survivors O
of O
breast O
cancer. O

RESULTS: O
Overall, O
834 O
patients O
with O
minor O
stroke O
were O
included O
in O
this O
subgroup, O
553 O
SAI O
(381 O
lacunar O
infarction, O
172 O
non-lacunar O
infarction) O
and O
281 O
MAIs. O

Publication O
date: O
2018/12/04 O
00:00 O
[accepted] O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Complication B-outcome
rates O
in O
all O
strategy O
groups O
were O
significantly O
lower O
than O
in O
the O
control O
group; O
however, O
no O
significant O
difference O
was O
found O
among O
the O
strategy O
groups. O

Resting O
blood O
samples O
were O
collected O
prior O
to O
and O
on O
completion O
of O
each O
diet O
to O
determine O
plasma O
intestinal B-outcome
fatty I-outcome
acid I-outcome
binding I-outcome
protein I-outcome
(I-FABP) I-outcome
as O
a O
marker O
of O
acute B-outcome
GI I-outcome
injury I-outcome
. O
RESULTS: O
Overall O
Irritable B-outcome
Bowel I-outcome
Syndrome-Severity I-outcome
Scoring O
System O
(IBS-SSS) O
score O
significantly O
reduced O
in O
the O
LOWFODMAP O
condition O
from O
81.1 O
+/- O
16.4 O
to O
31.3 O
+/- O
9.2 O
(arbitrary O
units; O
P O
= O
0.004). O

Title: O
Using O
the O
Borg O
rating O
of O
perceived B-outcome
exertion I-outcome
scale O
to O
grade O
the O
intensity B-outcome
of O
a O
functional O
training O
program O
of O
the O
affected O
upper O
limb O
after O
a O
stroke: O
a O
feasibility O
study. O

Journal-Name:BMC O
ophthalmology O

FUNDING: O
Seattle O
Genetics O
Inc, O
Millennium O
Pharmaceuticals O
Inc, O
a O
wholly O
owned O
subsidiary O
of O
Takeda O
Pharmacuetical O
Company O
Limited, O
and O
National O
Institutes O
of O
Health O
National O
Cancer O
Institute O
Cancer O
Center. O

A O
noninferiority O
margin O
of O
10 O
percentage O
points O
was O
used. O

Efficacy O
was O
evaluated O
again O
at O
day O
58, O
after O
completion O
of O
treatment. O

Journal-Name:International O
journal O
of O
environmental O
research O
and O
public O
health O

TPI O
group O
received O
TPIs O
with O
2 O
mL O
of O
0.2% O
ropivacaine, O
and O
EMLA O
group O
received O
an O
occlusive O
dressing O
with O
EMLA O
cream O
2 O
g O
on O
both O
shoulders. O

METHODS: O
We O
conducted O
a O
case O
study O
with O
a O
purposeful O
sample O
of O
18 O
trained O
PCPs. O

The O
most O
common O
adverse B-outcome
event I-outcome
was O
mucocutaneous B-outcome
bleeding I-outcome
, O
which O
was O
reported O
in O
65% O
of O
the O
patients O
in O
the O
caplacizumab O
group O
and O
in O
48% O
in O
the O
placebo O
group. O

Publication O
date: O
2019/01/29 O
06:00 O
[medline] O

Anticoagulants O
are O
effective O
as O
venous O
thromboprophylaxis, O
but O
with O
an O
increased O
risk O
of O
bleeding. O

Publication O
date: O
2019/03/01 O
06:00 O
[medline] O

After O
4 O
weeks, O
the O
levels O
of O
Trimethylamine B-outcome
N-oxide I-outcome
(TMAO) I-outcome
were O
significantly O
decreased O
in O
the O
treatment O
group O
compared O
to O
placebo O
(63.6% O
vs. O
0.54%, O
respectively, O
P O
< O
0.0001). O

The O
potential O
role O
of O
the O
clinical O
assessment O
of O
peripheral O
perfusion O
as O
a O
target O
during O
resuscitation O
in O
early O
septic O
shock O
has O
not O
been O
established. O

Pulpectomy O
was O
performed O
on O
27 O
primary O
teeth O
with O
necrosis O
or O
irreversible O
pulpitis, O
caused O
by O
dental O
caries O
or O
trauma, O
in O
23 O
children O
(2-7 O
years O
old). O

Funded O
by O
Ablynx; O
HERCULES O
ClinicalTrials.gov O
number, O
NCT02553317 O
.). O

3) O
Compared O
with O
combination O
group, O
improvement O
of O
sleep B-outcome
onset I-outcome
latency I-outcome
(SOL) I-outcome
and O
sleep B-outcome
efficiency I-outcome
(SE) I-outcome
in O
CBT-i O
group O
was O
superior O
(both O
P=0.01). O

The O
median O
intervention O
period O
was O
3.34 O
years. O

RESULTS: O
Sixty-five O
patients O
completed O
the O
study, O
including O
33 O
in O
the O
control O
group O
and O
32 O
in O
the O
treatment O
group. O

For O
all O
analyses O
a O
level O
of O
significance O
of O
95% O
(P O
< O
.05) O
will O
be O
considered. O

The O
Delta O
heart B-outcome
rate I-outcome
and O
Delta O
cardiac B-outcome
output O
values O
were O
lower O
in O
the O
Group O
R O
(P O
= O
.02 O
and O
P O
= O
.04, O
respectively). O

Because O
of O
the O
time O
spent O
at O
the O
workplace, O
workplaces O
can O
be O
optimal O
arenas O
for O
weight O
loss O
programs O
and O
these O
programs O
have O
been O
effective O
to O
decrease O
body O
weight. O

This O
could O
fill O
the O
gap O
between O
devices O
that O
fully O
compensate O
for O
walking O
and O
those O
which O
allow O
patients O
to O
maintain O
residual O
mobility. O

Publication O
Type: O
Journal O
Article O

This O
study O
was O
an O
exploratory O
analysis O
to O
investigate O
the O
secondary O
end-point O
of O
biochemical B-outcome
failure-free I-outcome
survival I-outcome
(BCFFS) I-outcome
of O
patients O
with O
long-term O
follow-up. O

TRIAL O
REGISTRATION: O
Clinicaltrials.gov O
Identifier: O
NCT03173339. O

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
prevalence O
and O
correlates O
of O
different O
indicators O
of O
psychological O
distress O
among O
13-14 O
year O
old O
low O
caste O
girls O
in O
rural, O
south O
India. O

Title: O
How O
mindfulness O
training O
promotes O
positive B-outcome
emotions I-outcome
: O
Dismantling O
acceptance O
skills O
training O
in O
two O
randomized O
controlled O
trials. O

The O
curative O
effect O
was O
compared O
before O
and O
after O
treatment, O
including O
ulcer B-outcome
surface I-outcome
pain I-outcome
(VAS O
score), O
time B-outcome
of I-outcome
ulcer I-outcome
healing I-outcome
, O
and O
the O
changes O
of O
T B-outcome
cell I-outcome
subsets I-outcome
( O
CD3(+) B-outcome
, O
CD4(+) B-outcome
, O
CD8(+) B-outcome
and O
CD4(+)/CD8(+) B-outcome
) O
before O
and O
after O
treatment O
were O
compared O
by O
SPSS O
22 O
software O
package. O

All O
outcomes O
were O
measured O
at O
baseline, O
at O
the O
end O
of O
6-week O
treatment O
and O
2-week O
follow-up O
after O
the O
treatment. O

METHODS: O
In O
a O
multicenter, O
double-blind, O
placebo-controlled, O
delayed-start O
trial, O
we O
randomly O
assigned O
patients O
with O
early O
Parkinson's O
disease O
to O
receive O
levodopa O
(100 O
mg O
three O
times O
per O
day) O
in O
combination O
with O
carbidopa O
(25 O
mg O
three O
times O
per O
day) O
for O
80 O
weeks O
(early-start O
group) O
or O
placebo O
for O
40 O
weeks O
followed O
by O
levodopa O
in O
combination O
with O
carbidopa O
for O
40 O
weeks O
(delayed-start O
group). O

PATIENTS O
AND O
METHODS: O
A O
multicentre, O
prospective, O
randomized, O
double-blind, O
placebo-controlled O
trial O
was O
undertaken O
involving O
229 O
patients O
undergoing O
primary O
cementless O
THA O
using O
a O
posterior O
approach, O
whose O
extended O
rivaroxaban O
thromboprophylaxis O
started O
on O
the O
day O
of O
surgery. O

Journal-Name:JAMA O

Conclusions: O
Our O
study O
demonstrates O
that O
NCH O
gel O
appears O
to O
be O
able O
to O
reduce O
the O
formation O
of O
intrauterine B-outcome
adhesions I-outcome
in O
women O
who O
undergo O
curettage O
in O
the O
second O
trimester, O
although O
larger O
controlled, O
randomized, O
multicenter O
studies O
are O
needed O
to O
confirm O
these O
results. O

BACKGROUND: O
Many O
men O
have O
limited O
knowledge O
about O
reproductive O
health O
and O
fertility. O

CONCLUSIONS: O
Ecabet O
sodium O
had O
a O
preventive O
effect O
on O
low-dose O
aspirin-induced O
small O
intestinal O
mucosal O
injury O
in O
the O
upper O
part O
of O
the O
small O
intestine. O

General O
fertility B-outcome
awareness I-outcome
increased O
from O
a O
mean O
score O
of O
4.6 O
to O
5.5 O
out O
of O
12 O
(P O
= O
0.004) O
in O
the O
IG. O

CONCLUSION: O
The O
findings O
demonstrated O
that O
both O
regimens O
of O
drugs O
can O
control O
the O
hemodynamic B-outcome
status O
of O
patients O
during O
laparoscopic O
cholecystectomy, O
which O
provides O
effective O
postoperative O
analgesia O
for O
pain B-outcome
management. O

Publication O
Type: O
Journal O
Article O

Statistical O
analyses O
will O
be O
conducted O
under O
the O
intention-to-treat O
principle. O

Although O
the O
concentration B-outcome
of I-outcome
fentanyl I-outcome
was O
higher O
than O
those O
of O
previous O
researches, O
there O
was O
no O
respiratory B-outcome
depression I-outcome
. O
But, O
there O
was O
no O
advantage O
of O
reducing O
pain B-outcome
score O
and O
the O
use B-outcome
of I-outcome
rescue I-outcome
analgesics I-outcome
. O
CLINICAL O
TRIAL O
REGISTRATION: O
(available O
at: O
http://cris.nih.go.kr, O
KCT0002221). O

METHODS: O
WISDOM O
was O
a O
multinational, O
randomized, O
double-blind, O
active-controlled, O
52-week O
study O
in O
patients O
with O
severe-to-very O
severe O
COPD. O

Fourteen O
patients O
in O
both O
the O
placebo-dexmedetomidine O
and O
acetaminophen-propofol O
groups O
(46% O
and O
45%) O
and O
7 O
in O
the O
acetaminophen-dexmedetomidine O
and O
placebo-propofol O
groups O
(24% O
and O
23%) O
had O
hypotension B-outcome
. O
Conclusions O
and O
Relevance: O
Among O
older O
patients O
undergoing O
cardiac O
surgery, O
postoperative O
scheduled O
IV O
acetaminophen, O
combined O
with O
IV O
propofol O
or O
dexmedetomidine, O
reduced O
in-hospital O
delirium B-outcome
vs O
placebo. O

CONCLUSION: O
Intrathecal O
5 O
mug O
Dex O
enhances O
the O
efficacy O
of O
spinal O
bupivacaine O
by O
24% O
in O
patients O
undergoing O
cesarean O
section O
with O
spinal O
anesthesia. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Journal O
ID: O
7511141 O

The O
studyPeden O
CJ, O
Stephens O
T, O
Martin O
G O
et O
al. O

Data O
was O
analyzed O
by O
repeated O
measures O
analysis O
of O
variance O
(rANOVA) O
and O
chi-squared O
test O
(chi O
test). O

Journal-Name:Nutrients O

CONCLUSIONS: O
This O
double O
blinded, O
randomized, O
and O
placebo-controlled O
trial O
demonstrated O
that O
the O
single O
use O
of O
20 O
mg O
nifedipine O
given O
30 O
minutes O
before O
embryo O
transfer O
did O
not O
improve O
the O
implantation B-outcome
rate O
or O
the O
clinical B-outcome
pregnancy I-outcome
rate O
of O
the O
infertility O
treatment. O

Analyses O
were O
done O
according O
to O
the O
intention-to-treat O
principle. O

The O
registration O
can O
be O
found O
at O
the O
following O
URL: O
https://clinicaltrials.gov/ct2/show/NCT01838668. O

METHODS: O
Sixty-seven O
stable O
COPD O
patients O
were O
enrolled O
and O
assigned O
to O
the O
experiment O
group O
(n O
= O
36) O
and O
the O
control O
group O
(n O
= O
31). O

Publication O
Type: O
Journal O
Article O

Using O
this O
approach, O
repellent O
(N,N-diethyl-benzamide O
- O
12% O
w/w, O
cream) O
is O
distributed O
by O
VHVs O
in O
villages O
sequentially O
throughout O
the O
malaria O
transmission O
season. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Exercise-related O
GI O
issues O
are O
a O
common O
cause O
of O
underperformance, O
with O
current O
evidence O
focusing O
on O
the O
use O
of O
FODMAP O
approaches O
with O
recreationally O
competitive O
or O
highly O
trained O
athletes. O

Journal-Name:Aerospace O
medicine O
and O
human O
performance O

CONCLUSION: O
This O
is O
the O
first O
randomised O
controlled O
trial O
to O
compare O
a O
structured O
multidisciplinary, O
multisite O
intervention O
with O
standard O
care O
in O
symptomatic O
childhood O
hypermobility. O

Band O
ligation O
is O
the O
main O
therapeutic O
option, O
but O
it O
may O
be O
technically O
difficult O
to O
perform O
in O
active O
bleeders. O

CONTEXT: O
Deviations O
in O
scapular O
motions O
and O
subsequent O
alterations O
in O
associated O
soft O
tissues O
are O
thought O
to O
contribute O
to O
overuse O
shoulder O
injuries O
in O
overhead O
athletes. O

The O
trained O
nodal O
teachers O
reported O
children O
with O
symptoms O
of O
acute O
pharyngitis O
and O
or O
RF/RHD O
in O
intervention O
arm O
and O
children O
taken O
to O
hospitals O
by O
parents O
for O
symptoms O
of O
acute O
pharyngitis O
and O
or O
RF/RHD O
under O
control O
arm O
through O
mobile O
phone O
to O
coordinating O
centre. O

The O
linear O
mixed O
model O
was O
used O
for O
data O
analysis, O
in O
which O
a O
5% O
significance O
level O
was O
adopted. O

CONCLUSION: O
There O
was O
no O
significant O
difference O
in O
clinical O
outcomes O
between O
the O
two O
trial O
arms. O

No O
adverse B-outcome
events I-outcome
related O
to O
test O
beverage O
ingestion O
were O
observed. O

TRIAL O
REGISTRATION O
NUMBER: O
NCT03386149 O
(clinicaltrials.gov) O
and O
KCT0002848 O
(Clinical O
Research O
Information O
Service O
of O
the O
Republic O
of O
Korea). O

RESULTS: O
There O
were O
in O
total O
80 O
reported O
adverse B-outcome
events I-outcome
during O
the O
follow-up; O
50 O
in O
placebo O
and O
30 O
in O
krill O
powder O
group. O

Title: O
Exercise O
training O
as O
an O
adjunctive O
therapy O
to O
montelukast O
in O
children O
with O
mild O
asthma: O
A O
randomized O
controlled O
trial. O

MATERIALS O
AND O
METHODS: O
In O
this O
randomized O
clinical O
trial, O
83 O
women O
with O
poor O
endometrial O
response O
to O
standard O
hormone O
replacement O
therapy O
(HRT) O
(endometrium O
thickness O
< O
7 O
mm) O
in O
the O
13th O
day O
of O
the O
cycle O
in O
a O
frozen-thawed O
embryo O
transfer O
(FET) O
were O
entered O
in O
two O
groups. O

The O
Taurisolo((R)) O
polyphenol O
content O
was O
evaluated O
by O
a O
High O
Performance O
Liquid O
Chromatography-diode-array O
detector O
(HPLC-DAD) O
method, O
and O
RSV O
was O
monitored O
as O
an O
indicative O
marker. O

Results: O
(1)Compared O
with O
the O
results O
at O
baseline, O
the O
total O
scores O
of O
Pittsburgh O
sleep B-outcome
quality I-outcome
index O
(PSQI)], O
Beck O
depression B-outcome
index O
(BDI) O
, O
Beck O
anxiety B-outcome
inventory O
(BAI) O
in O
both O
groups O
significantly O
decreased O
at O
the O
end O
of O
treatment: O
CBT-i O
group, O
PSQI O
(4.7+/-2.5) O
vs. O
(12.9+/-3.5); O
BDI O
(3.2+/-4.4) O
vs. O
(9.7+/-6.4); O
BAI O
(4.2+/-5.6) O
vs. O
(10.7+/-8.1); O
and O
combination O
group, O
PSQI O
(5.8+/-2.8) O
vs. O
(13.9+/-3.1); O
BDI O
(4.5+/-4.8) O
vs. O
(13.8+/-8.7); O
BAI O
(4.4+/-4.0) O
vs. O
(14.1+/-6.3) O
(all O
P<0.01). O
( O

The O
mean O
value O
of O
137 O
kcal/serving O
is O
16% O
lower O
(p O
< O
0.0001) O
than O
what O
is O
typically O
found O
on O
food O
labels. O

Journal O
ID: O
101230586 O

Over O
the O
36-month O
period, O
there O
were O
no O
significant O
changes O
in O
the O
location B-outcome
of I-outcome
mesial I-outcome
or Seperator
distal I-outcome
papilla I-outcome
in O
any O
group. O

Publication O
date: O
2018/12/19 O
06:00 O
[entrez] O

Several O
studies O
demonstrated O
that O
polyphenols O
are O
able O
to O
inhibit O
the O
growth O
of O
TMA-producing O
bacterial O
strains, O
and O
resveratrol O
(RSV) O
reduced O
TMAO O
levels O
in O
mice. O

Incidence O
of O
treatment-related B-outcome
AEs I-outcome
with O
tretinoin O
0.05% O
lotion O
was O
lower O
than O
in O
the O
overall O
study O
population; O
the O
most O
frequently O
were O
application O
site O
pain B-outcome
(2.0%), O
dryness B-outcome
(1.4%), O
and O
erythema B-outcome
(1.2%). O

DISCUSSION: O
The O
evidence O
provided O
will O
inform O
program O
investment O
and O
design, O
and O
contribute O
to O
the O
literature O
on O
the O
effect O
of O
menstrual O
health-based O
interventions O
on O
girls' O
agency B-outcome
, O
safety O
and O
life B-outcome
outcomes. O

Title: O
Single-Dose O
Tafenoquine O
to O
Prevent O
Relapse B-outcome
of O
Plasmodium O
vivax O
Malaria. O

Title: O
The O
Effects O
of O
Oral O
Magnesium O
Supplementation O
on O
Glycemic B-outcome
Response I-outcome
among O
Type O
2 O
Diabetes O
Patients. O

Title: O
Prevalence O
and O
correlates O
of O
psychological O
distress O
among O
13-14 O
year O
old O
adolescent O
girls O
in O
North O
Karnataka, O
South O
India: O
a O
cross-sectional O
study. O

Final O
irrigation O
was O
done O
with O
cold O
(4 O
degrees O
C, O
2.5 O
degrees O
C, O
and O
room O
temperature) O
17% O
EDTA O
and O
10 O
mL O
of O
cold O
saline O
solution. O

CONCLUSIONS: O
In O
this O
study O
on O
patients O
with O
chronic O
low O
back O
pain O
and O
Modic O
changes O
at O
the O
level O
of O
a O
previous O
disc O
herniation, O
three O
months O
of O
treatment O
with O
amoxicillin O
did O
not O
provide O
a O
clinically O
important O
benefit O
compared O
with O
placebo. O

Title: O
Can O
autologous O
platelet O
rich O
plasma O
expand O
endometrial B-outcome
thickness I-outcome
and O
improve O
pregnancy B-outcome
rate O
during O
frozen-thawed O
embryo O
transfer O
cycle? O

Major B-outcome
adverse I-outcome
cardiac I-outcome
events I-outcome
( O
cardiac B-outcome
death I-outcome
, O
nonfatal B-outcome
MI I-outcome
, O
unplanned B-outcome
hospitalization I-outcome
for Seperator
heart I-outcome
failure I-outcome
) O
occurred O
in O
15 O
patients O
(10.1%) O
in O
the O
placebo O
group, O
18 O
(12.9%) O
in O
the O
10-mg O
alteplase O
group, O
and O
12 O
(8.2%) O
in O
the O
20-mg O
alteplase O
group. O

Title: O
beta-Eudesmol, O
an O
Oxygenized O
Sesquiterpene, O
Reduces O
the O
Increase O
in O
Saliva O
3-Methoxy-4-Hydroxyphenylglycol B-outcome
After O
the O
"Trier O
Social O
Stress O
Test" O
in O
Healthy O
Humans: O
A O
Randomized, O
Double-Blind, O
Placebo-Controlled O
Cross-Over O
Study. O

The O
intervention O
was O
scheduled O
to O
occur O
early O
during O
the O
primary O
PCI O
procedure, O
after O
reperfusion O
of O
the O
infarct-related O
coronary O
artery O
and O
before O
stent O
implant. O

Title: O
Oral O
versus O
Intravenous O
Antibiotics O
for O
Bone O
and O
Joint O
Infection. O

In O
the O
MRI-guided O
group, O
the O
treatment O
goal O
was O
absence B-outcome
of I-outcome
MRI I-outcome
bone I-outcome
marrow I-outcome
edema I-outcome
combined I-outcome
with Seperator
clinical I-outcome
remission I-outcome
, O
defined O
as O
DAS28-CRP O
of O
3.2 O
or O
less O
and O
no O
swollen O
joints. O

Publication O
date: O
2018/10/16 O
00:00 O
[accepted] O

In O
experimental O
group O
one, O
a O
15-minute O
trial O
of O
pelvis O
reposition O
exercise O
was O
carried O
out. O
[ O

Retrospectively O
registered O
12 O
March O
2018. O

Publication O
Type: O
Multicenter O
Study O

Interventions: O
Participants O
were O
randomized O
to O
an O
intervention O
group O
that O
encouraged O
an O
energy-reduced O
Mediterranean O
diet, O
promoted O
physical O
activity, O
and O
provided O
behavioral O
support O
(n O
= O
3406) O
or O
to O
a O
control O
group O
that O
encouraged O
an O
energy-unrestricted O
Mediterranean O
diet O
(n O
= O
3468). O

Title: O
Denosumab O
effects O
on O
serum O
levels O
of O
the O
bone O
morphogenetic O
proteins O
antagonist O
noggin B-outcome
in O
patients O
with O
transfusion-dependent O
thalassemia O
and O
osteoporosis. O

Conclusion: O
Compared O
with O
conventional O
chemotherapy, O
induction O
chrono-chemotherapy O
seemed O
to O
reduce O
chemotherapy-related O
toxicities B-outcome
and O
improve O
average O
local O
relapse O
time O
in O
patients O
treated O
with O
combined O
chemoradiotherapy O
for O
NPC. O

The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
preoperative O
celecoxib O
administration O
in O
alleviating O
postoperative O
pain B-outcome
in O
knee O
osteoarthritis O
(OA) O
patients O
undergoing O
total O
knee O
arthroplasty O
(TKA).A O
total O
of O
226 O
knee O
OA O
patients O
underwent O
TKA O
were O
consecutively O
recruited O
and O
randomized O
into O
preoperative O
analgesia O
group O
and O
postoperative O
analgesia O
group O
as O
1:1 O
ratio. O

Moreover, O
results O
prove O
that O
participants O
positively O
respond B-outcome
to O
health-related O
information, O
whereas O
information O
on O
bitterness-taste O
generates O
lower O
preferences B-outcome
. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Title: O
Music-instruction O
intervention O
for O
treatment O
of O
post-traumatic O
stress O
disorder: O
a O
randomized O
pilot O
study. O

At O
4-weeks O
post-baseline O
there O
were O
significant O
increases O
in O
identified B-outcome
regulation I-outcome
, O
integrated B-outcome
regulation I-outcome
, O
intrinsic B-outcome
motivation I-outcome
, O
social B-outcome
norms I-outcome
and O
intentions B-outcome
in O
intervention O
compared O
to O
control O
participants. O

Journal O
ID: O
8205248 O

Title: O
Decolonization O
to O
Reduce O
Postdischarge O
Infection B-outcome
Risk O
among O
MRSA O
Carriers. O

We O
compared O
the O
efficacy O
and O
safety O
of O
a O
modified O
FOLFIRINOX O
regimen O
with O
gemcitabine O
as O
adjuvant O
therapy O
in O
patients O
with O
resected O
pancreatic O
cancer. O

Journal-Name:Complementary O
therapies O
in O
clinical O
practice O

Our O
results O
suggest O
that O
a O
HIIT O
training O
program O
with O
TRX O
have O
benefits O
in O
BMI B-outcome
, O
handgrip B-outcome
strength I-outcome
, O
gait B-outcome
speed I-outcome
, O
and O
quality B-outcome
of I-outcome
life I-outcome
in O
older O
adults. O

Although O
none O
of O
our O
patient O
had O
significant O
elevation O
of O
CPK B-outcome
. O
CONCLUSION: O
This O
study O
concluded O
that O
both O
doses O
of O
atorvastatin O
(40 O
& O
80mg) O
are O
equally O
efficacious O
in O
improving O
dyslipidemia B-outcome
but O
higher O
dose O
leads O
to O
more O
incidence O
of O
myalgia B-outcome
. O

Hispanic O
subjects O
(aged O
11 O
to O
50 O
years, O
N=766) O
were O
randomized O
(1:1) O
to O
receive O
tretinoin O
0.05% O
lotion O
or O
vehicle, O
once-daily O
for O
12 O
weeks. O

This O
study O
was O
an O
eight-week, O
double-blind, O
randomized, O
parallel-arm, O
and O
placebo-controlled O
trial. O

Publication O
date: O
2019/02/06 O
06:00 O
[entrez] O

In O
part O
C, O
patients O
who O
had O
recurrent O
attacks O
were O
randomly O
assigned O
to O
receive O
injections O
of O
one O
of O
two O
doses O
of O
givosiran O
(2.5 O
or O
5.0 O
mg O
per O
kilogram) O
or O
placebo O
once O
monthly O
(total O
of O
four O
injections) O
or O
once O
quarterly O
(total O
of O
two O
injections) O
during O
a O
12-week O
period, O
starting O
on O
day O
0. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Blood B-outcome
lactate I-outcome
([La-]b O
mmol. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Journal-Name:BMC O
gastroenterology O

Achaogen, O
South O
San O
Francisco, O
CA. O

The O
goal O
of O
the O
study O
was O
to O
evaluate O
the O
results O
of O
medial O
patellofemoral O
ligament O
reconstruction O
in O
children. O

MATERIALS O
AND O
METHODS: O
This O
is O
a O
double-blind, O
randomized O
controlled O
multicenter O
prospective O
trial. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

METHODS: O
Prospective O
randomized O
clinical O
trial O
including O
21 O
mothers O
of O
preterms O
admitted O
to O
the O
Neonatal O
Intensive O
Care O
Unit O
of O
a O
tertiary O
hospital, O
recruited O
from O
August O
2015 O
to O
September O
2017, O
and O
divided O
into O
control O
group O
(CG; O
n O
= O
11) O
and O
music O
therapy O
group O
(MTG; O
n O
= O
10). O

Purpose: O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
efficacy O
and O
toxicities B-outcome
of O
induction O
chronomodulated O
chemotherapy O
in O
comparison O
with O
conventional O
induction O
chemotherapy O
for O
nasopharyngeal O
carcinoma O
(NPC). O

RESULTS: O
After O
treatment, O
patients O
in O
both O
groups O
achieved O
promising O
effectiveness. O

Daily O
drainage B-outcome
and O
all O
adverse B-outcome
events I-outcome
after O
operation O
were O
also O
compared. O

The O
primary O
outcome O
measurement O
was O
the O
headache B-outcome
intensity I-outcome
. O
Secondary O
outcomes O
were O
frequency O
and O
duration B-outcome
of I-outcome
headache B-outcome
, O
and O
quality B-outcome
of I-outcome
life I-outcome
, O
assessed O
by O
the O
Short O
Form-36. O

Journal-Name:Nutrients O

Title: O
A O
Pilot O
Randomized O
Controlled O
Trial O
of O
Transcutaneous O
Electrical O
Nerve O
Stimulation O
for O
Patients O
With O
Acute O
Tinnitus. O

The O
study O
involves O
140 O
public O
primary O
schools O
in O
three O
rural O
sub-counties O
(Magarini, O
Kaloleni O
and O
Ganze) O
of O
Kilifi O
County O
in O
the O
Coastal O
area O
of O
Kenya. O

Journal-Name:Indian O
heart O
journal O

DISCUSSION: O
To O
our O
knowledge, O
APPAC O
II O
trial O
is O
the O
first O
randomised O
controlled O
trial O
comparing O
per O
oral O
antibiotic O
monotherapy O
with O
intravenous O
antibiotic O
therapy O
continued O
by O
per O
oral O
antibiotics O
in O
the O
treatment O
of O
uncomplicated O
acute O
appendicitis. O

CONCLUSION: O
The O
results O
of O
this O
study O
revealed O
that O
oral O
Mg O
supplementation O
reduces O
insulin B-outcome
resistance I-outcome
and O
improves O
the O
glycemic B-outcome
control I-outcome
indicators O
among O
T2D O
patients. O

METHODS: O
The O
BabyGel O
pilot O
was O
a O
cluster O
randomised O
trial O
that O
assessed O
the O
post-partum O
use O
of O
alcohol-based O
hand O
rub O
(ABHR) O
to O
prevent O
neonatal B-outcome
infections I-outcome
in O
Mbale, O
Uganda. O

Interventions: O
Hospitals O
randomized O
to O
the O
intervention O
(n O
= O
131 O
[6436 O
patients]) O
provided O
patients O
with O
co-payment O
vouchers O
for O
clopidogrel O
or O
ticagrelor O
for O
1 O
year O
(median O
voucher O
value O
for O
a O
30-day O
supply, O
$137 O
[25th-75th O
percentile, O
$20-$339]). O

In O
the O
low-dose O
remifentanil O
(LR) O
group O
(n O
= O
46), O
remifentanil O
was O
infused O
at O
a O
rate O
of O
0.05 O
mug/kg/min. O

There O
was O
no O
statistically O
significant O
difference O
between O
the O
bracket O
adhesives O
in O
the O
numbers O
with O
at O
least O
1 O
new O
demineralized B-outcome
lesion I-outcome
(risk O
ratio,1.25; O
95% O
confidence O
interval, O
0.74-2.13; O
P O
= O
0.403) O
or O
first-time O
bracket O
failure O
(risk O
ratio,0.88; O
95% O
confidence O
interval, O
0.67-1.16; O
P O
= O
0.35). O

Journal O
ID: O
2985248R O

Journal-Name:Brazilian O
oral O
research O

Title: O
Efficacy O
of O
different O
interaction O
devices O
using O
non-immersive O
virtual O
tasks O
in O
individuals O
with O
Amyotrophic O
Lateral O
Sclerosis: O
a O
cross-sectional O
randomized O
trial. O

Pain B-outcome
, O
global B-outcome
quality I-outcome
of I-outcome
life I-outcome
(GQoL) I-outcome
and O
quality B-outcome
of I-outcome
life I-outcome
specific O
for O
CD O
(QoLCD) O
were O
assessed O
before O
and O
after O
the O
intervention. O

Title: O
A O
randomized O
controlled O
trial O
of O
neuromuscular O
electrical O
stimulation O
for O
chronic O
urinary O
retention O
following O
traumatic O
brain O
injury. O

Background O
& O
objectives: O
: O
Three O
doses O
of O
intermittent O
preventive O
treatment O
with O
sulphadoxine-pyrimethamine O
(IPTp-SP) O
has O
been O
adopted O
as O
the O
new O
recommendation O
for O
prevention O
of O
malaria B-outcome
in O
pregnancy. O

Publication O
date: O
2018/11/20 O
00:00 O
[accepted] O

Journal-Name:JAMA O

BACKGROUND: O
Delayed-release O
dimethyl O
fumarate O
(DMF) O
has O
demonstrated O
efficacy O
and O
a O
favorable O
benefit-risk O
profile O
in O
phase O
2 O
and O
3 O
studies O
that O
enrolled O
predominantly O
white O
patients O
with O
relapsing-remitting O
multiple O
sclerosis O
(RRMS). O

Key O
exclusion O
criteria O
included O
diagnosis O
of O
neuromyelitis O
optica O
spectrum O
disorder. O

Publication O
Type: O
Multicenter O
Study O

There O
were O
no O
adverse B-outcome
effects I-outcome
. O
CONCLUSIONS: O
There O
is O
no O
evidence O
that O
the O
use O
of O
resin O
modified O
glass O
ionomer O
cement O
over O
light-cured O
composite O
for O
bonding O
brackets O
reduces O
the O
incidence O
of O
new O
demineralized B-outcome
lesions I-outcome
or O
bond B-outcome
failures I-outcome
. O
There O
might O
be O
other O
reasons O
for O
using O
resin O
modified O
glass O
ionomer O
cement. O

The O
median O
difference O
in O
morphine B-outcome
consumption I-outcome
between O
the O
PCM O
+ O
IBU O
group O
vs O
PCM O
alone O
was O
16 O
mg O
(99.6% O
CI, O
6.5 O
to O
24; O
P O
< O
.001); O
for O
the O
PCM-alone O
group O
vs O
HS-PCM O
+ O
IBU, O
8 O
mg O
(99.6% O
CI, O
-1 O
to O
14; O
P O
= O
.001); O
and O
for O
the O
PCM O
+ O
IBU O
group O
vs O
IBU O
alone, O
6 O
mg O
(99.6% O
CI, O
-2 O
to O
16; O
P O
= O
.002). O

BACKGROUND: O
E-cigarettes O
are O
commonly O
used O
in O
attempts O
to O
stop O
smoking, O
but O
evidence O
is O
limited O
regarding O
their O
effectiveness O
as O
compared O
with O
that O
of O
nicotine O
products O
approved O
as O
smoking-cessation O
treatments. O

Journal O
ID: O
100968567 O

The O
clinical O
and O
radiographic O
twelve-month O
outcomes O
indicated O
successful B-outcome
treatment I-outcome
, O
independently O
of O
the O
root O
filling O
material O
used. O

No O
protocol-related O
serious B-outcome
adverse I-outcome
reactions I-outcome
were O
confirmed. O

CONCLUSIONS: O
HP O
had O
superior O
rates O
of O
hemostasis B-outcome
, O
shorter O
preparation B-outcome
time I-outcome
, O
and O
a O
similar O
safety O
profile O
compared O
to O
G O
+ O
T O
in O
this O
prospective, O
randomized O
trial O
using O
quantitative O
bleeding B-outcome
severity I-outcome
criteria. O

Journal O
ID: O
9113221 O

Publication O
Type: O
Randomized O
Controlled O
Trial O

The O
measures O
represent O
the O
exposure O
in O
a O
normal O
workload O
schedule O
of O
ninety O
randomly O
selected O
workers O
over O
a O
3-month O
period, O
extrapolated O
to O
1 O
year. O

Under O
PCV O
mode, O
with O
the O
increase O
in O
atomized O
oxygen O
flow, O
inspiratory B-outcome
tidal I-outcome
volume I-outcome
monitored O
by O
ventilator O
in O
different O
preset O
suction O
pressure O
groups O
was O
decreased O
gradually, O
and O
exhaled B-outcome
tidal I-outcome
volume I-outcome
was O
increased O
gradually, O
but O
peak B-outcome
airway I-outcome
pressure I-outcome
monitored O
by O
ventilator O
did O
not O
changed O
significantly. O

Improvement O
in O
body B-outcome
composition I-outcome
was O
achieved O
by O
the O
intervention O
group O
(n O
= O
13) O
with O
a O
median O
decrease O
of O
2.1% O
body O
fat O
compared O
with O
a O
non-exercising O
group O
(n O
= O
7) O
(0.1% O
increase; O
p O
= O
0.022). O

Publication O
Type: O
Randomized O
Controlled O
Trial O

METHODS: O
In O
this O
multicentre, O
randomised, O
double-blind, O
placebo-controlled, O
parallel-group, O
phase O
2a O
study, O
we O
recruited O
adults O
(aged O
21-75 O
years) O
with O
a O
body-mass O
index O
of O
at O
least O
25 O
kg/m(2), O
biopsy-confirmed O
non-alcoholic O
steatohepatitis O
(fibrosis O
stage O
1-3), O
and O
a O
hepatic O
fat O
fraction O
of O
at O
least O
10% O
when O
assessed O
by O
magnetic O
resonance O
imaging-proton O
density O
fat O
fraction. O

RESULTS: O
A O
total O
of O
1773 O
adult O
patients O
with O
episodic O
migraine O
(n O
= O
444 O
for O
galcanezumab O
120 O
mg; O
n O
= O
435 O
for O
galcanezumab O
240 O
mg; O
n O
= O
894 O
for O
placebo O
for O
2 O
studies O
pooled) O
and O
1113 O
patients O
with O
chronic O
migraine O
(n O
= O
278 O
for O
galcanezumab O
120 O
mg; O
n O
= O
277 O
for O
galcanezumab O
240 O
mg; O
n O
= O
558 O
for O
placebo) O
were O
evaluated. O

The O
G1 O
presented O
higher O
values O
of O
CRP B-outcome
in O
relation O
to O
the O
G2 O
significantly O
(p O
? O

The O
objective O
of O
this O
study O
was O
to O
investigate O
the O
immediate O
effectiveness O
of O
2 O
counterforce O
orthoses O
in O
improving O
the O
sensorimotor B-outcome
abilities O
of O
the O
hand O
in O
patients O
with O
lateral O
elbow O
tendinopathy. O

Captured O
drug O
was O
quantified O
using O
Eu-labeled O
protein O
A O
and O
time-resolved O
fluorescence. O

Main B-outcome
curve I-outcome
correction I-outcome
success O
rate O
was O
in O
association O
with O
patients' O
age O
and O
type O
of O
rod O
(P-value=0.054, O
r=-1.863 O
and O
P-value=0.001, O
r=8.865 O
respectively). O

METHODS: O
Sixty-two O
10- O
to O
14-year-old O
patients O
were O
randomly O
allocated O
to O
either O
full-time O
(FT, O
22 O
hours O
daily) O
or O
part-time O
(PT, O
12 O
hours O
daily) O
wear O
of O
a O
modified O
Twin-block O
appliance. O

Journal-Name:BMC O
complementary O
and O
alternative O
medicine O

Publication O
Type: O
Journal O
Article, O
Randomized O
Controlled O
Trial, O

Title: O
[Effects O
of O
propofol O
sedation O
on O
psychological B-outcome
stress I-outcome
in O
surgical O
patients O
under O
epidural]. O

Journal-Name:Medicine O

Title: O
Plazomicin O
for O
Infections O
Caused O
by O
Carbapenem-Resistant O
Enterobacteriaceae. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

METHOD: O
an O
experimental O
and O
blind O
study O
composed O
of O
120 O
dyads O
of O
first-time O
mothers O
and O
full-term O
newborns, O
who O
practiced O
breastfeeding. O

Title: O
Effectiveness O
of O
the O
Nutritional O
App O
"MyNutriCart" O
on O
Food B-outcome
Choices I-outcome
Related O
to O
Purchase B-outcome
and Seperator
Dietary B-outcome
Behavior E1-outcome
: O
A O
Pilot O
Randomized O
Controlled O
Trial. O

HR's O
for O
levofloxacin O
and O
moxifloxacin, O
compared O
to O
beta-lactam O
monotherapy, O
on O
any O
cardiac B-outcome
event I-outcome
were O
0.40 O
(95% O
CI O
0.18;0.87)and O
0.56 O
(95% O
CI O
0.36;0.87), O
respectively. O

Journal-Name: O
Revista O
da O
Associacao O
Medica O
Brasileira O
(1992) O

Intensive O
BP O
control O
significantly O
reduced O
the O
risk O
of O
mild O
cognitive B-outcome
impairment I-outcome
(14.6 O
vs O
18.3 O
cases O
per O
1000 O
person-years; O
HR, O
0.81; O
95% O
CI, O
0.69-0.95) O
and O
the O
combined O
rate O
of O
mild O
cognitive B-outcome
impairment I-outcome
or Seperator
probable I-outcome
dementia I-outcome
(20.2 O
vs O
24.1 O
cases O
per O
1000 O
person-years; O
HR, O
0.85; O
95% O
CI, O
0.74-0.97). O

This O
trial O
is O
registered O
with O
ClinicalTrials.gov, O
number O
NCT02181413, O
and O
follow-up O
is O
ongoing. O

Publication O
Type: O
Journal O
Article O

No O
trial-dependent O
differences O
were O
observed O
in O
the O
Recovery O
period. O

Title: O
Are O
(All) O
Consumers O
Averse B-outcome
to I-outcome
Bitter I-outcome
Taste I-outcome
? O

RESULTS: O
From O
October O
2009 O
through O
April O
2012, O
we O
randomly O
assigned O
103 O
patients O
to O
the O
hybrid-procedure O
group O
and O
104 O
to O
the O
open-procedure O
group. O

Journal-Name: O
The O
New O
England O
journal O
of O
medicine O

Title: O
Does O
Doctor O
Race O
Affect O
the O
Health O
of O
Black O
Men? O

There O
were O
no O
significantly O
difference O
of O
the O
numbers O
of O
bucking B-outcome
or O
body B-outcome
moving I-outcome
, O
the O
satisfaction B-outcome
of O
operators O
and O
patients, O
and O
adverse B-outcome
events I-outcome
(all O
P>0.05). O

Between-group O
differences O
were O
not O
significant. O

The O
results O
of O
this O
trial O
could O
support O
decision-making O
by O
clinicians O
regarding O
aPDT O
using O
aPDT O
for O
treating O
halitosis. O

Journal O
ID: O
101521595 O

Conclusion: O
Compared O
with O
the O
posterolateral O
approach, O
the O
SuperPATH O
approach O
can O
reduce O
muscle B-outcome
damage I-outcome
, O
relieve O
early O
pain B-outcome
, O
promote O
recovery B-outcome
, O
and O
obtain O
the O
similar O
short-term O
effectiveness. O

Publication O
date: O
['2019/10/16 O
06:00' O

Publication O
date: O
2018/12/21 O
06:00 O
[entrez] O

Title: O
Comparing O
the O
effect O
between O
continuous O
infusion O
and O
intermittent O
bolus O
of O
rocuronium O
for O
intraoperative O
neurophysiologic O
monitoring O
of O
neurointervention O
under O
general O
anesthesia. O

Unhealthy O
food O
sponsorship O
also O
led O
to O
greater O
perceived O
event-sponsor B-outcome
fit I-outcome
and Seperator
transfer B-outcome
of I-outcome
perceptions E1-outcome
of O
the O
sporting O
event O
to O
the O
unhealthy O
food O
sponsor O
brands, O
relative O
to O
the O
control O
group. O

BACKGROUND: O
To O
compare O
the O
superiority O
of O
teaching O
methods O
for O
acquiring O
a O
proficient O
level O
of O
surgical O
skill B-outcome
in O
a O
robotic O
surgery-naive O
individual O
using O
a O
robotic O
virtual O
reality O
simulator. O

Publication O
date: O
2019/01/05 O
06:00 O
[pubmed] O

The O
intervention O
group O
received O
additional O
individual O
pre-discharge O
pharmacotherapeutic O
education O
about O
the O
discharge O
prescriptions. O

Physical B-outcome
activity-related I-outcome
fear I-outcome
was O
reduced O
only O
in O
the O
Exercise-arm O
(p O
= O
0.008). O

Linear O
regressions O
examined O
between-groups O
relationships O
for O
foot O
and O
ankle O
characteristics O
and O
the O
FPPA. O

Title: O
Evaluation O
of O
a O
Single O
Dose O
of O
Azithromycin O
for O
Trachoma O
in O
Low-Prevalence O
Communities. O

Journal-Name:Zhonghua O
wei O
zhong O
bing O
ji O
jiu O
yi O
xue O

The O
primary O
efficacy O
endpoint O
was O
measured O
by O
the O
Tinnitus B-outcome
Severity I-outcome
Scale O
(TSS) O
and O
Tinnitus B-outcome
Questionnaire O
(TQ) O
sum O
score. O

To O
date, O
no O
published O
study O
has O
examined O
the O
effect O
of O
an O
active, O
music-instruction O
intervention O
as O
a O
complementary O
strategy O
to O
improve O
the O
psychological O
well-being O
of O
veterans O
with O
PTSD. O

In O
third O
postoperative O
day, O
mean O
was O
3.18 O
for O
the O
first O
group O
and O
3.11 O
for O
the O
traditional O
group O
(p=0.937). O

Baltimore O
Community-based O
Organizations O
Neighborhood O
Network: O
Enhancing O
Capacity O
Together O
(CONNECT) O
was O
a O
randomized, O
controlled O
trial O
based O
on O
the O
core O
tenets O
of O
the O
World O
Health O
Organization's O
(WHO) O
African O
Partnerships O
for O
Patient O
Safety O
Community O
Engagement O
(ACE) O
approach. O

Registered O
1 O
February O
2013. O

Publication O
date: O
2019/01/07 O
00:00 O
[accepted] O

Title: O
Effectiveness O
and O
cost-effectiveness O
of O
neuromuscular O
exercise O
and O
back O
care O
counseling O
in O
female O
healthcare O
workers O
with O
recurrent O
non-specific O
low O
back O
pain: O
a O
blinded O
four-arm O
randomized O
controlled O
trial. O

Compared O
to O
controls, O
elite O
football O
players O
showed O
lower O
antioxidant B-outcome
power I-outcome
and O
higher O
oxidative B-outcome
stress I-outcome
paralleled O
by O
an O
increase O
in O
muscle B-outcome
damage I-outcome
markers. O

There O
were O
30 O
statistically O
significant O
metabolite B-outcome
differences O
in O
the O
stool O
of O
participants O
that O
consumed O
navy O
bean O
at O
day O
28 O
compared O
to O
the O
participants' O
baseline O
(p O
</= O
0.05) O
and O
26 O
significantly O
different O
metabolites B-outcome
when O
compared O
to O
the O
control O
group. O

Publication O
date: O
2019/01/10 O
06:00 O
[entrez] O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Journal O
ID: O
9420934 O

BACKGROUND: O
Studies O
have O
reported O
that O
the O
ED50 O
of O
intrathecal O
ropivacaine O
was O
increased O
when O
using O
prophylactic O
infusion O
of O
phenylephrine O
to O
prevent O
spinal-induced O
hypotension. O

A O
common O
approach O
to O
deliver O
malaria O
services O
is O
to O
assign O
Village O
Health O
Volunteers O
(VHVs) O
to O
villages, O
particularly O
where O
limited O
or O
no O
services O
exist. O

Results: O
The O
authors O
compared O
the O
EG O
results O
at O
the O
initial O
and O
final O
assessments O
and O
found O
a O
statistically O
significant O
improvement O
in O
severity O
of O
urinary B-outcome
incontinence I-outcome
(P=0.001) O
and O
depression B-outcome
severity O
(P=0.006), O
and O
a O
decrease O
in O
myostatin B-outcome
concentration O
(P</=0.001). O

Journal-Name:Ophthalmic O
epidemiology O

Objective: O
To O
investigate O
the O
efficacy O
of O
cognitive-behavioral O
therapy O
for O
insomnia O
(CBT-i) O
or O
combination O
with O
tapered O
hypnotic O
agents. O

There O
was O
no O
significant O
difference O
between O
groups O
in O
the O
median O
cumulative O
time O
with O
mean O
arterial O
pressure O
below O
60 O
mm O
Hg O
(7 O
vs O
7 O
minutes; O
difference, O
0.0 O
[95% O
CI, O
-1.7 O
to O
1.7]). O

METHODS: O
This O
is O
a O
3-arm, O
waitlist, O
single-blind O
randomised O
controlled O
trial O
testing O
the O
efficacy O
of O
the O
Stay O
Strong O
App O
in O
improving O
psychological B-outcome
distress I-outcome
, O
depressive B-outcome
symptoms I-outcome
, O
quality B-outcome
of I-outcome
life I-outcome
and O
treatment B-outcome
adherence I-outcome
among O
Indigenous O
clients O
undergoing O
haemodialysis O
for O
ESKD O
in O
Alice O
Springs O
and O
Darwin O
with O
follow O
up O
over O
two O
periods O
of O
3 O
months O
(total O
of O
6 O
months O
observation). O

After O
12 O
months, O
the O
Combined-arm O
showed O
reduced O
intensity B-outcome
of I-outcome
low I-outcome
back I-outcome
pain I-outcome
(p O
= O
0.006; O
effect O
size O
0.70, O
confidence O
interval O
0.23 O
to O
1.17) O
and O
pain B-outcome
interfering I-outcome
with Seperator
work I-outcome
(p O
= O
0.011) O
compared O
with O
the O
Control-arm. O

OBJECTIVE: O
To O
pilot O
test O
the O
effectiveness O
of O
"MyNutriCart", O
a O
smartphone O
application O
(app) O
that O
generates O
healthy O
grocery O
lists, O
on O
diet B-outcome
and O
weight B-outcome
. O
METHODS: O
A O
pilot O
randomized O
trial O
was O
conducted O
to O
test O
the O
efficacy O
of O
using O
the O
"MyNutriCart" O
app O
compared O
to O
one O
face-to-face O
counseling O
session O
(Traditional O
group) O
in O
Hispanic O
overweight O
and O
obese O
adults. O

Wound B-outcome
complications I-outcome
in O
the O
first O
30 O
days O
and O
incisional B-outcome
hernia I-outcome
rates O
were O
assessed. O

Both O
techniques O
created O
the O
same O
level O
of O
epithelial B-outcome
thickness I-outcome
increase O
and O
variation, O
with O
a O
significantly O
higher O
mid-peripheral B-outcome
epithelial I-outcome
thickness I-outcome
increase. O

Topical O
repellents O
are O
an O
intervention O
that O
can O
be O
used O
to O
target O
residual O
malaria O
transmission O
not O
covered O
by O
long O
lasting O
insecticide O
nets O
and O
indoor O
residual O
spraying. O

Objective: O
To O
investigate O
the O
effects O
of O
dexmedetomidine O
on O
perioperative O
stress B-outcome
and O
postoperative O
pain B-outcome
in O
patients O
with O
radical O
resection O
of O
esophageal O
cancer O
under O
combined O
thoracoscope O
and O
laparoscope. O

The O
blood O
levels O
of O
sICAM-1 B-outcome
, O
sVCAM-1 B-outcome
, O
endothelin-1 B-outcome
, O
and O
sE-selectin B-outcome
were O
quantified; O
the O
activities O
of O
catalase B-outcome
, O
superoxide B-outcome
dismutase I-outcome
, O
glutathione B-outcome
peroxidase I-outcome
, O
glutathione B-outcome
reductase I-outcome
and O
concentrations O
of O
reduced O
glutathione B-outcome
, O
oxidized B-outcome
glutathione I-outcome
, O
and O
thiobarbituric B-outcome
acid I-outcome
reactive O
substances, O
were O
also O
quantified O
before O
and O
after O
the O
treatment O
period. O
( O

The O
total B-outcome
sleep I-outcome
time I-outcome
and O
arousal B-outcome
time I-outcome
were O
obtained O
by O
bispectral O
index O
(BIS) O
monitoring O
from O
20: O
00 O
(the O
first O
day) O
to O
6: O
00 O
(the O
second O
day). O

The O
secondary O
objective O
was O
to O
investigate O
the O
postinduction O
levels O
of O
serum O
neurohormones B-outcome
in O
an O
attempt O
to O
explain O
the O
mechanisms O
involved. O

Importance: O
Abnormal O
peripheral O
perfusion O
after O
septic O
shock O
resuscitation O
has O
been O
associated O
with O
organ O
dysfunction O
and O
mortality. O

Journal-Name:Zhonghua O
lao O
dong O
wei O
sheng O
zhi O
ye O
bing O
za O
zhi O
= O
Zhonghua O
laodong O
weisheng O
zhiyebing O
zazhi O
= O
Chinese O
journal O
of O
industrial O
hygiene O
and O
occupational O
diseases O

Secondary O
outcomes O
were O
from O
start O
of O
the O
propofol O
infusion O
time B-outcome
to I-outcome
loss I-outcome
of I-outcome
consciousness I-outcome
(LOC) I-outcome
, O
rocuronium B-outcome
onset I-outcome
time I-outcome
, O
time B-outcome
to I-outcome
Bispectral I-outcome
index I-outcome
(BIS) I-outcome
60 I-outcome
, O
and O
hemodynamic B-outcome
variables. O

RESULTS: O
The O
fentanyl O
level O
peaked O
1 O
h O
after O
operation O
in O
the O
TFP O
group O
(3.27 O
+/- O
0.34 O
ng/mL) O
and O
24 O
h O
postoperatively O
in O
the O
IV O
group O
(2.9 O
+/- O
0.42 O
ng/mL). O

CONCLUSIONS: O
Both O
LASIK O
and O
SMILE O
resulted O
in O
significant O
epithelial B-outcome
thickening I-outcome
. O
This O
response O
seemed O
to O
be O
surprisingly O
quite O
similar O
between O
the O
2 O
different O
techniques. O

Two O
clinical O
trials O
have O
examined O
this O
strategy O
and O
reported O
controversial O
results. O

For O
the O
comparison O
of O
the O
Ocular B-outcome
Surface I-outcome
Disease I-outcome
Index O
(OSDI)], O
subjective O
evaluation O
scores, O
tear B-outcome
breakup I-outcome
time I-outcome
(TBUT) I-outcome
and O
fluorescein B-outcome
staining I-outcome
, O
statistically O
significant O
improvements O
were O
noted O
in O
the O
BCL O
group, O
especially O
on O
days O
7 O
and O
14 O
(P O
< O
0.001, O
P O
< O
0.001; O
P O
= O
0.031, O
P O
= O
0.009; O
P O
= O
0.021, O
P O
= O
0.028; O
and O
P O
= O
0.03, O
P O
= O
0.032, O
respectively). O

RESULTS: O
HSS, O
KSS, O
NASS O
scores, O
and O
ROM O
were O
elevated O
after O
patients O
receiving O
TKA. O

Journal O
ID: O
101160020 O

The O
aim O
of O
the O
study O
was O
to O
evaluate O
if O
Reproductive O
Life O
Plan O
(RLP)-based O
counselling O
during O
a O
sexual O
health O
visit O
could O
increase O
men's O
fertility B-outcome
awareness I-outcome
. O
MATERIAL O
AND O
METHODS: O
The O
study O
was O
a O
randomized O
controlled O
trial O
including O
201 O
men O
aged O
18-50 O
who O
visited O
either O
of O
two O
participating O
sexual O
health O
clinics O
in O
Sweden O
for O
sexually O
transmitted O
infection O
testing O
during O
2014-2016. O

The O
aim O
of O
this O
study O
was O
to O
exploit O
the O
effect O
of O
cocoa O
polyphenols O
on O
oxidative B-outcome
stress I-outcome
and O
muscular B-outcome
injuries I-outcome
induced O
by O
intensive O
physical O
exercise O
in O
elite O
football O
players. O

On O
intention-to-treat O
analysis, O
Hp B-outcome
eradication I-outcome
rates O
in O
FZD O
and O
CLA O
groups O
were O
90.22% O
and O
86.02% O
(P O
= O
.378); O
in O
per-protocol O
analysis, O
their O
eradication B-outcome
rates O
were O
93.26% O
and O
87.91%, O
respectively O
(P O
= O
.220). O

Journal-Name:Eye O
& O
contact O
lens O

The O
exercise O
group O
performed O
40 O
min O
of O
resistance O
exercises O
on O
machines O
followed O
by O
30 O
min O
of O
aerobic O
training O
on O
a O
treadmill O
3x/wk. O

PMID: O
31618328 O

Secondary O
endpoints O
in O
rank O
order O
included: O
superiority O
of O
HP O
relative O
to O
G O
+ O
T O
in O
mean O
preparation B-outcome
time I-outcome
; O
non-inferiority O
of O
HP O
relative O
to O
G O
+ O
T O
for O
achieving O
hemostasis B-outcome
within O
3 O
min; O
superiority O
of O
HP O
relative O
to O
G O
+ O
T O
for O
achieving O
hemostasis B-outcome
within O
6 O
min; O
and O
superiority O
of O
HP O
relative O
to O
G O
+ O
T O
for O
success O
for O
achieving O
hemostasis B-outcome
within O
3 O
min. O

The O
1st O
group O
contained O
22 O
patients O
and O
surgery O
was O
performed O
using O
a O
fascia O
lata O
allograft. O

Title: O
Pegbelfermin O
(BMS-986036), O
a O
PEGylated O
fibroblast O
growth O
factor O
21 O
analogue, O
in O
patients O
with O
non-alcoholic O
steatohepatitis: O
a O
randomised, O
double-blind, O
placebo-controlled, O
phase O
2a O
trial. O

Discussion: O
Short-term O
use O
of O
IQOS(TM) O
has O
a O
minimal O
impact O
on O
exhaled B-outcome
CO I-outcome
, O
is O
equally O
effective O
in O
reducing O
cigarette B-outcome
craving I-outcome
and O
withdrawal B-outcome
symptoms I-outcome
as O
an O
e-cigarette, O
and O
is O
slightly O
preferred B-outcome
. O

Achaogen, O
South O
San O
Francisco, O
CA. O

Subjects O
were O
randomly O
allocated O
to O
take O
either O
50,000 O
IU O
vitamin O
D O
every O
2 O
weeks O
plus O
8 O
x O
10(9) O
CFU/day O
probiotic O
(n O
= O
30) O
or O
placebo O
(n O
= O
30) O
for O
12 O
weeks. O

Journal O
ID: O
100968547 O

CONCLUSIONS: O
Among O
patients O
with O
TTP, O
treatment O
with O
caplacizumab O
was O
associated O
with O
faster O
normalization B-outcome
of I-outcome
the Seperator
platelet I-outcome
count I-outcome
; O
a O
lower O
incidence O
of O
a O
composite O
of O
TTP-related B-outcome
death I-outcome
, O
recurrence B-outcome
of O
TTP, O
or O
a O
thromboembolic B-outcome
event I-outcome
during O
the O
trial O
treatment O
period; O
and O
a O
lower O
rate O
of O
recurrence B-outcome
of O
TTP O
during O
the O
trial O
than O
placebo. O
( O

The O
corresponding O
rates O
between O
weeks O
44 O
and O
80 O
were O
0.10+/-0.25 O
and O
0.03+/-0.28 O
(difference, O
0.07; O
two-sided O
90% O
CI, O
0.03 O
to O
0.10); O
the O
difference O
in O
the O
rate O
of O
progression B-outcome
between O
weeks O
44 O
and O
80 O
did O
not O
meet O
the O
criterion O
for O
noninferiority O
of O
early O
receipt O
of O
levodopa O
to O
delayed O
receipt. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Follow-up O
period O
was O
2 O
years. O

Publication O
Type: O
Multicenter O
Study O

RESULTS: O
At O
T2, O
the O
intervention O
group O
reported O
significantly O
higher O
self-efficacy B-outcome
to O
cope O
with O
stress O
(effect O
size O
[Cohen's O
d O
= O
0.53), O
better O
emotional O
coping B-outcome
response O
(d O
= O
0.38), O
less O
stress B-outcome
(d O
= O
0.34), O
fewer O
depressive B-outcome
symptoms I-outcome
(d O
= O
- O
0.27), O
and O
more O
positive B-outcome
affect I-outcome
(d O
= O
0.31) O
than O
the O
comparison O
group. O

Results: O
The O
self-assessment O
scores O
of O
WDCs' O
capacity O
to O
fulfil O
their O
roles O
improved O
more O
in O
the O
intervention O
than O
in O
the O
comparison O
area O
for O
all O
six O
components, O
but O
for O
only O
1 O
of O
the O
6 O
was O
the O
improvement O
statistically O
significant O
(monthly O
and O
quarterly O
meetings O
in O
which O
Peer O
Supervisor O
and/or O
CHW O
supervision O
was O
an O
agenda O
item). O

Data O
were O
analysed O
using O
Systematic O
Text O
Condensation. O

Publication O
date: O
2018/11/04 O
00:00 O
[accepted] O

Results: O
Twenty-four O
children O
with O
HIV O
and/or O
PHE O
were O
randomized O
into O
one O
of O
the O
two O
intervention O
groups. O

Journal-Name:JAMA O

Participants O
were O
followed O
for O
1 O
year. O

BACKGROUND: O
Ambulatory O
patients O
receiving O
systemic O
cancer O
therapy O
are O
at O
varying O
risk O
for O
venous O
thromboembolism. O

Publication O
date: O
2019/01/08 O
06:00 O
[entrez] O

Dental B-outcome
, O
skeletal B-outcome
, O
and O
soft B-outcome
tissue I-outcome
measurements O
were O
performed O
on O
lateral O
cephalograms O
taken O
just O
before O
and O
at O
the O
end O
of O
the O
Herbst O
appliance O
therapy. O

Journal-Name:Indian O
heart O
journal O

RESULTS: O
Seventy-one O
patients O
(45% O
PAH, O
55% O
CTEPH; O
53.5% O
female; O
60 O
+/- O
13 O
years, O
mean O
pulmonary O
arterial O
pressure O
46 O
+/- O
10 O
mmHg, O
mean O
PVR O
700 O
+/- O
282dynes.sec.cm-5) O
were O
included. O

Five O
of O
7 O
household O
behaviors O
judged O
to O
be O
amenable O
to O
promotion O
by O
CHWs O
improved O
more O
in O
the O
intervention O
area O
than O
in O
the O
comparison O
area, O
and O
2 O
out O
of O
the O
5 O
were O
statistically O
significant O
(feeding O
colostrum O
and O
appropriate O
infant O
and O
young O
child O
feeding). O

We O
measured O
and O
compare O
the O
knowledge B-outcome
of I-outcome
and Seperator
incidences X
of X
hand B-outcome
food I-outcome
mouth I-outcome
disease E4-outcome
between O
2 O
groups. O

Outcomes O
will O
be O
assessed O
at O
baseline O
and O
at O
3, O
6, O
and O
10 O
weeks O
after O
screening. O

Trial O
Registration: O
ISRCTN53448131. O

Compared O
with O
SFC, O
IND/GLY O
treatment O
was O
associated O
with O
reductions O
in O
the O
annualized O
rates O
of O
moderate/severe O
exacerbations B-outcome
(rate O
ratio O
[95% O
CI]: O
0.81 O
[0.73-0.91], O
0.89 O
[0.74-1.07] O
in O
men O
and O
women, O
respectively). O

Electromyographic O
analysis O
of O
the O
pectoralis O
major O
and O
triceps O
brachii O
were O
monitored O
during O
3 O
maximal O
isometric O
contractions O
and O
a O
fatiguing O
endurance O
task. O

OBJECTIVE: O
The O
objective O
of O
this O
study O
was O
to O
compare O
enhancement B-outcome
of O
the O
aorta O
and O
liver O
on O
hepatic O
dynamic O
computed O
tomography O
scans O
acquired O
with O
contrast O
material O
doses O
based O
on O
the O
lean O
body O
weight O
(LBW) O
or O
the O
total O
body O
weight O
(TBW). O

Does O
the O
timing O
of O
hCG O
support O
make O
a O
difference? O

Cumulative O
incidence O
and O
relative O
risks O
with O
95% O
confidence O
intervals O
for O
death B-outcome
from I-outcome
any Seperator
cause I-outcome
, O
death B-outcome
from I-outcome
prostate I-outcome
cancer I-outcome
, O
and O
metastasis B-outcome
were O
estimated O
in O
intention-to-treat O
and O
per-protocol O
analyses, O
and O
numbers O
of O
years O
of O
life O
gained O
were O
estimated. O

Title: O
Impact O
of O
a O
Local O
Vision O
Care O
Center O
on O
Glasses B-outcome
Ownership I-outcome
and O
Wearing B-outcome
Behavior I-outcome
in O
Northwestern O
Rural O
China: O
A O
Cluster-Randomized O
Controlled O
Trial. O

CONCLUSION: O
This O
study O
does O
not O
support O
the O
use O
of O
TENS O
in O
the O
treatment O
of O
patients O
with O
chronic O
LBP O
even O
though O
patients O
benefited O
from O
a O
therapeutic O
education O
program O
by O
a O
pain O
resource O
nurse. O

Trial O
registered O
with O
Current O
Controlled O
Trials, O
number O
ISRCTN17975376. O

Journal-Name:Zhonghua O
yi O
xue O
za O
zhi O

Publication O
date: O
2019/01/31 O
06:00 O
[medline] O

Contours O
were O
analysed O
with O
Monaco O
ADMIRE O
(research O
v. O
2.0) O
to O
assess O
interobserver O
variability O
and O
accuracy O
by O
comparison O
with O
a O
gold O
standard O
clinician O
contour. O

The O
mean O
number O
of O
accurate O
lifestyle B-outcome
factors I-outcome
(that O
could O
affect O
fertility) O
mentioned O
increased O
from O
3.6 O
to O
4.4 O
(P O
< O
0.001) O
in O
the O
IG. O

BACKGROUND/AIM: O
The O
analysis O
of O
prognostic O
factors O
is O
important O
to O
identify O
determinants O
of O
disease-free O
survival O
(DFS) O
and O
overall O
survival O
(OS) O
in O
resected O
non-small-cell O
lung O
cancer O
(NSCLC). O

Funded O
by O
the O
British O
Heath O
Foundation O
and O
others; O
Current O
Controlled O
Trials O
number, O
ISRCTN46552265 O
.). O

METHODS: O
A O
total O
of O
82 O
patients O
with O
UIAS O
were O
randomly O
assigned O
to O
2 O
groups O
that O
received O
NMES O
therapy O
(NMES O
group) O
or O
sham O
NMES O
(sham O
group) O
for O
10 O
weeks. O

POC O
patients O
were O
randomly O
divided O
into O
group O
A O
(n=40) O
and O
group O
B O
(n=39). O

Belatacept O
serum O
concentrations O
were O
determined O
at O
several O
time O
points O
between O
belatacept O
infusions. O

Publication O
date: O
2019/01/12 O
06:00 O
[medline] O

Journal O
ID: O
2985248R O

Journal O
ID: O
2985248R O

Participants O
were O
randomly O
administered O
loading O
doses O
of O
prasugrel O
60 O
mg O
(group O
A, O
n O
= O
166) O
or O
30 O
mg O
(group O
B, O
n O
= O
166) O
before O
undergoing O
elective O
PCI O
in O
a O
1:1 O
manner. O

Conclusions: O
Tretinoin O
0.05% O
lotion O
was O
significantly O
more O
effective O
than O
its O
vehicle O
in O
achieving O
treatment B-outcome
success I-outcome
and O
reducing O
inflammatory O
and O
noninflammatory O
acne O
lesions B-outcome
in O
a O
Hispanic O
population. O

A O
significance O
level O
of O
p O
< O
0.05 O
was O
established. O

Journal O
ID: O
8208604 O

Furthermore, O
we O
identified O
two O
different O
pathways O
characterizing O
ways O
to O
success O
(consistency: O
81%, O
coverage: O
52%). O

lacrimal O
duct O
probing O
is O
the O
major O
treatment. O

CONCLUSIONS: O
Both O
techniques O
were O
effective O
in O
the O
short-term O
(18-30 O
months) O
in O
treatment O
of O
recurrent O
patellar O
dislocation. O

Publication O
Type: O
Journal O
Article O

Eligible O
patients O
were O
stratified O
by O
type O
2 O
diabetes O
status O
and O
they O
were O
randomly O
assigned O
(1:1:1) O
by O
a O
computer-based O
system O
to O
receive O
subcutaneous O
injections O
of O
placebo O
once O
a O
day, O
10 O
mg O
pegbelfermin O
once O
a O
day, O
or O
20 O
mg O
pegbelfermin O
once O
a O
week, O
all O
for O
16 O
weeks. O

In O
as-treated O
analyses, O
participants O
in O
the O
decolonization O
group O
who O
adhered O
fully O
to O
the O
regimen O
had O
44% O
fewer O
MRSA B-outcome
infections I-outcome
than O
the O
education O
group O
(hazard O
ratio, O
0.56; O
95% O
CI, O
0.36 O
to O
0.86) O
and O
had O
40% O
fewer O
infections B-outcome
from O
any O
cause O
(hazard O
ratio, O
0.60; O
95% O
CI, O
0.46 O
to O
0.78). O

30 O
individuals O
with O
CD O
were O
divided O
into O
2 O
groups: O
16 O
in O
the O
experimental O
group O
(EG) O
and O
14 O
in O
the O
control O
group O
(CG). O

The O
chi O
independent O
test O
or O
2-tailed O
paired O
t O
test O
were O
performed O
for O
statistical O
analysis. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

BACKGROUND: O
Medical O
researchers O
have O
been O
reluctant O
to O
use O
neuromuscular O
blocking O
drugs O
(NMBD) O
during O
the O
use O
of O
intraoperative O
motor O
evoked O
potential O
(MEP) O
monitoring O
despite O
the O
possibility O
of O
patient O
movement. O

Additional O
analyses O
showed O
that O
changes O
in O
active B-outcome
B12 I-outcome
, O
HcY B-outcome
and O
folate B-outcome
measures O
during O
WPI O
treatment O
correlated O
with O
improvements O
in O
cognitive B-outcome
function I-outcome
(all O
p O
< O
0.05). O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Clinical O
assessments, O
including O
neurological O
examination O
and O
EDSS O
scoring, O
were O
conducted O
at O
baseline O
and O
at O
weeks O
12 O
and O
24. O

The O
patients O
in O
the O
control O
group O
were O
given O
routine O
treatment O
and O
respiratory O
function O
exercise, O
and O
those O
in O
the O
observation O
group O
were O
given O
nursing O
intervention O
in O
addition O
to O
the O
treatment O
in O
the O
control O
group. O

The O
original O
trial O
(number, O
NCT00678275) O
and O
follow-up O
extension O
(number, O
NCT03042676) O
are O
registered O
at O
ClinicalTrials.gov. O

Title: O
A O
dose-finding O
randomized O
Phase O
II O
study O
of O
oral O
netupitant O
in O
combination O
with O
palonosetron O
.75 O
mg O
intravenous O
for O
the O
prevention O
of O
chemotherapy-induced O
nausea B-outcome
and O
vomiting B-outcome
in O
Japanese O
patients O
receiving O
highly O
emetogenic O
chemotherapy. O

PE O
teachers O
(n O
= O
29) O
from O
eleven O
schools O
will O
apply O
the O
intervention O
program O
to O
students O
(n O
= O
502) O
in O
PE O
classes O
for O
one O
month. O

Title: O
Prognostic O
Factors O
in O
Early-stage O
NSCLC: O
Analysis O
of O
the O
Placebo O
Group O
in O
the O
MAGRIT O
Study. O

CONCLUSIONS: O
Findings O
highlight O
the O
complexity O
of O
implementing O
a O
mhGAP-based O
training O
given O
its O
interaction O
with O
contextual O
factors O
to O
influence O
the O
attainment O
of O
expected O
outcomes. O

Conclusion:Compared O
with O
CHOP+IMRT O
regimen, O
the O
LOP+IMRT O
regimen O
for O
nasal O
NK/T-cell O
lymphoma O
patients O
resulted O
in O
higher O
overall O
remission B-outcome
rate, O
survival B-outcome
rate O
and O
lower O
adverse B-outcome
reactions I-outcome
, O
so O
it O
is O
worth O
in O
clinical O
promotion. O

Publication O
Type: O
Multicenter O
Study O

Patient O
follow-up O
to O
3 O
months O
was O
completed O
on O
April O
12, O
2018. O

Journal-Name:Journal O
of O
foot O
and O
ankle O
research O

Under O
VCV O
mode, O
the O
levels O
of O
peak B-outcome
airway I-outcome
pressure I-outcome
and O
exhaled B-outcome
tidal I-outcome
volume I-outcome
were O
increased O
with O
the O
increase O
in O
atomized O
oxygen O
flow, O
and O
there O
was O
significant O
difference O
at O
9 O
L/min O
as O
compared O
with O
those O
before O
atomization O
[ O
peak B-outcome
airway I-outcome
pressure I-outcome
(cmH2O): O
29.44+/-4.58 O
vs. O
24.39+/-4.64, O
exhaled B-outcome
tidal I-outcome
volume I-outcome
(mL): O
896.26+/-24.91 O
vs. O
497.61+/-8.67, O
both O
P O
< O
0.05]. O
There O
was O
no O
significant O
change O
in O
inspiratory B-outcome
tidal I-outcome
volume I-outcome
, O
and O
no O
significant O
difference O
at O
9 O
L/min O
of O
atomized O
oxygen O
flow O
as O
compared O
with O
that O
before O
atomization O
(mL: O
494.67+/-3.07 O
vs. O
492.61+/-6.05, O
P O
> O
0.05). O

There O
was O
no O
significant O
difference O
in O
Pittsburgh O
Sleep B-outcome
Quality I-outcome
Index O
(PSQI) O
score O
and O
Treatment O
Emergent O
Symptom O
Scale O
(TESS) O
score O
between O
the O
two O
groups. O

BACKGROUND: O
Systematic O
pelvic O
and O
paraaortic O
lymphadenectomy O
has O
been O
widely O
used O
in O
the O
surgical O
treatment O
of O
patients O
with O
advanced O
ovarian O
cancer, O
although O
supporting O
evidence O
from O
randomized O
clinical O
trials O
has O
been O
limited. O

One O
hundred O
and O
thirty O
adult O
patients O
with O
T2DM O
who O
were O
discharged O
to O
the O
community O
were O
randomly O
assigned O
to O
either O
the O
intervention O
or O
the O
control O
group. O

STUDY O
IDENTIFICATION O
AND O
TRIAL O
REGISTRATION: O
Study O
Identification: O
EVOLVE-1 O
(I5Q-MC-CGAG); O
EVOLVE-2 O
(I5Q-MC-CGAH); O
REGAIN O
(I5Q-MC-CGAI) O
TRIAL O
REGISTRATION: O
ClinicalTrials.gov O
; O
NCT02614183 O
(EVOLVE-1); O
NCT02614196 O
(EVOLVE-2); O
NCT02614261 O
(REGAIN). O

Before O
and O
after O
supplementation, O
we O
determined O
plasma O
fatty B-outcome
acid I-outcome
concentrations, O
latencies O
of O
visually B-outcome
evoked I-outcome
potentials I-outcome
, O
fine B-outcome
and Seperator
gross B-outcome
motor I-outcome
behaviour E2-outcome
, O
and O
IQ B-outcome
. O
Fatty O
acid O
desaturase O
genotypes O
were O
also O
determined. O

We O
also O
examined O
how O
health O
warning O
severity O
influences O
these O
reactions B-outcome
and O
whether O
there O
is O
an O
interaction O
between O
self-affirmation O
and O
severity. O

PARTICIPANTS: O
13 O
046 O
women O
aged O
16 O
years O
or O
older O
with O
a O
low O
risk O
singleton O
pregnancy. O

After O
baseline O
competency O
assessment, O
parents O
received O
instruction O
according O
to O
their O
group. O

METHODS: O
A O
total O
of O
98 O
dyslipidemic O
patients O
were O
enrolled O
and O
divided O
into O
amla O
and O
placebo O
groups. O

Journal O
ID: O
8200894 O

Publication O
date: O
2019/01/08 O
06:00 O
[medline] O

However, O
we O
found O
that O
using O
the O
motion O
tracking O
device O
led O
to O
transfer B-outcome
of O
performance O
to O
the O
touchscreen. O

Journal-Name:Complementary O
therapies O
in O
clinical O
practice O

Title: O
Comparison O
of O
sufentanil-midazolam O
and O
sevoflurane O
for O
anesthesia O
induction O
in O
children O
undergoing O
cardiac O
surgery O
by O
real-time O
hemodynamic B-outcome
and O
cardiac B-outcome
efficiency O
monitoring: O
A O
prospective O
randomized O
study. O

In O
addition, O
gene O
expression O
analysis O
in O
PBMC O
showed O
subtle O
changes O
in O
superoxide B-outcome
metabolic I-outcome
processes. O

Compared O
with O
the O
preoperative O
levels, O
serum O
cortisol B-outcome
level O
at O
the O
end O
of O
the O
operation O
was O
increased O
in O
the O
sedation O
group O
but O
lowered O
in O
the O
control O
group, O
and O
the O
variations O
of O
serum O
cortisol B-outcome
level O
differed O
significantly O
between O
the O
two O
groups O
(t=4.75, O
P O
&lt; O
0.01). O

The O
clinical O
examination O
included O
hematology B-outcome
and O
blood B-outcome
chemistry I-outcome
tests, O
urinalysis B-outcome
, O
vital B-outcome
signs I-outcome
, O
body B-outcome
weight I-outcome
, O
and O
electrocardiogram B-outcome
(ECG) I-outcome
. O
RESULTS: O
Eleven O
adverse B-outcome
reactions I-outcome
were O
observed O
in O
ten O
subjects O
receiving O
BT-11 O
while O
seven O
adverse B-outcome
reactions I-outcome
in O
six O
subjects O
receiving O
placebo. O

The O
tendency O
to O
use O
different O
methods O
of O
complementary O
medicine O
to O
control O
menopausal O
symptoms O
is O
increasing. O

HR's O
for O
erythromycin, O
compared O
to O
beta-lactam O
monotherapy, O
on O
any O
cardiac B-outcome
event I-outcome
and O
heart B-outcome
failure I-outcome
were O
1.60 O
(95% O
CI O
1.09;2.36) O
and O
1.89 O
(95% O
CI O
1.22;2.91), O
respectively. O

Journal-Name:Medicine O

More O
interestingly, O
preoperative O
analgesia O
group O
patients O
consumed O
less O
patient-controlled O
analgesia B-outcome
compared O
to O
postoperative O
analgesia O
group O
patients O
at O
72 O
hours O
post O
operation. O

Results O
were O
extrapolated O
to O
two O
years O
after O
randomization. O

Whether O
L-valine O
affects O
energy O
intake, O
and O
the O
gastrointestinal O
functions O
involved O
in O
the O
regulation O
of O
energy O
intake, O
as O
well O
as O
blood O
glucose, O
in O
humans, O
is O
currently O
unknown. O

However, O
ED95 O
is O
more O
meaningful O
to O
clinical O
practice O
than O
ED50. O

PURPOSE: O
To O
determine O
the O
effects O
of O
botulinum O
toxin O
type O
A O
(BTX-A) O
injection O
on O
dry B-outcome
eye I-outcome
signs I-outcome
, Seperator
symptoms S2-outcome
, O
and O
tear O
cytokine B-outcome
levels O
in O
patients O
with O
intractable O
dry O
eye O
disease O
(DED). O

Journal-Name:British O
journal O
of O
anaesthesia O

Journal-Name:Indian O
heart O
journal O

Journal-Name:Medicine O

Withdrawal B-outcome
symptoms I-outcome
declined O
immediately O
after O
smoking O
or O
using O
IQOS(TM), O
and O
with O
some O
delay O
after O
vaping. O

There O
are O
also O
no O
studies O
that O
establish O
a O
clear O
relationship O
between O
EEN O
in O
MAP O
and O
levels O
of O
albuminemia O
and O
CRP. O

Journal-Name:Journal O
of O
the O
International O
Society O
of O
Sports O
Nutrition O

Patients O
who O
received O
Ahmed O
glaucoma O
valve O
implantation O
surgery O
from O
August O
2015 O
to O
January O
2017 O
at O
the O
Xiamen O
Eye O
Center O
were O
randomly O
divided O
into O
2 O
groups. O

Adult O
mothers O
of O
children O
born O
in O
participating O
maternity O
wards O
were O
recruited O
between O
March O
2014 O
and O
February O
2015. O

No O
statistical O
difference O
was O
also O
observed O
in O
safety O
laboratory O
tests, O
vital B-outcome
signs I-outcome
, O
and O
electrocardiogram B-outcome
(ECG) I-outcome
between O
two O
groups. O

Journal-Name:Radiation O
oncology O
(London, O
England) O

Logistic O
regression O
analyses O
were O
used O
for O
between O
treatment O
comparisons. O

Statistically O
significant O
differences O
in O
cumulative O
QALYs O
and O
costs B-outcome
were O
found O
at O
six O
and O
12 O
months O
for O
the O
decompression O
versus O
no O
treatment O
comparison O
only. O

Refractory B-outcome
disease I-outcome
developed O
in O
no O
patients O
in O
the O
caplacizumab O
group O
and O
in O
three O
patients O
in O
the O
placebo O
group. O

Publication O
date: O
2018/12/04 O
00:00 O
[accepted] O

BACKGROUND: O
Transcutaneous O
electrical O
nerve O
stimulation O
(TENS) O
is O
often O
used O
for O
the O
treatment O
of O
low-back O
pain O
(LBP). O

They O
were O
randomly O
assigned O
to O
an O
intervention O
group O
(410 O
participants) O
or O
comparison O
group O
(202 O
participants). O

Journal O
ID: O
0414003 O

We O
assessed O
the O
effectiveness O
of O
the O
interventions O
on O
intensity B-outcome
of I-outcome
low I-outcome
back I-outcome
pain I-outcome
, O
pain B-outcome
interfering I-outcome
with Seperator
work I-outcome
and O
fear O
avoidance O
beliefs B-outcome
against O
the O
Control, O
and O
calculated O
the O
incremental O
cost-effectiveness O
ratios O
for O
sickness B-outcome
absence I-outcome
and O
QALY. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Journal O
ID: O
0417355 O

CONCLUSIONS: O
Endometrial O
scratching O
did O
not O
result O
in O
a O
higher O
rate O
of O
live B-outcome
birth I-outcome
than O
no O
intervention O
among O
women O
undergoing O
IVF. O
( O

Fatal B-outcome
adverse I-outcome
events I-outcome
occurred O
in O
seven O
(3%) O
patients O
in O
the O
A+CHP O
group O
and O
nine O
(4%) O
in O
the O
CHOP O
group. O

Each O
group O
was O
subdivided O
into O
the O
3 O
classes O
based O
on O
the O
body O
mass O
index O
(BMI; O
low, O
normal, O
high). O

Twelve O
patients O
were O
treated O
with O
SuperPATH O
approach O
(SuperPATH O
group) O
and O
12 O
patients O
with O
posterolateral O
approach O
(control O
group). O

Serum O
epinephrine B-outcome
in O
group O
D O
were O
significantly O
lower O
than O
them O
in O
group O
C O
at O
T(2), O
T(3), O
T(4), O
T(5) O
(t=6.153, O
8.774, O
9.127, O
8.409, O
respectively; O
all O
P<0.05), O
but O
there O
were O
no O
difference O
between O
these O
two O
groups O
at O
T(0), O
T(1), O
T(6), O
T(7), O
T(8)(all O
P>0.05). O

During O
the O
follow-up, O
no O
loosening B-outcome
or O
migration B-outcome
was O
observed. O

Title: O
A O
Randomized O
Trial O
of O
E-Cigarettes O
versus O
Nicotine-Replacement O
Therapy. O

Journal O
ID: O
7511141 O

Group O
A O
(n O
= O
53) O
was O
the O
single-shot O
group O
(16 O
female O
patients O
and O
37 O
male O
patients O
with O
a O
mean O
age O
of O
63.9 O
years O
(sd O
9.6)), O
group O
B O
(n O
= O
51) O
was O
the O
24-hour O
infusion O
group O
(22 O
female O
patients O
and O
29 O
male O
patients O
with O
a O
mean O
age O
of O
66.5 O
years O
(sd O
8.5)), O
and O
group O
C O
(n O
= O
52) O
was O
the O
48-hour O
infusion O
group O
(18 O
female O
patients O
and O
34 O
male O
patients O
with O
a O
mean O
age O
of O
62.2 O
years O
(sd O
8.7)). O

The O
efficacy O
of O
short- O
and O
long-TXA O
protocols O
in O
the O
reduction O
of O
perioperative O
real O
blood B-outcome
loss I-outcome
(RBL) O
was O
compared O
with O
a O
placebo O
group. O

National O
and O
Kapodistrian O
University O
of O
Athens, O
Athens, O
Greece. O

Were O
used O
highly B-outcome
sensitive I-outcome
troponin I-outcome
(HF-Tr) I-outcome
and O
creatine B-outcome
phosphokinase-MB I-outcome
as O
an O
irreversible O
myocardial O
damage O
biomarkers. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

In O
this O
study, O
we O
investigated O
mtDNA B-outcome
, O
mitochondrial B-outcome
dynamics I-outcome
, Seperator
function S1-outcome
and O
metabolic O
pathways O
to O
determine O
if O
mitochondrial O
damage O
plays O
a O
critical O
role O
in O
the O
development O
of O
tubular O
injury O
in O
DKD O
patients. O

Title: O
[Effects O
of O
early O
enteral O
nutrition O
in O
patients O
with O
mild O
acute O
pancreatitis. O

Title: O
Comparison O
of O
prostate O
delineation O
on O
multimodality O
imaging O
for O
MR-guided O
radiotherapy. O

BACKGROUND: O
The O
onset O
of O
puberty O
and O
menarche O
is O
a O
specifically O
vulnerable O
time O
for O
girls, O
during O
which O
they O
begin O
to O
show O
interest O
in O
the O
opposite O
sex, O
while O
becoming O
exposed O
to O
a O
myriad O
of O
external O
pressures, O
including O
sexual O
coercion O
or O
harassment O
from O
boys O
and O
men, O
expectations O
to O
marry O
from O
their O
families, O
and O
the O
need O
to O
perform O
well O
in O
primary O
school O
in O
order O
to O
qualify O
for O
secondary O
school. O

All O
patients O
were O
anaesthetized O
(induced O
and O
maintained) O
with O
intravenous O
target-controlled O
infusion(TCl) O
of O
propofol O
and O
remifentanil, O
and O
intermittent O
intravenous O
injection O
of O
cisatracuriumbesylate. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

BACKGROUND: O
Proprietary O
spearmint O
extract O
(PSE) O
containing O
a O
minimum O
14.5% O
rosmarinic O
acid O
and O
24% O
total O
phenolic O
content, O
has O
evinced O
positive O
effects O
on O
cognition O
in O
individuals O
aged O
50-70 O
with O
memory O
impairment O
after O
chronic O
supplementation. O

A O
single O
agent O
to O
reduce O
cholesterol O
as O
well O
as O
TG O
is O
rare. O

All O
participants O
were O
tested O
(test-1) O
following O
an O
introductory O
course O
of O
basic O
ultrasonography. O

The O
3-year O
survival B-outcome
rate O
of O
group O
A O
was O
higher O
than O
that O
of O
group O
BP<0.05. O

Publication O
Type: O
Journal O
Article O

The O
forearm O
band O
showed O
better O
scores O
on O
joint B-outcome
position I-outcome
reproduction I-outcome
at O
70 O
degrees O
compared O
with O
the O
elbow O
sleeve O
(P O
= O
.006), O
whereas O
the O
elbow O
sleeve O
showed O
better O
scores O
at O
110 O
degrees O
(P O
< O
.001). O

We O
aimed O
to O
determine O
if O
a O
program O
of O
aerobic O
and O
resistance O
exercise O
could O
safely O
achieve O
body B-outcome
composition I-outcome
changes O
in O
patients O
with O
Inflammatory O
Bowel O
Disease. O

It O
builds O
on O
an O
existing O
program O
of O
mental O
health O
research O
with O
demonstrated O
efficacy O
- O
the O
Aboriginal O
and O
Islander O
Mental O
Health O
Initiative O
(AIMhi) O
- O
to O
test O
the O
newly O
developed O
electronic O
motivational O
care O
planning O
(MCP) O
therapy O
- O
the O
AIMhi O
Stay O
Strong O
App. O

It O
was O
found O
that O
exhausted O
terminal O
programmed O
cell O
death O
1 O
(PD1)+ O
CD8+ O
T O
cells O
in O
the O
peripheral O
blood O
are O
independently O
associated O
with O
worse O
progression B-outcome
free I-outcome
survival I-outcome
(PFS) I-outcome
and O
overall B-outcome
survival I-outcome
(OS) I-outcome
. O
Notably, O
hydrogen O
gas O
decreased O
the O
abundance O
of O
exhausted O
terminal O
PD1+ B-outcome
CD8+ I-outcome
T I-outcome
cells I-outcome
, O
increased O
that O
of O
active O
terminal O
PD1 B-outcome
CD8+ I-outcome
T I-outcome
cells I-outcome
, O
and O
improved O
progression B-outcome
free I-outcome
survival I-outcome
(PFS) I-outcome
and O
overall B-outcome
survival I-outcome
(OS) I-outcome
times, O
suggesting O
that O
the O
balance O
between O
terminal O
PD1+ B-outcome
and Seperator
PD1 B-outcome
CD8+ I-outcome
cells E3-outcome
is O
critical O
for O
cancer O
prognosis. O

The O
OSTAP O
group O
showed O
a O
statistically O
significant O
reduction O
at O
the O
postoperative O
24th O
hour O
tramadol B-outcome
consumption O
(mean O
difference O
22 O
mg, O
95% O
confidence O
interval O
-38.4 O
to O
-5.6 O
mL; O
P O
= O
.009). O

Title: O
Wellbeing O
intervention O
for O
chronic O
kidney O
disease O
(WICKD): O
a O
randomised O
controlled O
trial O
study O
protocol. O

No O
statistically O
significant O
difference O
was O
found O
between O
the O
orthoses' O
effects O
on O
pain B-outcome
reduction O
and O
grip B-outcome
strength I-outcome
(P O
> O
.05). O

Journal-Name:American O
journal O
of O
orthodontics O
and O
dentofacial O
orthopedics O
: O
official O
publication O
of O
the O
American O
Association O
of O
Orthodontists, O
its O
constituent O
societies, O
and O
the O
American O
Board O
of O
Orthodontics O

RESULTS: O
We O
conducted O
three O
sub-studies O
in O
consecutive O
years O
of O
2011, O
2012, O
and O
2013 O
to O
reach O
an O
adequate O
sample O
size. O

Publication O
date: O
2019/02/23 O
06:00 O
[medline] O

Journal-Name: O
Revista O
latino-americana O
de O
enfermagem O

Publication O
date: O
2019/01/05 O
00:00 O
[accepted] O

CONCLUSIONS: O
Once-monthly O
injections O
of O
givosiran O
in O
patients O
who O
had O
recurrent O
porphyria B-outcome
attacks O
resulted O
in O
mainly O
low-grade O
adverse B-outcome
events I-outcome
, O
reductions O
in O
induced O
ALAS1 B-outcome
mRNA I-outcome
levels, O
nearly O
normalized O
levels O
of O
the O
neurotoxic O
intermediates O
delta B-outcome
aminolevulinic I-outcome
acid I-outcome
and O
porphobilinogen B-outcome
, O
and O
a O
lower O
attack B-outcome
rate O
than O
that O
observed O
with O
placebo. O
( O

In O
addition, O
22 O
patients O
treated O
by O
monthly O
regimen O
were O
evaluated O
after O
18 O
months O
of O
treatment. O

Participants O
were O
randomly-assigned O
to O
receive O
either O
CM O
or O
CHO O
immediately O
post-exercise. O

Conclusion: O
High-fidelity O
simulation O
training O
is O
superior O
to O
low-fidelity O
CPR O
manikin O
training O
for O
teaching O
fourth-year O
medical O
students O
implementation O
of O
high-quality O
CPR O
for O
chest B-outcome
compression I-outcome
depth I-outcome
and O
compression B-outcome
fraction I-outcome
. O

Follow O
up O
of O
the O
participants' O
outcomes O
was O
conducted O
via O
electronic O
medical O
records. O

Publication O
date: O
2019/02/17 O
06:00 O
[entrez] O

Journal O
ID: O
8912748 O

BACKGROUPD: O
This O
study O
investigated O
the O
plasma O
fentanyl O
concentration O
and O
efficacy O
of O
transdermal O
fentanyl O
patch O
(TFP) O
(25 O
mug/h) O
in O
the O
management O
of O
acute O
postoperative O
pain B-outcome
. O
METHODS: O
Patients O
undergoing O
laparoscopic O
cholecystectomy O
were O
randomly O
allocated O
to O
2 O
groups. O

In O
multivariate O
analysis O
of O
disease-free B-outcome
survival I-outcome
, O
SPC-prognosis O
[hazard O
ratio O
(HR): O
1.879 O
(1.101-3.205), O
2.399 O
(1.415-4.067), O
p=0.003 O
and O
MSI O
status O
(HR: O
0.363, O
95% O
confidence O
interval: O
0.161-0.820, O
p=0.015) O
were O
independent O
prognostic O
factors O
along O
with O
age, O
Lauren O
classification, O
TNM O
stage, O
and O
chemotherapy. O

Haematology O

Knee B-outcome
function I-outcome
was O
assessed O
using O
HSS, O
KSS, O
NASS, O
and O
ROM. O

At O
3 O
years, O
overall B-outcome
survival I-outcome
was O
67% O
(95% O
CI, O
57 O
to O
75) O
in O
the O
hybrid-procedure O
group, O
as O
compared O
with O
55% O
(95% O
CI, O
45 O
to O
64) O
in O
the O
open-procedure O
group; O
disease-free B-outcome
Survival I-outcome
was O
57% O
(95% O
CI, O
47 O
to O
66) O
and O
48% O
(95% O
CI, O
38 O
to O
57), O
respectively. O

TRIAL O
REGISTRATION: O
Clinical O
trials, O
NCT01949558 O
, O
2013-09-24. O

PMID: O
31613945 O

CLINICAL O
TRIAL O
REGISTRATION: O
NCT00788398. O

Publication O
date: O
2019/01/08 O
06:00 O
[entrez] O

DESIGN: O
Open O
randomized O
monocentric O
study. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Publication O
date: O
['2019/10/15 O
06:00' O

After O
144 O
weeks O
of O
treatment, O
HBV B-outcome
DNA I-outcome
levels O
were O
similarly O
suppressed O
in O
both O
groups O
(ETV O
vs O
TDF; O
-6.6485 O
vs O
-6.692 O
log10IU/mL, O
P O
= O
.807). O

Conclusion: O
The O
results O
suggest O
that O
it O
is O
feasible O
to O
use O
the O
Borg O
rating O
of O
perceived B-outcome
exertion I-outcome
scale O
to O
adjust O
FT O
intensity. O

Parents O
were O
taught O
the O
same O
3 O
infant-handling O
techniques O
after O
random O
assignment O
to O
the O
(1) O
direct, O
(2) O
video, O
or O
(3) O
written-pictorial O
instructional O
groups. O

The O
incidence O
of O
hand B-outcome
food I-outcome
mouth I-outcome
disease I-outcome
(2.1%) O
in O
intervention O
group O
was O
significantly O
lower O
than O
that O
in O
control O
group O
(4.2%) O
at O
year O
2 O
(chi O
= O
22.138, O
P O
<.001). O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Journal O
ID: O
7501160 O

On O
the O
basis O
of O
traditional O
treatment, O
the O
children O
in O
the O
SBH O
treatment O
group O
were O
given O
SBH O
treatment O
within O
6 O
hours O
after O
birth. O

Journal O
ID: O
2985248R O

A O
net O
cost B-outcome
analysis O
from O
an O
employer O
perspective O
demonstrated O
the O
intervention O
group O
was O
associated O
with O
a O
mean O
of O
2.97 O
h O
less O
absenteeism B-outcome
over O
a O
4 O
week O
period O
(p O
= O
0.62), O
which O
could O
result O
in O
net O
savings O
ranging O
from O
pound66 O
to O
pound735 O
depending O
on O
the O
wage O
rate O
employed. O

The O
primary O
efficacy O
endpoint O
was O
non-inferiority O
of O
HP O
relative O
to O
G O
+ O
T O
for O
success O
at O
achieving O
hemostasis B-outcome
within O
6 O
minutes. O

Full-mouth O
scaling O
and O
root O
planing O
(SRP) O
was O
performed O
followed O
by O
the O
application O
of O
curcumin O
gel O
on O
a O
single O
side. O

There O
was O
a O
minor O
change O
(0.0 O
to O
0.3 O
mm) O
in O
peri-implant B-outcome
mucosal I-outcome
zenith I-outcome
positions I-outcome
over O
time O
and O
between O
groups. O

Publication O
date: O
2019/03/01 O
06:00 O
[entrez] O

Introduction: O
Videoconferencing O
has O
been O
employed O
in O
numerous O
medical O
education O
settings O
ranging O
from O
remote O
supervision O
of O
medical O
trainees O
to O
conducting O
residency O
interviews. O

METHODS: O
The O
study O
included O
20 O
men O
(20-31 O
yrs., O

BACKGROUND: O
Based O
on O
epidemiological O
and O
clinical O
data O
acute O
appendicitis O
can O
present O
either O
as O
uncomplicated O
(70-80%) O
or O
complicated O
(20-30%) O
disease. O

METHODS: O
50 O
patients O
with O
chronic O
low O
back O
pain O
(78% O
female, O
49.7+/-10.0 O
years) O
were O
randomized O
to O
two O
Gua O
Sha O
treatments O
(n=25) O
or O
waitlist O
control O
(n=25). O

The O
OR O
Study O
intervention O
was O
delayed O
because O
of O
interruptions O
in O
finalizing O
the O
national O
CHW O
policy, O
two O
separate O
cholera O
epidemics, O
and O
the O
Ebola O
epidemic O
lasting O
more O
than O
2 O
years. O

Publication O
Type: O
Journal O
Article O

BACKGROUND: O
Tafenoquine, O
a O
single-dose O
therapy O
for O
Plasmodium O
vivax O
malaria, O
has O
been O
associated O
with O
relapse O
prevention O
through O
the O
clearance O
of O
P. O
vivax O
parasitemia O
and O
hypnozoites, O
termed O
"radical O
cure." O

Protrusion B-outcome
and Seperator
proclination B-outcome
of I-outcome
mandibular I-outcome
incisors E3-outcome
were O
greater O
in O
the O
IA O
group O
(95.90 O
degrees O
+/- O
5.34 O
degrees O
) O
compared O
with O
the O
MA O
group O
(92.04 O
degrees O
+/- O
7.92 O
degrees O
). O

BACKGROUND: O
Many O
surgical O
procedures O
have O
been O
described O
to O
treat O
recurrent O
patellar O
dislocation, O
but O
none O
of O
these O
techniques O
has O
been O
successful O
in O
all O
patients. O

Title: O
A O
randomized O
controlled O
trial O
of O
ultrasound-guided O
pulsed O
radiofrequency O
for O
patients O
with O
frozen O
shoulder. O

After O
further O
exclusions, O
75 O
(94%) O
patients O
were O
randomly O
assigned O
to O
groups, O
received O
at O
least O
one O
dose O
of O
treatment O
(25 O
patients O
to O
receive O
10 O
mg O
pegbelfermin O
once O
a O
day; O
24 O
patients O
to O
receive O
20 O
mg O
pegbelfermin O
once O
a O
week, O
and O
26 O
patients O
to O
receive O
placebo), O
and O
were O
included O
in O
the O
primary O
analysis. O

At O
day O
5, O
composite O
cure B-outcome
was O
observed O
in O
88.0% O
of O
the O
patients O
(168 O
of O
191 O
patients) O
in O
the O
plazomicin O
group O
and O
in O
91.4% O
(180 O
of O
197 O
patients) O
in O
the O
meropenem O
group O
(difference, O
-3.4 O
percentage O
points; O
95% O
confidence O
interval O
[CI], O
-10.0 O
to O
3.1). O

RESULTS: O
After O
followed O
up O
for O
6 O
to O
20 O
months, O
a O
thinner O
appearance B-outcome
was O
seen O
in O
3 O
eyes O
(2.2%) O
in O
the O
corneal O
graft O
group O
and O
7 O
eyes O
(5.5%) O
in O
the O
scleral O
group. O

OBJECTIVE: O
To O
reduce O
the O
inappropriate O
identification O
of O
eye O
drops, O
through O
the O
use O
of O
different O
colors. O

A O
prespecified O
interim O
analysis O
at O
week O
8 O
showed O
a O
greater O
than O
expected O
change O
in O
the O
primary O
outcome O
and O
supported O
early O
closing O
of O
patient O
enrolment, O
since O
this O
analysis O
indicated O
that O
the O
full O
planned O
sample O
size O
was O
not O
needed. O

A O
total O
of O
55 O
patients O
with O
histologically O
and O
clinically O
diagnosed O
stage O
IV O
colorectal O
carcinoma O
were O
enrolled O
between O
July O
2014 O
and O
July O
2017. O

The O
study O
consisted O
of O
a O
pre-screening, O
screening, O
day O
0 O
baseline O
(randomization O
visit) O
and O
three O
follow-up O
visits O
on O
days O
14, O
28 O
and O
56. O

RESULTS: O
Of O
131 O
subjects O
who O
underwent O
routine O
phacoemulsification, O
analyzable O
endothelial O
images O
at O
24 O
months O
were O
available O
for O
126 O
subjects O
(96.2%). O

AIMS O
OF O
THE O
STUDY: O
The O
safety O
and O
efficacy O
of O
a O
hemostatic O
powder O
(HP) O
versus O
a O
control O
agent, O
absorbable O
gelatin O
sponge O
and O
thrombin O
(G O
+ O
T), O
were O
assessed, O
using O
a O
validated, O
quantitative O
bleeding B-outcome
severity I-outcome
scale. O

PROTOCOL: O
The O
protocol O
was O
not O
published O
before O
trial O
commencement. O

METHODS: O
The O
study O
was O
a O
randomised, O
double-blinded, O
placebo-controlled O
intervention O
study O
with O
35 O
overweight O
subjects O
with O
mildly O
or O
moderately O
elevated O
blood O
pressure, O
who O
took O
4 O
g O
krill O
oil O
powder O
or O
4 O
g O
of O
placebo O
during O
an O
8-week O
follow-up O
period. O

Title: O
Effectiveness O
of O
routine O
third O
trimester O
ultrasonography O
to O
reduce O
adverse B-outcome
perinatal I-outcome
outcomes I-outcome
in O
low O
risk O
pregnancy O
(the O
IRIS O
study): O
nationwide, O
pragmatic, O
multicentre, O
stepped O
wedge O
cluster O
randomised O
trial. O

Results O
The O
TC O
had O
produced O
significant O
positive O
chances O
in O
depression B-outcome
and O
some O
heart B-outcome
rate I-outcome
variability I-outcome
parameters O
(mean O
heart B-outcome
rate I-outcome
, O
RMSSD B-outcome
, O
HF B-outcome
, O
LFnorm B-outcome
, O
and O
HFnorm B-outcome
) O
(p O
< O
0.05), O
whereas O
these O
positive O
results O
were O
not O
observed O
in O
the O
control O
group. O

Twelve O
deaths B-outcome
(8 O
in O
the O
omadacycline O
group O
and O
4 O
in O
the O
moxifloxacin O
group) O
occurred O
during O
the O
trial. O

Title: O
Does O
L-Methylfolate O
Supplement O
Methylphenidate O
Pharmacotherapy O
in O
Attention-Deficit/Hyperactivity O
Disorder?: O

Publication O
date: O
2018/05/09 O
00:00 O
[accepted] O

BACKGROUND: O
Maintenance O
of O
effect O
following O
treatment O
with O
galcanezumab O
compared O
to O
placebo O
in O
adult O
patients O
with O
episodic O
or O
chronic O
migraine O
was O
evaluated. O

min(-1); O
CON O
= O
0.19 O
+/- O
0.05 O
degrees O
C O
. O

Publication O
date: O
2019/02/15 O
06:00 O
[medline] O

We O
aimed O
to O
compare O
the O
immunogenicity B-outcome
and O
safety O
of O
the O
most O
commonly O
used O
HA O
vaccines O
in O
ethnic O
Korean O
children O
aged O
12 O
to O
18 O
months. O

Journal-Name:BMC O
public O
health O

The O
initial O
3 O
mg O
dose O
was O
increased O
to O
4 O
mg O
from O
cycle O
5 O
if O
tolerated O
during O
cycles O
1-4. O

It O
may O
be O
used O
as O
an O
alternative O
drug O
for O
fentanyl O
in O
pain O
control O
after O
orthopedic O
surgery. O

Our O
purpose O
was O
to O
investigate O
the O
effectiveness O
and O
cost-effectiveness O
of O
three O
intervention-arms O
(combined O
neuromuscular O
exercise O
and O
back O
care O
counselling O
or O
either O
alone) O
compared O
with O
non-treatment. O

Journal-Name:Nutrients O

Publication O
Type: O
Journal O
Article O

METHODS: O
In O
this O
randomized O
controlled O
trial, O
we O
compared O
the O
efficacy O
of O
DR O
versus O
EODR O
by O
measuring O
lipid B-outcome
indices O
and O
serum O
HMGCR B-outcome
levels O
at O
baseline O
and O
after O
12 O
weeks O
of O
10mg O
atorvastatin O
therapy. O

A O
sequential O
design O
was O
used O
with O
a O
triangular O
continuation O
region. O

Publication O
Type: O
Randomized O
Controlled O
Trial O

L(- O
1); O
PL: O
8.7 O
+/- O
0.9 O
mmol. O

They O
were O
randomly O
treated O
by O
endoscopic O
sclerotherapy O
or O
cyanoacrylate O
injection O
as O
banding O
was O
not O
suitable O
for O
those O
patients O
due O
to O
profuse O
bleeding O
making O
unclear O
endoscopic O
visual O
field. O

Aim: O
To O
clinically O
assess O
the O
efficacy O
of O
resin O
infiltration O
versus O
fluoride O
varnish O
for O
arresting O
white B-outcome
spot I-outcome
lesions I-outcome
(WSLs) I-outcome
on O
permanent O
teeth O
in O
children. O

METHODS: O
A O
cross-sectional O
study O
was O
carried O
out O
among O
healthy O
controls O
(HCs, O
n O
= O
65), O
diabetes O
patients O
without O
kidney O
disease O
(DCs, O
n O
= O
48) O
and O
DKD O
patients O
(n O
= O
60). O

PATIENTS: O
A O
total O
of O
288 O
patients O
with O
clinically O
confirmed O
uncontrolled O
chronic O
rhinosinusitis O
were O
subjected O
to O
randomization O
(1:1 O
ratio). O

METHODS: O
This O
prospective O
study O
included O
113 O
cirrhotic O
patients O
with O
actively O
bleeding O
esophageal O
varices. O

Children O
with O
phenylketonuria O
(PKU) O
follow O
a O
protein O
restricted O
diet O
with O
negligible O
amounts O
of O
docosahexaenoic O
acid O
(DHA). O

Publication O
date: O
2019/01/31 O
06:00 O
[entrez] O

Journal O
ID: O
7511141 O

Belatacept O
concentrations O
were O
determined O
in O
a O
total O
of O
203 O
serum O
samples O
collected O
during O
26 O
infusion O
intervals O
from O
5 O
renal O
transplant O
recipients. O

The O
selection O
of O
proper O
respirators O
and O
training O
would O
be O
beneficial O
to O
the O
safety O
of O
healthcare O
providers. O

Undoubtedly, O
further O
in O
vitro O
and O
in O
vivo O
studies O
need O
to O
be O
performed O
in O
order O
to O
elucidate O
possible O
mechanisms O
of O
action O
and O
corroborate O
our O
preliminary O
results. O

Obesity O
prevention O
campaign O
sponsorship O
promoted O
higher O
campaign O
awareness B-outcome
and O
perceived B-outcome
event-sponsor I-outcome
fit I-outcome
, O
but O
did O
not O
impact O
food O
attitudes B-outcome
or O
preference B-outcome
for O
unhealthy O
versus O
healthier O
foods. O

Publication O
date: O
2019/01/08 O
06:00 O
[entrez] O

The O
BRPE O
could O
be O
a O
valuable O
tool O
for O
clinicians O
to O
dose O
FT O
intensity O
after O
a O
stroke, O
but O
this O
remains O
to O
be O
tested. O

Journal-Name:The O
New O
England O
journal O
of O
medicine O

Journal O
ID: O
101234168 O

Four-hundred O
twenty-four O
patients O
with O
septic O
shock O
were O
included O
between O
March O
2017 O
and O
March O
2018. O

Title: O
Does O
all O
single O
infarction O
have O
lower O
risk O
of O
stroke B-outcome
recurrence O
than O
multiple O
infarctions O
in O
minor O
stroke? O

However, O
this O
needs O
reconfirmation O
in O
a O
larger O
study. O

Journal-Name:Nutrients O

TRIAL O
REGISTRATION: O
This O
trial O
was O
registered O
prior O
to O
enrollment O
at O
the O
Registry O
for O
International O
Impact O
Evaluations O
(RIDIE O
STUDY O
ID: O
582a2462ae2ab): O
http://ridie.3ieimpact.org/index.php?r=search/detailView&id=492 O
. O

RESULTS: O
Despite O
similar O
fluoroscopy O
times O
(20.4+/-9.4min O
with O
RADPAD O
vs. O
19.4+/-9.2min O
without O
RADPAD, O
P=0.871) O
and O
total O
radiation O
dose O
(3.4+/-4.3 O
Gy O
with O
RADPAD O
vs. O
2.3+/-1.4 O
Gy, O
P=0.198), O
the O
relative B-outcome
operator I-outcome
exposure I-outcome
was O
significantly O
less O
with O
RADPAD O
(1.39+/-0.95) O
as O
compared O
to O
no O
RADPAD O
group O
(2.27+/-1.4) O
(p=0.004) O
amounting O
to O
a O
39% O
reduction. O

Results: O
After O
the O
treatment, O
the O
improvement O
of O
glycosylated B-outcome
hemoglobin I-outcome
(HbA1c) I-outcome
, O
blood B-outcome
urea I-outcome
nitrogen I-outcome
(BUN) I-outcome
, O
systolic B-outcome
pressure I-outcome
(SP), O
high B-outcome
sensitive I-outcome
C-reactive I-outcome
protein I-outcome
(hs-CRP) I-outcome
, O
erythrocyte B-outcome
sedimentation I-outcome
rate I-outcome
(ESR) I-outcome
, O
estimated B-outcome
glomerular I-outcome
filtration I-outcome
rate I-outcome
(eGFR) I-outcome
in O
the O
intervention O
group O
were O
significantly O
better O
than O
those O
in O
the O
control O
group O
(all O
P<0.05), O
as O
well O
as O
the O
urine O
albumin/creatine B-outcome
ratio I-outcome
[47(26, O
120) O
mg/g O
vs O
103(42, O
267) O
mg/g, O
P<0.001]and O
serum O
cystatin B-outcome
C I-outcome
[(0.83+/-0.30) O
mg/L O
vs O
(0.98+/-0.25) O
mg/L, O
P=0.031]. O
However, O
there O
was O
no O
statistically O
significant O
difference O
of O
urine O
albumin/creatine B-outcome
ratio I-outcome
and O
cystatin B-outcome
C I-outcome
between O
before O
and O
after O
treatment O
in O
the O
control O
group O
(all O
P>0.05). O

Training O
was O
performed O
by O
lecture, O
real-time O
feedback, O
and O
fit O
check. O

Freedom O
from O
recurrence B-outcome
of O
P. O
vivax O
parasitemia O
at O
6 O
months O
was O
the O
primary O
efficacy O
outcome O
in O
a O
planned O
patient-level O
meta-analysis O
of O
the O
current O
trial O
and O
another O
phase O
3 O
trial O
of O
tafenoquine O
and O
primaquine O
(per-protocol O
populations), O
and O
an O
odds O
ratio O
for O
recurrence B-outcome
of O
1.45 O
(tafenoquine O
vs. O
primaquine) O
was O
used O
as O
a O
noninferiority O
margin. O

RESULTS: O
A O
total O
of O
366 O
patients O
(mean O
age, O
48.5 O
years; O
280 O
men) O
were O
enrolled. O

Exploratory O
analyses O
suggested O
that O
variation O
in O
a O
guanosine O
triphosphate O
cyclohydrolase O
gene O
predicted O
association O
with O
higher O
doses B-outcome
of I-outcome
methylphenidate I-outcome
(P O
< O
0.001). O

Title: O
Comparison O
of O
analgesic B-outcome
efficacy O
of O
oxycodone O
and O
fentanyl O
after O
total O
hip O
replacement O
surgery: O
A O
randomized O
controlled O
trial. O

BACKGROUND: O
Postoperative O
complications B-outcome
, O
especially O
pulmonary B-outcome
complications I-outcome
, O
affect O
more O
than O
half O
the O
patients O
who O
undergo O
open O
esophagectomy O
for O
esophageal O
cancer. O

Cry B-outcome
and Seperator
fuss B-outcome
time E1-outcome
were O
measured O
with O
validated O
Baby's O
Day O
Diary O
on O
days O
0 O
and O
28. O

The O
primary O
outcome O
included O
bacteriological B-outcome
cure I-outcome
. O
It O
was O
assessed O
by O
the O
eradication O
of O
urogenital O
gonorrhea O
at O
any O
site O
cultured O
after O
taken O
the O
study O
medications. O

Journal-Name:Occupational O
therapy O
international O

Furthermore, O
the O
100-mm O
VAS O
for O
radiating B-outcome
pain I-outcome
, O
Oswestry O
disability B-outcome
index O
(ODI)], O
Roland-Morris O
disability B-outcome
questionnaire O
(RMDQ)], O
EuroQol O
5 O
Dimensions O
5 O
Levels O
(EQ-5D-5L)], O
global B-outcome
perceived I-outcome
effect O
(GPE), O
and O
deficiency B-outcome
syndrome I-outcome
of I-outcome
kidney I-outcome
index O
(DSKI) O
will O
be O
used O
to O
evaluate O
secondary O
outcomes. O

Publication O
date: O
2018/06/12 O
00:00 O
[accepted] O

There O
were O
significant O
differences O
favoring O
acetaminophen O
vs O
placebo O
for O
3 O
prespecified O
secondary O
outcomes: O
delirium B-outcome
duration I-outcome
(median, O
1 O
vs O
2 O
days; O
difference, O
-1 O
[95% O
CI, O
-2 O
to O
0]), O
ICU B-outcome
length I-outcome
of I-outcome
stay I-outcome
(median, O
29.5 O
vs O
46.7 O
hours; O
difference, O
-16.7 O
[95% O
CI, O
-20.3 O
to O
-0.8]), O
and O
breakthrough O
analgesia B-outcome
(median, O
322.5 O
vs O
405.3 O
microg O
morphine O
equivalents; O
difference, O
-83 O
[95% O
CI, O
-154 O
to O
-14]). O

Respiratory O
muscle O
training O
of O
the O
experiment O
group O
was O
performed O
using O
the O
respiratory O
endurance O
training O
device O
combined O
with O
traditional O
techniques. O

Publication O
Type: O
Journal O
Article O

Publication O
date: O
2018/12/19 O
06:00 O
[entrez] O

Journal O
ID: O
101521595 O

The O
administration O
of O
gonadotrophin-releasing O
hormone O
(GnRH) O
agonists O
prior O
to O
IVF/ICSI O
can O
improve O
the O
successful O
pregnancy O
rate. O

Publication O
Type: O
Journal O
Article O

Pain B-outcome
is O
an O
important O
factor O
that O
inversely O
correlates O
with O
the O
improvements O
in O
quality B-outcome
of I-outcome
life I-outcome
. O

BACKGROUND: O
This O
study O
assessed O
the O
feasibility B-outcome
and O
acceptability B-outcome
of O
two O
common O
types O
of O
exercise O
training-high-intensity O
interval O
training O
(HIIT) O
and O
moderate-intensity O
continuous O
training O
(MICT)-in O
adults O
with O
Crohn's O
disease O
(CD). O

Further O
investigation O
would O
be O
required O
to O
confirm O
this O
effect O
and O
its O
mechanism O
and O
the O
genotype O
prediction O
of O
effects O
on O
dosing. O

RESULTS: O
After O
4-week O
treatment, O
the O
patients O
undergoing O
verum O
TENS O
showed O
statistically O
efficacy O
of O
symptoms B-outcome
relief, O
as O
measured O
by O
the O
scales O
of O
Tinnitus B-outcome
Severity I-outcome
Scale O
(TSS) O
(P O
< O
.01), O
Tinnitus B-outcome
Questionnaire O
(TQ) O
(P O
< O
.01), O
and O
Tinnitus B-outcome
Handicap I-outcome
Inventory O
(THI)], O
(P O
< O
.01), O
and O
improvement O
of O
quality B-outcome
of I-outcome
life I-outcome
, O
as O
assessed O
by O
the O
SF-12 O
(P O
< O
.01), O
compared O
with O
patients O
receiving O
sham O
TENS. O

In O
the O
conventional O
group, O
the O
treatment O
goal O
was O
clinical B-outcome
remission I-outcome
. O
Main O
Outcomes O
and O
Measures: O
Co-primary O
outcomes O
were O
proportions O
of O
patients O
achieving O
DAS28-CRP B-outcome
remission I-outcome
(DAS28-CRP O
<2.6) O
and O
with O
no O
radiographic B-outcome
progression I-outcome
(no O
increase O
in O
total O
van O
der O
Heijde-modified O
Sharp O
score) O
at O
24 O
months. O

The O
primary O
end O
point O
was O
investigator-assessed O
progression-free B-outcome
survival I-outcome
; O
rates O
of O
objective B-outcome
response I-outcome
and O
adverse B-outcome
events I-outcome
were O
also O
evaluated. O

Title: O
[Randomized O
controlled O
trial O
of O
comparison O
between O
the O
SuperPATH O
and O
posterolateral O
approaches O
in O
total O
hip O
arthroplasty]. O

Functional B-outcome
outcomes O
were O
similar O
in O
all O
three O
groups O
in O
POD O
1 O
and O
POD O
2. O

Methods: O
Seventy-five O
patients O
were O
randomized O
into O
either O
CBT-i O
group O
(n=37) O
or O
combination O
group O
(n=38). O

RESULTS: O
In O
the O
dry O
needling O
group, O
intensity B-outcome
of, I-outcome
frequency X
and X
duration B-outcome
of I-outcome
headache B-outcome
, O
and O
the O
scores O
of O
Short O
Form-36 O
subscales O
were O
significantly O
improved O
after O
treatment O
(P O
< O
.05). O

RESULTS: O
After O
6 O
weeks O
treatment, O
lactulose O
showed O
better O
outcomes O
in O
daily O
stool B-outcome
frequency I-outcome
(P O
< O
.01), O
and O
stool B-outcome
consistency I-outcome
(P O
< O
.01), O
except O
the O
abdominal B-outcome
pain I-outcome
(P O
= O
.24), O
and O
flatulence B-outcome
(P O
= O
.44), O
compared O
with O
the O
placebo. O

At O
the O
test-of-cure O
visit, O
a O
higher O
percentage O
of O
patients O
in O
the O
plazomicin O
group O
than O
in O
the O
meropenem O
group O
were O
found O
to O
have O
microbiologic B-outcome
eradication I-outcome
, O
including O
eradication O
of O
Enterobacteriaceae O
that O
were O
not O
susceptible O
to O
aminoglycosides O
(78.8% O
vs. O
68.6%) O
and O
Enterobacteriaceae O
that O
produce O
extended-spectrum O
beta-lactamases O
(82.4% O
vs. O
75.0%). O

BACKGROUND: O
Endometrial O
scratching O
(with O
the O
use O
of O
a O
pipelle O
biopsy) O
is O
a O
technique O
proposed O
to O
facilitate O
embryo B-outcome
implantation I-outcome
and O
increase O
the O
probability O
of O
pregnancy B-outcome
in O
women O
undergoing O
in O
vitro O
fertilization O
(IVF). O

Conclusions O
and O
Relevance: O
Among O
older O
adults O
undergoing O
major O
surgery, O
EEG-guided O
anesthetic O
administration, O
compared O
with O
usual O
care, O
did O
not O
decrease O
the O
incidence O
of O
postoperative O
delirium B-outcome
. O
This O
finding O
does O
not O
support O
the O
use O
of O
EEG-guided O
anesthetic O
administration O
for O
this O
indication. O

Significant O
survival O
benefit O
from O
adjuvant O
chemotherapy O
was O
observed O
by O
SPC-Prediction O
in O
MSS O
and O
EBV-negative O
gastric O
cancer. O

There O
is O
evidence O
that O
supplementation O
with O
L-methylfolate O
augments O
antidepressant O
agent O
effects O
and O
thus O
might O
also O
augment O
ADHD O
treatment O
effects O
by O
a O
common O
catecholaminergic O
mechanism. O

Journal O
ID: O
101521595 O

Funded O
by O
the O
University O
of O
Auckland O
and O
others; O
PIP O
Australian O
New O
Zealand O
Clinical O
Trials O
Registry O
number, O
ACTRN12614000626662 O
.). O

Journal O
ID: O
0255562 O

The O
ratio B-outcome
of I-outcome
Apo I-outcome
B I-outcome
to I-outcome
Apo I-outcome
A1 I-outcome
was O
reduced O
more O
(p O
= O
0.0866) O
in O
the O
amla O
group O
as O
compared O
to O
the O
placebo. O

None O
of O
the O
intervention-arms O
was O
cost-effective O
for O
sickness B-outcome
absence I-outcome
. O
There O
was O
85% O
probability O
of O
exercise-arm O
being O
cost-effective O
if O
willing O
to O
pay O
euro3550 O
for O
QALY O
gained. O

The O
preventive, O
complex O
psychological O
intervention O
comprised O
promotion O
of O
a O
therapeutic O
ICU O
environment O
plus O
3 O
stress O
support O
sessions O
and O
a O
relaxation O
and O
recovery O
program O
delivered O
by O
trained O
ICU O
nurses O
to O
high-risk O
(acutely O
stressed) O
patients. O

We O
measured O
the O
correct O
index O
in O
the O
identification B-outcome
of O
the O
eye O
drops O
of O
the O
two O
groups. O

Journal-Name:Revista O
medica O
de O
Chile O

All O
other O
adverse B-outcome
reactions I-outcome
observed O
during O
the O
test O
period O
were O
resolved O
completely O
without O
special O
treatment. O

During O
clinically O
apparent O
infection, O
a O
reduction O
in O
the O
diversity O
of O
micro-organisms O
in O
a O
DFU O
was O
often O
observed O
due O
to O
expansion O
of O
one O
or O
two O
taxa, O
with O
recovery O
in O
diversity O
at O
resolution. O

Trimethylamine O
N-oxide O
(TMAO) O
is O
considered O
a O
novel O
risk O
factor O
for O
cardiovascular O
diseases. O

Side B-outcome
effects I-outcome
(all O
mild) O
occurred O
in O
4.2% O
of O
the O
participants. O

Periprosthetic B-outcome
fracture I-outcome
occurred O
in O
1 O
case O
of O
the O
SuperPATH O
group. O

Pain B-outcome
scores, O
opioid B-outcome
requirements I-outcome
, O
PT O
test O
results, O
and O
patient-reported O
outcome O
instruments O
were O
compared O
between O
the O
three O
groups. O

2019; O
90(1):12-17. O

Journal-Name:Graefe's O
archive O
for O
clinical O
and O
experimental O
ophthalmology O
= O
Albrecht O
von O
Graefes O
Archiv O
fur O
klinische O
und O
experimentelle O
Ophthalmologie O

Publication O
Type: O
Randomized O
Controlled O
Trial O

Journal O
ID: O
101160941 O

The O
combination O
of O
an O
unsatisfying O
quality B-outcome
of I-outcome
implementing I-outcome
the Seperator
intervention I-outcome
and O
a O
low O
previous O
knowledge B-outcome
about O
the O
intervention O
showed O
the O
highest O
empirical O
relevance. O

Title: O
A O
High O
Adherence O
to O
Six O
Food O
Targets O
of O
the O
Mediterranean O
Diet O
in O
the O
Late O
First O
Trimester O
is O
Associated O
with O
a O
Reduction O
in O
the O
Risk O
of O
Materno-Foetal O
Outcomes: O
The O
St. O
Carlos O
Gestational O
Diabetes O
Mellitus O
Prevention O
Study. O

RESULTS: O
Twenty-two O
patients O
(44%) O
were O
still O
assessable O
at O
the O
end-of-study O
visit, O
whereas O
33 O
(70%) O
were O
assessable O
at O
the O
same O
time O
point O
in O
the O
TENS-TEP O
group O
(P O
= O
.013). O

Journal O
ID: O
101521595 O

Group O
A O
consisted O
of O
66 O
patients O
who O
received O
dexmedetomidine, O
and O
Group O
B O
included O
66 O
patients O
with O
paracetamol O
administration. O

Journal O
ID: O
2985248R O

RESULTS: O
At O
3 O
and O
6 O
month O
follow O
up, O
Atorvastatin O
40mg O
leads O
to O
mean O
LDL B-outcome
cholesterol I-outcome
reduction O
of O
47.18+/-20.81 O
& O
50.03+/-18.06 O
respectively. O

Thirty O
minutes O
before O
operation, O
control O
group O
received O
intranasal O
placebo O
(0.9% O
saline) O
0.02 O
mL/kg, O
and O
DEX O
group O
received O
intranasal O
DEX O
2 O
mug/kg. O

Journal O
ID: O
2985248R O

Twelve O
(9.5%) O
and O
10 O
(7.9%) O
subjects O
experienced O
>30% O
endothelial B-outcome
cell I-outcome
loss O
(ECL) O
at O
12 O
and O
24 O
months, O
respectively. O

OBJECTIVE: O
To O
investigate O
the O
use O
of O
Bilevel O
Positive O
Airway O
Pressure O
(BiPAP) O
in O
morbidly O
obese O
individuals O
in O
two O
moments O
following O
bariatric O
surgery O
(Roux-en-Y O
gastric O
bypass): O
post-anesthetic O
recovery O
(PAR) O
and O
first O
postoperative O
day O
(1PO). O

Title: O
[Effects O
of O
intranasal O
dexmedetomidine O
for O
children O
undergoing O
dental O
rehabilitation O
under O
general O
anesthesia: O
a O
double-blinded O
randomized O
controlled O
trial]. O

Only O
one O
tooth O
of O
G1 O
was O
unsuccessful B-outcome
; O
hence, O
pulpectomy B-outcome
performance I-outcome
in O
both O
groups O
was O
not O
influenced O
by O
the O
filling O
material, O
nor O
by O
any O
other O
analyzed O
variable. O

C-group O
received O
a O
brochure. O

The O
frequency O
of O
live B-outcome
birth I-outcome
was O
180 O
of O
690 O
women O
(26.1%) O
in O
the O
endometrial-scratch O
group O
and O
176 O
of O
674 O
women O
(26.1%) O
in O
the O
control O
group O
(adjusted O
odds O
ratio, O
1.00; O
95% O
confidence O
interval, O
0.78 O
to O
1.27). O

FUNDING: O
National O
Institute O
for O
Health O
Research O
Efficacy O
and O
Mechanism O
Evaluation O
Programme. O

The O
results O
of O
nine-gene O
based O
SPC O
assay O
were O
classified O
as O
prognostication O
(SPC-prognosis) O
and O
prediction O
of O
chemotherapy O
benefit O
(SPC-prediction). O

Title: O
Chocolate O
Milk O
versus O
carbohydrate O
supplements O
in O
adolescent O
athletes: O
a O
field O
based O
study. O

Results O
were O
similar O
for O
all O
(mild/moderate/severe) O
exacerbations B-outcome
. O
Improvements O
in O
lung B-outcome
function I-outcome
, O
health B-outcome
status O
and O
rescue B-outcome
medication I-outcome
use I-outcome
with O
IND/GLY O
vs O
SFC O
were O
comparable O
between O
men O
and O
women. O

Participants O
are O
randomised O
to O
receive O
MCP O
either O
at O
baseline O
(early O
treatment) O
or O
after O
3 O
months O
(delayed O
treatment). O

The O
positive O
percent O
of O
coli-form B-outcome
on O
the O
hand O
swabs O
in O
intervention O
group O
(2.00%) O
were O
significantly O
lower O
than O
that O
in O
control O
group O
(9.45%) O
at O
the O
end O
of O
year O
2.The O
intervention O
of O
intensive O
education O
on O
hand O
hygiene O
effectively O
improved O
the O
personal B-outcome
hygiene I-outcome
both O
of O
children O
and O
parents, O
as O
well O
as O
reduced O
the O
incidence O
of O
hand B-outcome
food I-outcome
mouth I-outcome
disease I-outcome
. O
We O
suggested O
expanding O
the O
intervention O
measures O
in O
community O
to O
prevent O
HFMD. O

Publication O
date: O
2019/02/12 O
06:00 O
[medline] O

The O
data O
were O
analyzed O
using O
repeated O
measures O
MANOVA. O

Whey O
protein O
isolate O
(WPI) O
is O
high O
in O
vitamin O
B12 O
and O
folate. O

Such O
guidelines O
are O
made O
available O
for O
strength O
training O
(ST) O
using O
the O
1 O
repetition O
maximum O
(1RM), O
which O
has O
been O
linked O
to O
individuals' O
self-rated O
level O
of O
exertion O
using O
the O
Borg O
rating O
of O
perceived O
exertion O
(BRPE) O
scale. O

Patients O
in O
the O
routine O
chemotherapy O
group O
(n O
= O
30, O
RC O
group) O
received O
cisplatin O
infusion O
within O
1 O
h O
and O
5-FU O
infusion O
for O
about O
24 O
h. O
The O
dose O
in O
the O
RC O
group O
was O
the O
same O
as O
that O
in O
the O
CC O
group. O

METHODS: O
A O
sample O
of O
37 O
patients O
poststroke O
(29 O
males) O
was O
randomly O
allocated O
to O
either O
SPT O
control O
group O
(n O
= O
18) O
or O
SPT O
and O
SMV O
(SPT-SMV) O
experimental O
group O
(n O
= O
19). O

RESULTS: O
Participants O
identified O
more O
barriers O
than O
facilitators O
when O
describing O
contextual O
factors O
influencing O
the O
mhGAP-based O
training's O
expected O
outcomes. O

Publication O
date: O
2019/01/10 O
06:00 O
[entrez] O

min(-1)). O

TRIAL O
REGISTRATION: O
Registered O
with O
Clinical O
Trials O
Registry- O
India O
at O
www.ctri.nic.in O
(Registration O
number: O
CTRI/2015/04/005682 O
) O
on O
8 O
April O
2015 O
(retrospectively O
registered). O

Whether O
a O
briefer O
treatment O
interval O
would O
be O
efficacious O
has O
not O
been O
studied. O

Journal-Name:Journal O
of O
the O
International O
Society O
of O
Sports O
Nutrition O

Serum O
levels O
of O
AdipoR1 O
were O
positively O
correlated O
with O
APN O
(r O
= O
0.726, O
P<0.01), O
and O
negatively O
correlated O
with O
BMI, O
SBP, O
DBP, O
FBG, O
TC O
and O
LDL-C O
(r O
= O
-0.440, O
-0.446, O
-0.374, O
-0.444, O
-0.344, O
-0.709, O
respectively; O
all O
P<0.01). O

Statistical O
significance O
was O
set O
at O
P O
</= O
0.05. O

Publication O
date: O
2019/03/12 O
06:00 O
[medline] O

Single-arm O
studies O
have O
suggested O
that O
a O
10-day O
schedule O
of O
decitabine O
cycles O
leads O
to O
better O
outcomes O
than O
the O
usual O
5-day O
schedule. O

The O
interruption O
of O
the O
blood O
supply O
to O
the O
donor O
liver O
during O
cold O
storage O
damages O
the O
liver, O
affecting O
how O
well O
the O
liver O
will O
function O
after O
transplant. O

METHODS: O
In O
this O
randomised O
placebo-controlled O
trial, O
we O
recruited O
very O
preterm O
infants O
born O
before O
32 O
weeks' O
gestation O
in O
37 O
UK O
hospitals O
and O
younger O
than O
72 O
h O
at O
randomisation. O

Journal O
ID: O
101224380 O

CONCLUSION: O
The O
findings O
of O
this O
study O
showed O
that O
BZSF O
as O
an O
adjunctive O
therapy O
to O
ceftriaxone O
may O
be O
not O
superior O
to O
the O
ceftriaxone O
alone O
for O
Chinese O
female O
patients O
with O
uncomplicated O
gonorrhea O
after O
10 O
days O
treatment. O

Publication O
date: O
2018/11/30 O
00:00 O
[accepted] O

Based O
on O
the O
benefit O
of O
polyphenolic O
compounds O
on O
osteoporosis, O
we O
hypothesized O
that O
the O
polyphenol-rich O
herbal O
congee O
containing O
the O
combined O
extract O
of O
Morus O
alba O
and O
Polygonum O
odoratum O
leaves O
should O
improve O
bone B-outcome
turnover I-outcome
markers O
in O
menopausal O
women. O

The O
secondary O
outcome O
was O
the O
incidence O
of O
severe B-outcome
hypoxemia I-outcome
, O
defined O
as O
an O
oxygen O
saturation O
of O
less O
than O
80%. O

After O
the O
exercise, O
improvement O
was O
noted O
in O
Ober O
test O
(P O
= O
.005; O
d O
= O
0.75 O
on O
the O
right O
side, O
P O
= O
.005; O
d O
= O
0.78 O
on O
the O
left O
side) O
and O
in O
the O
Thomas O
test O
(P O
= O
.005; O
d O
= O
0.66 O
on O
the O
right O
side, O
P O
= O
.005; O
d O
= O
0.67 O
on O
the O
left O
side). O

Title: O
Bilevel O
positive O
airway O
pressure O
in O
two O
moments O
after O
bariatric O
surgery. O

Title: O
A O
Phase O
II O
Study O
Alternating O
Erlotinib O
With O
Second-line O
mFOLFOX6 O
or O
FOLFIRI O
for O
Metastatic O
Colorectal O
Cancer. O

Both O
inspiratory B-outcome
tidal I-outcome
volume I-outcome
and O
exhaled B-outcome
tidal I-outcome
volume I-outcome
monitored O
by O
ventilator O
could O
not O
reflect O
the O
patient's O
tidal B-outcome
volume I-outcome
under O
either O
VCV O
or O
PCV O
mode. O

AIM: O
To O
assess O
the O
effectiveness O
of O
a O
self-administered O
rehabilitation O
program O
in O
adults O
with O
shoulder O
pain O
syndrome O
in O
primary O
care. O

The O
preoperative O
sedation B-outcome
score, O
the O
status B-outcome
of I-outcome
separation I-outcome
from I-outcome
parents I-outcome
, O
compliance B-outcome
with O
the O
mask O
and O
hemodynamic B-outcome
parameters O
were O
recorded O
by O
an O
anesthesiologists O
until O
anesthesia O
induction. O

Journal-Name:Journal O
of O
drugs O
in O
dermatology O
: O
JDD O

RESULTS: O
The O
incidence O
of O
involuntary B-outcome
movement I-outcome
and O
spontaneous B-outcome
movement I-outcome
were O
measured O
as O
significantly O
lower O
in O
group O
I O
(P O
< O
.05). O

RESULTS: O
Among O
42 O
HIE O
children, O
1 O
child O
of O
severe O
congenital O
malformation O
and O
1 O
child O
of O
platelet O
count O
(PLT) O
< O
50x10(9)/L O
were O
excluded, O
and O
40 O
children O
were O
enrolled O
in O
the O
study O
group. O

Overall, O
the O
study O
demonstrated O
the O
acceptability B-outcome
of O
an O
adapted O
version O
of O
the O
WHO O
Moments O
for O
Hand O
Hygiene O
poster O
in O
the O
introduction O
of O
an O
intervention O
in O
the O
community. O

OBJECTIVE: O
To O
investigate O
the O
effects O
of O
aerosol O
inhalation O
on O
respiratory B-outcome
mechanical I-outcome
parameters O
under O
different O
ventilation O
patterns O
and O
ventilator O
parameters O
in O
patients O
on O
mechanical O
ventilation O
and O
simulated O
model O
of O
aqualung O
in O
vitro. O

The O
secondary O
outcomes O
consisted O
of O
stool B-outcome
consistency I-outcome
, O
measured O
by O
the O
Bristol O
Stool O
Form O
Scale, O
abdominal B-outcome
pain I-outcome
, O
flatulence B-outcome
, O
as O
well O
as O
the O
adverse B-outcome
events I-outcome
. O
All O
outcomes O
were O
measured O
at O
baseline O
and O
after O
6-weeks O
treatment. O

CONCLUSIONS: O
Among O
patients O
with O
early O
Parkinson's O
disease O
who O
were O
evaluated O
over O
the O
course O
of O
80 O
weeks, O
treatment O
with O
levodopa O
in O
combination O
with O
carbidopa O
had O
no O
disease-modifying O
effect. O
( O

The O
mean O
age O
of O
the O
patients O
was O
14.9 O
years O
and O
the O
mean O
follow-up O
was O
24 O
months. O

Background O
Intravenous O
sufentanil-midazolam O
and O
inhalational O
sevoflurane O
are O
widely O
used O
for O
anesthetic O
induction O
in O
children O
undergoing O
cardiac O
surgery. O

